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Abstract 
 
The Echinococcus granulosus tapeworm infects intermediate hosts as humans and sheep, 
inducing Echinococcosis that leads predominantly to liver cysts. An effective manner for 
preventing E. granulosus infection of the intermediate hosts, is through the interruption of 
its life cycle, by directly treating the definitive hosts, as are dogs. 
Bacillus subtilis is an extensively studied Gram-positive bacteria that possess several 
advantages, as i) the generation of robust spores; which resist to harsh environmental 
conditions; ii) it is genetically tractable; iii) considered as a safe probiotic, making of this 
bacteria a good candidate for an enteric vaccine approach. Additionally, B. subtilis 
develops in biofilms, which are bacterial communities with an extracellular matrix. TasA, 
a main biofilm matrix protein, when fused at the C-terminal with the fluorescent protein 
mCherry showed to be distributed in the whole biofilm. By taking advantage of the 
widespread distribution of TasA in the biofilm, we intended to express E. granulosus 
antigens, as tropomyosin (EgTrp) and paramyosin (EgA31) fused at the C-terminal of 
TasA. Thus, spores of recombinant B. subtilis strains for these antigens had been orally 
provided to animals with the aim of bypassing the stomach barrier, germinate in the gut 
and develop in a biofilm that will expose on its surface the antigens of interest. These 
antigens would eventually stimulate the gut-associated lymphoid tissues allowing the 
establishment of a humoral and cellular immune response against the E. granulosus 
tapeworm. To test this hypothesis, series of B. subtilis were engineered for carrying 
antigenic peptides for EgTrp and EgA31. The obtained recombinant and wild-type B. 
subtilis spores showed the same resistance to harsh conditions as are high temperature, 
shelf-life survival, and acidic conditions. In a first instance, when testing the recombinant 
spores in orally administered Balb/c mice, the spores showed to be able to germinate after 
the passage through the gastrointestinal tract. Interestingly, mice developed a 
significantly increased humoral immune response, detectable as secreted IgA in the feces 
when inoculated with spores carrying (102-278)EgTrp. In a second instance, when 
treating mice with an antibiotic cocktail (to favor the B. subtilis germination in the gut) 
previous to the spore oral gavage, the mice developed a significant increase in local and 
systemic humoral immune response to both EgTrp antigenic peptides, (102-207)EgTrp 
and (102-278)EgTrp. However, the mice receiving recombinant spores carrying EgA31 
antigenic peptides were unable to develop a detectable humoral or cellular immune 
response under any of the tested conditions. 
The recombinant spores were also tested in dogs, as they are the main target group for a 
potential vaccine against echinococcosis. The results obtained from the spore 
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administration in dogs were similar to the mouse experimentation. Thus, one out of two 
dogs receiving recombinant spores for EgTrp and one out of two dogs receiving the 
mixture of spores (EgTrp and EgA31) can elicit an immune response. However, dogs 
receiving EgA31 showed signs to develop a tolerance towards paramyosin, as one dog 
was showing an increase in proliferation of T-regulatory cells during the experiment. This 
data was consistent with the result obtained from mouse experimentation, indicating that 
paramyosin is not a good antigen for enhancing the humoral immune response. 
Finally, we were able to develop a carrier. The B. subtilis spores based carrier of 
recombinant E. granulosus antigens resulted in a significant increase of detected 
antibodies in mice and an increase of antibodies in dogs against components of the 
recombinant B. subtilis biofilm of the (102-207)EgTrp strain. However, this potential 
vaccine needs to be challenged in dogs with E. granulosus tapeworms to prove its real 
efficacy. 
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Zusammenfassung 
 
Der Hundebandwurm Echinococcus granulosus infiziert Zwischenwirte (z.B. Menschen 
und Schafe) und verursacht Echinococcosis. Die Infektion mit E. granulosus führt 
vornämlich in der Leber zu Bildung von Zysten. Ein effektiver Weg um Zwischenwirte 
vor einer solchen Infektion zu schützen, ist den Hauptwirt (z.B. Hunde und Wölfe) gegen 
den Bandwurm zu behandeln.  
Bacillus subtilis ist ein gut erforschtes Gram-positives Bakterium mit einigen Vorzügen, 
wie zum Beispiel: i) die Bildung von robusten Sporen, welche harschen 
Umweltbedingungen widerstehen, ii) die genetische Modifizierbarkeit und iii) die 
Anerkennung als sicheres Probiotikum, machen dieses Bakterium zu einem guten 
Kandidaten für einen enteralen Impfstoff. Zusätzlich bilden B. subtilis Bakterien 
Verbünde, geschützt durch eine extrazelluläre Matrix, sogenannte Biofilme. TasA, ein 
Hauptprotein der extrazellulären Matrix, zeigt sich über die gesamte Oberfläche des 
Biofilms verteilt, wenn man es C-terminal mit einem fluoreszierenden mCherry Protein 
fusioniert. Den Vorteil nützend das TasA so verteilt ist im Biofilm, beabsichtigten wir die 
E. granulosus Antigene Tropomyosin (EgTrp) und Paramyosin (EgA31) an den C-
Terminus von TasA zu fusionieren.  
Sporen von rekombinanten B. subtilis Stämmen mit diesen Antigenen werden oral an 
Tiere verabreicht. Dies mit dem Ziel, dass die Sporen den Magen passieren, im Darm 
germinieren, und sich zu einem Biofilm entwickeln. Dadurch würden die Antigene 
exprimiert. Diese Antigene werden möglicherweise die Darm-assoziierten lymphatischen 
Gewebe stimulieren und zu einer humoralen und zellulären Immunantwort gegen E. 
granulosus führen. Zu diesem Zweck wurden Stämme von B. subtilis entwickelt welche 
die Peptide EgTrp und EgA31 exprimieren können. Die erhaltenen rekombinanten sowie 
auch die wildtyp B. subtilis Sporen zeigten eine starke Widerstandsfähigkeit gegen 
äussere Einflüsse wie hohe Temperaturen, Langzeit-Exposition zu Raumtemperatur und 
sauren Bedingungen.  
In einem ersten Schritt zeigten Sporen die Fähigkeit, dass sie die Passage durch den 
Gastrointestinal-Trakt überstehen. Interessanterweise entwickelten Mäuse ein 
signifikanter Anstieg der humoralen Immunantwort welche sich durch sekretierte IgA im 
Stuhl von mit (102-278)EgTrp inokulierten Mäusen zeigte. In einem zweiten Schritt 
wurden die Mäuse vor der Gabe von rekombinanten Sporen mit Antibiotika behandelt um 
die germinierung von B. subtilis zu begünstigen. In diesem Fall entwickelten die Mäuse 
eine lokale und systemische humorale Immunantwort gegen beide EgTrp Varianten, 
(102-207)EgTrp und (102-278)EgTrp. Im Gegensatz dazu, entwickelten Mäuse welche 
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EgA31 exprimierende rekombinante B. subtilis verabreicht erhielten keine humorale oder 
zelluläre Immunantwort unter den getesteten Bedingungen. 
Die rekombinanten Sporen wurden auch an Hunden getestet, da diese die Zielgruppe für 
einen Impfstoff gegen Echinococcosis darstellen. Die Resultate waren vergleichbar zu 
den Resultaten aus den Maus Experimenten. Einer von zwei Hunden die EgTrp Sporen 
erhielten und einer von zwei Hunden die ein Gemisch aus EgTrp und EgA31 Sporen 
erhielten, entwickelten eine Immunantwort gegen Komponenten des Biofilms des (102-
207)EgTrp B. subtilis Stamms. Im Gegensatz dazu entwickelte ein Hund welcher 
rekombinante EgA31 Sporen erhielt Zeichen einer Toleranz gegen Paramyosin. 
Abschliessend können wir festhalten, dass wir einen Träger basierend auf B. subtilis 
Sporen entwickelten und dieser zu einem vorsichtig positiven Resultat in der oralen 
Immunisierung von Mäusen und Hunden gegen E. granulosus führte. Jedoch muss der 
Impfstoff mit einer Behandlung der Hunde mit E. granulosus Bandwürmern getestet 
werden, um die wirkliche Effizienz zu beweisen. 
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Introduction 
The history of vaccines 
The history of vaccine development is linked to the deadly poxvirus "variola", 
which causes smallpox in humans for which records go back more than 3500 years 1. The 
beginning of the vaccination dates from the first observations reported by Thucydides in 
430 BC. He observed that people who survived a severe and contagious disease would 
not suffer from the same illness a second time 2. Then the first active immunization was 
reported during the Middle Age in China, where the so-called “variolation” was 
practiced. In this procedure, healthy people were exposed to air-dried pustules of 
smallpox from humans. This procedure was also practiced in Turkey from where the wife 
of the British ambassador in Istanbul, Lady Mary Wortley Montagu imported the 
variolation to Britain. However, the variolation procedure was frequently accompanied by 
severe side effects and often lead to death 3. In the eighteenth centuries, Edward Jenner, 
an English physician, and scientist (1749–1823) combined the procedure of variolation 
with his observation that the milkmaids in contact with the cowpox pustules did not suffer 
from smallpox. The proof of principle for the vaccination was given by the Jenner's 
vaccination experiment in 1796. James Phipps, an eight-year-old boy, was vaccinated 
with a cowpox lesion from a milkmaid. Followed by a smallpox challenge, which 
remained without adverse effects for James 3,4. From there on, variolation was performed 
using cowpox pustules to immunize and protect people against deadly smallpox.  
Then, in 1879, Louis Pasteur (1822-1895) did the following important step in the 
vaccines history, when observing that chickens were not dying of a fowl cholera 
challenge after a former injection of accidently attenuated cholera bacteria. Pasteur 
realized that he demonstrated the immunization by artificially attenuated agents. He used 
this discovery to develop an attenuated anthrax vaccine, which he tested successfully by 
1881 5. Based on these findings, life attenuated pathogens, and parts of it were used to 
raise immunity in humans and animals against various diseases.  
Apart from protecting the individual animal and its flock from a disease, the animal 
vaccines have an additional goal to protect humans from anthropozoonoses 6. 
Furthermore, the development of vaccines for animals differs from vaccination for people 
by ethical issues surrounding the experimentation and testing as well as the economic 
considerations, which are guiding the way of handling a disease. Also, alternative 
measures can be taken to hinder a disease from spreading, as is, for example, the 
slaughter of sick animals 6,7. The vaccination of animals goes back to the inoculation of 
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sheep with serous fluid from infected animals to protect them from sheep-pox, named as 
“clavélisation”. However, due to the historic vaccination advents, it remains unclear if 
this kind of inoculation leads to the idea of human variolation or vice versa 6. 
The story of animal vaccines continued with Louis Pasteur's finding in 1882 that 
pathogens affecting one species and passed through another species do not affect the 
same severity the first species anymore. Which was based on the empirical observation of 
farmers and veterinarians and he then developed the method of “lapinised vaccines”. In 
this case, Pasteur attenuated the Erysipelothrix rhusiopathiae Gram-positive bacteria, the 
causing agent for swine erysipelas, by injecting it in series to rabbits before inoculating 
the swine 8. The discoveries of Jenner and Pasteur had allowed the production of 
attenuated pathogens for different vaccines used against various pathogens, as diphtheria 
toxoid (1923), Polio (1963), Adenovirus (1980), Rotavirus (RotaTeq® 2006, Rotarix® 
2008), and 21-Valent pneumococcus (2012) 9. 
Also, with the progress in science and technology, new modes of vaccination have been 
introduced, like is the gene-based delivery of antigens, which derive an immune response 
through synthesizing antigenic proteins within antigen-presenting cells. This 
methodology has proven its effectiveness, in particular against human influenza virus by 
using DNA-expression vectors or replication-defective virus 10,11. Also, other alternative 
methods of vaccination had been developed as antigenic protein expression through 
replicons, virus-like particles, live-attenuated viruses, purified antigenic peptides or by 
recombinant bacteria expressing antigens 9,12–15. 
Up to date, 84 different vaccines are available and are licensed in Switzerland for its use 
in humans (Swissmedic, 31st October 2015 16) and 137 vaccines for veterinary purposes. 
Among those, 23 vaccines are destined for dogs in Switzerland (Institute of Virology and 
Immunology, 31st October 2015 17). However, the current world health conditions are 
differing from the Swiss sanitary conditions as has been reflected by the estimation of the 
Global Alliance for Vaccines and Immunization (GAVI) that more than 1.5 million 
children die annually from vaccine-preventable diseases. Mainly due to the lack of 
vaccine availability in developing countries because of the economic and political context 
9,18. Besides, there is a need for improvement of vaccines against several important 
diseases. Few examples are viruses like Dengue, Ebola or HIV and as bacteria 
Mycobacterium tuberculosis, Mycobacterium lepromatosis and as parasites Plasmodium 
malariae or the tapeworm Echinococcus granulosus 19–21. 
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Bacillus subtilis: biofilm and spores 
A potential vaccine for developing countries needs to be easily administered, 
independent of a cold chain, cost efficient in production and in a safe biological 
background 22. A good candidate corresponds to the spores of Bacillus subtilis (B. 
subtilis) because of the possibility to be orally administered, the independence of a cold 
chain, the low-cost preparation, and purification, the use of safe food supplement and the 
resistance to harmful chemicals 23–28. B. subtilis is a Gram-positive bacterium commonly 
present in soil and water 29. Importantly, Bacillus species can establish an endosymbiotic 
relationship with their host, surviving and proliferating within the gastrointestinal tract 
(GIT) 30. For example, it has been described that the spores B. subtilis var. natto can 
germinate within the GIT of mice 31. B. subtilis possess the status of "generally 
recognized as safe" (GRAS) by the American food and drug administration (FDA GRAS 
notice 562 23). In the GRAS notice are listed ten studies using B. subtilis for human 
ingestion that declare B. subtilis as having no adverse effects. 
Biofilms: bacterial communities with extracellular matrix  
Surface-associated Multicellular communities encased in a self-produced 
extracellular matrix (ECM) are referred to as biofilms 32–34. The ECM of biofilms is 
composed of extracellular polymeric substances, as carbohydrate-binding proteins 35,36, 
pili, flagella, adhesive fibers 37 and extracellular DNA 38. The matrix does not only 
stabilize the biofilm but also traps nutrients and water through H-bond interactions 39. 
These structural components of the matrix keep bacteria in close contact and enable direct 
cell-to-cell interactions as used for DNA exchange 40 and also, protecting the bacteria 
from dehydration, predation, oxidizing molecules and other damaging agents as 
antibiotics 40–43. Biofilms can be problematic in clinical settings as they are harder to treat 
due to their inherent resistance to environmental insults 41,42,44. An example of this is the 
formation of a Pseudomonas aeruginosa biofilm in the upper respiratory tract that leads 
to persistent and recalcitrant infections45,46 or the urinary tract infections that are induced 
by the biofilm of the uropathogenic Escheria coli 47. In contrast, there are cutting edge 
applications in which biofilms can be used to facilitate industrial processes as the bio-
catalysis. Some examples of bio-catalysis supported by biofilms correspond to the 
catalysis of acetic acid, ethanol or butane-2,3-diol 48 and the bio-removal in waste water 
treatment of heavy metal as is the trivalent chromium using B. subtilis biofilms 49. 
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Bacillus subtilis biofilm formation 
 B. subtilis strains have the ability to form biofilms 50. The ECM is formed by 
proteins, exopolysaccharides, and nucleic acids and corresponds to more than 90% of the 
dry weight of the biofilms 40. The ECM proteins are essential in the biofilm structure and 
can form fibrous amyloid-like structures 35,51,52. These particular fibers are composed by 
TasA in the extracellular space and get anchored to the cell wall by TapA 53. These two 
proteins, TasA and TapA, are processed and secreted to the extracellular space by the 
signal peptidase sipW. These three proteins are encoded in the three-gene operon tapA-
sipW-tasA (tapA operon) as schematically represented in Figure 1 34,35.  
 
Furthermore, the extracellular matrix production of B. subtilis is under the control of the 
ratio of Spo0A to phosphorylated Spo0A~P 54. A low level of phosphorylated Spo0A~P 
induces matrix production, and a higher level favors the sporulation of the bacteria 
whereas the dephosphorylated Spo0A induce a motile form of the bacteria 55. The 
phosphorylation and therefore activation of Spo0A is induced by five different kinases 
(KinA-E) 56. Spo0A~P is inducing the expression of SinI, which is inhibiting the 
transcription repressor SinR. The repressor SinR directly binds and inhibits the promoter 
of the operons epsA-O and tapA-sipW-tasA coding for the exopolysaccharide (EPS) and 
Figure 1. Regulation of the biofilm formation in B. subtilis through the Spo0A 
phosphorylation relay adapted from Mielich-Süss et al. The kinases KinA–E get activated 
through the indicated pathways, which are triggered by different stimuli as increase of 
surfactin concentration, respiration or Glycerol, Manganese and L-malic acid. In the absence 
of spores or matrix forming environmental conditions, Spo0A gets dephosphorylated, and 
hence, it is inactive. This condition permits the binding of SinR and AbrB to the Tap promoter 
driving its inactivation. SinR is regulated by SlrR in a double negative feedback loop. By 
changing environmental conditions the KinA-E get activated and phosphorylate Spo0A. 
Spo0A~P is inducing the expression of SinI a SinR inhibitor and as well inhibiting AbrB. By 
this, the tasA operon remains unrepressed any longer and the matrix-related genes are 
expressed. Adapted from Mielich-Suess et al 60.  
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the matrix protein TasA, respectively 35,57. Also, SinR could be inactivated by SlrA 58,59, 
which in turns is under the control of the transcription repressor YwcC, then be involved 
in a double negative feedback loop 60. However, the signal cascade triggering this second 
pathway is unknown 61.  
The analysis of the activated tapA promoter (formerly known as yqxM) within a formed 
biofilm was performed by Vlamakis et al. in 2008 by cloning the tapA promoter in front 
of the fluorescent protein YFP tag into the lacA locus. By visualizing the YFP by flow 
cytometer and fluorescent imaging, they determined the time point and localization in the 
biofilm of the activation of the tapA promoter. They could show that in vitro a B. subtilis 
biofilm contains, at 24 h post-inoculation, about 81 % of cells with an active tapA 
promoter, which are therefore seen as matrix-producing cells. The fraction of matrix-
producing (PtapA) cells drops then to 65 % (48 h) and 38 % (72 h) whereas the fraction of 
cells with activated sporulation (PsspB) promoter increase in numbers. The fraction of 
motile cells is dropping earliest; 70 % at 12 h and only 26 % at 24 h express the motility 
promoter Phag. Further Vlamakis et al. emphasize that the sporulation of the bacteria is 
dependent on the formation of an architecturally complex community 62. 
 
As first, TasA was considered as a protein with antimicrobial activity associated to spores 
51. In 2006, Branda and collaborators 35 found that TasA is the major protein component 
of the ECM in biofilms formed by B. subtilis. By co-culturing a tasA deficient strain 
together with a strain deficient in eps expression it shows that the TasA and the 
exopolysaccharides are shared by the bacteria within a biofilm, and the two deficient 
strains were able to form together a complemented biofilm 35. In 2010, Romero and 
collaborators were able to determine the TasA structure as amyloid-like fibers, 
corresponding to a fiber conformation only when stimulated by hydrophobic surfaces 52 
or in an acidic environment 34. The secondary structure of TasA is dependent on the 
states, corresponding to an alpha-helix rich in the oligomeric state whereas in the fiber 
state are privileged the beta sheet structures 34.  
B. subtilis spores 
To survive periods of starvation B. subtilis can form dormant endospores. The 
spores can survive in this dormant state for many years 63 or even for millions of years as 
suggested by Cano et al. 64. For the formation of an endospore, a B. subtilis single cell 
divides asymmetrically. As depicted in Figure 2 in the “asymmetric septation” phase the 
two generated daughter cells are morphologically different 54,65,66. The large and the small 
daughter cells are called mother cell and forespore, respectively. The mother cell, which 
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held to the forespore by the external cell wall, starts to engulf the forespore generating a 
double membrane inside its cytoplasm 67. Finally, the formed spore partially dehydrates 
and develops into a dormant spore that is highly resistant to harsh environmental 
conditions, whereas the mother cell undergoes programmed cell death 67,68. 
 
 
The sporulation process for B. subtilis, as illustrated in Figure 2, has been traditionally 
separated in four different stages ("I" to "IV"). However, these steps are not strictly 
separated and overlap each other 67,69. The stages of the spore development and the three 
phases of the transition from the spore to the vegetative cell are described in detail below:  
 
Spore differentiation stages (represented in Figure 2): 
 
• Stage 0: Initiation of the sporulation in the vegetative cell: In a biofilm formed by 
B. subtilis, the sporulation does occur in subpopulations and not simultaneously for all 
cells 70. The process for a single cell to start the sporulation is tightly regulated by the 
Figure 2: The stages of B. subtilis endospore assembly adapted from McKenney et al.  
Stage 0) Increasing amounts of phosphorylated Spo0A-P initiate the sporulation of the 
vegetative cells starting by the chromosome duplication. Stage I) Control of the number of 
chromosomes. Stage II) Asymmetric septation with temporary genetic asymmetry. Stage III) 
Engulfment of the forespore by the mother cell. Stage IV) Formation of the coat and the 
cortex, followed by the lysis of the mother cell and ending with the release of the endospore. 
In favorable conditions, the spore can germinate and go into a vegetative cell to start 
replication. Adapted from McKenney et al 79. 
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phosphorylation of Spo0A. Lower levels of Spo0A~P lead to biofilm formation and 
extracellular matrix production, whereas higher levels of Spo0A~P lead to sporulation 
55,71,72.  
 
• Stage I: Control of the chromosome copy number. When the sporulation process 
starts, the cell contains two chromosomes aligned to each of the cell poles 73. At the 
initiation of the replication, each chromosome interacts with the positioning control of the 
division site (DivIVA complex). In this manner, each new daughter cell receives one 
chromosome 67,74. At least three different control proteins as SirA (inhibitor of replication 
in sporulation), Sda (dnaA1 suppressor) and Spo0A~P are involved in the correct 
allocation of the chromosomes 67. The sirA is under the control of Spo0A~P and occurs 
upon sporulation is started. SirA is inhibiting the DNA replication by direct interaction 
with DnaA, which is inhibiting the binding and initiation at the origin of replication 75. 
Additional to the indirect regulation of Spo0A~P it is a direct regulator of the DNA 
replication by its ability to bind to sites around the origin of replication, inhibiting DNA 
replication during sporulation 73. The entry into sporulation is restricted to the period 
between rounds of DNA replication by Sda binding to the sporulation histidine kinase 
KinA during active DNA replication 67,76. 
 
• Stage II: Asymmetric septation. In this stage, a temporary genetic asymmetry 
arises when the polar septum that separates the chromosome, includes only one-third of 
the chromosome in the forespore. The remaining chromosomal part is pumped by 
SpoIIIE, a DNA translocase, from the mother cell to the forespore 67,77. 
 
• Stage III: Engulfment. In this stage, the mother cell engulfs the forespore by 
bending the polar septum around it, leading to a free floating cell in the cytosol of the 
mother cell 67. 
 
• Stage IV: Late sporulation and release of the spore. In this final stage, the two 
shells, coat, and cortex, that protect the spore from environmental conditions are formed. 
The external shell (coat) and the inner shell (cortex) are composed of proteins and 
peptidoglycans 78,79. Also, the coat consists of four layers: basement layer, inner coat, 
outer coat and the crust 79. Thus, to release the spore the mother goes into a process of cell 
lysis and dies 67. 
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Transition phases from spore to vegetative cell: 
The spores survive for long periods of unfavorable life conditions. As soon as the 
environmental conditions allow it, the spore gets reactivated. 
• Re-activation of the spore: The re-activation of the spore triggered by 
environmental conditions as temperature, pH and chemical exposure leading to the so-
called germination. Interestingly, this activation process can be reversible and does not 
necessarily lead to germination and outgrowth 80.  
• Germination: Once the germination initiates, it becomes irreversible being unable 
to return to its dormant state 80,81. Various stimuli can lead to germination, as are for 
example nutrients, ions, cationic surfactants and chelators 80,82. 
• Outgrowth: This stage defined as all the events taking place after the germination 
concluded, which include the metabolism initiation, the macromolecules synthesis, the 
spore swelling, the emerge (outer spore layers shed) and the growth of the new cell 80. 
 
The B. subtilis spore structure 
In the case of B. subtilis, the spore is organized into eight main compartments 
shown in Figure 3, described from outside to inside: i) the crust, ii) the outer coat, iii) the 
inner coat, iv) the basement layer, v) the outer forespore membrane, vi) the cortex, vii) 
the inner forespore membrane and 
viii) the core containing the 
chromosome 25,79. The spore coat is 
composed of several layers of more 
than 50 different proteins, responsible 
for the resistance to some chemicals 
and lytic enzymes but not to heat and 
radiation 25,83,84. Most of these 
proteins are spore-specific and not 
found in the vegetative cell 85,86. The 
outer forespore membrane is essential 
for the spore formation, but the spore 
resistance is not altered by 
modifications of the outer forespore 
membrane 66,84.  
The cortex of B. subtilis spores is mainly composed of peptidoglycans similar to those 
present in vegetative cells but has some spore specific modifications as the presence of 
Figure 3. B. subtilis endospore representation 
adapted from McKenney et al. Schematic 
representation (A) and electron micrograph (B) of 
the B. subtilis endospore with the indicated 
structures. Adapted from McKenney et al 79. 
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modified sugar muramic-∂-lactam and a low level of peptide cross-links between the 
glycan strands 87. The cortex is essential in the spore, particularly for the reduction of the 
water content in the spore core. During the spore germination, the cortex is degraded, a 
process that is essential for the expansion of the spore core and the outgrowth 82. 
The inner forespore membrane permeability provides the resistance to many chemicals, in 
particular, those damaging the chromosomal DNA 84,88. In the dormant spore, the lipids of 
the inner forespore membrane are largely immobile, but they become fully mobile when 
the spore germinates 89. The innermost structure corresponds to the spore core that 
contains the DNA, ribosomes, tRNA and enzymes, which are identical to those present in 
vegetative cells 25. The low water content in the core is the major factor for the enzymatic 
dormancy and the resistance of the spore to moist heat 88. Additionally, pyridine-2,6-
dicarboxylic acid (dipicolinic acid, DPA), which found in about 5 – 15 % of the dry 
weight of the spore, has also been associated with resistance. The DPA exclusively locate 
in the core representing several functions as; i) chelating divalent cations, as Ca2+ 25, ii) 
reducing the water content during the sporulation and iii) a strong photosensitizer 85,90. 
 
B. subtilis colonization of the gastrointestinal tract 
B. subtilis spores were found to germinate in the jejunum and ileum of mice 91. It 
is estimated that less than 1 % of the given spores per oral route to mice will germinate in 
the GIT 91,92. A study with B. subtilis, spores denoted their full resistance to simulated 
gastric solutions. This study also showed that almost the same number of spores was 
recovered from the small intestine as orally administered to mice 93. Two studies in 
chickens regarding the persistence of B. subtilis within the GIT showed the presence of 
spores in feces up to 36 days post-oral gavage 94,95. In mice, the transit time in GIT for B. 
subtilis spores resulted to be 15 days 96. Interestingly, an in vitro study that analyzed the 
interaction between recombinant and parental B. subtilis spores with human macrophages 
showed that B. subtilis spores get phagocytized at a frequency lower than 2.5 % and most 
of the internalized spores are killed by 6 hours 97. 
Hoa et al. 98 found more spores shed than the number given to the mice by oral gavage, 
suggesting that spores were germinating and replicating in the GIT before re-sporulating 
and getting shed. Further proof going into the direction that B. subtilis is a gut commensal 
rather than an exclusive soil bacteria was found, when the team of S. Cutting isolated B. 
subtilis strains from human gastrointestinal tract 99. 
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B. subtilis use in oral immunization 
The immunogenicity of B. subtilis spores was shown in the studies realized by the 
group of S. Cutting 15,100 using the Tetanus toxin fragment C as an antigenic model. In this 
case, the antigen was fused to the coat protein CotB. The recombinant spores were used 
to immunize mice that lead to protection against tetanus toxin in a challenge. However, as 
the protein is displayed on the surface of the spore, the presence of the fusion protein at 
the place of immunization after bypassing the stomach is uncertain 92. Additionally, to the 
effect provided by the protein presented B. subtilis spores have already been used as 
probiotics in both humans and animals 101. Probiotics are defined as live microbial feed 
supplements that can benefit the host by improving its intestinal balance 102, which 
include the competitive exclusion of pathogens 103 by competition for host mucosal 
receptor sites, secretion of antimicrobials, competition for essential nutrients and 
stimulation of host immune functions 103–106. Also, B. subtilis can convert in vitro 
genotoxins to unreactive products 107. In the specific case of B. subtilis, the probiotic 
effect is denoted by the immune stimulation of Peyer’s Patches, mesenteric lymph nodes 
and primary lymphoid tissue from the gut associated lymphoid tissue (GALT) 100,108.  
Antibiotics and the microbiota 
The gastrointestinal tract of animals is populated by various bacterial 
communities, which are referred to as microbiota 109–111. The interaction between the host 
and the microbiota is symbiotic, as the host provides a physical niche and nutrition for the 
microbiota and in retribution, the microbiota enhances the resistance of the host against 
infections and facilitates for some nutrients the absorption out of ingested food 112–115. 
Moreover, the microbiota is essential for the development of the host’s immune system 
and changes in the microbiota can have severe effects on the host as infections, atopy, 
arthritis, inflammatory bowel disease and diabetes 116–121. 
The treatment with antibiotics leads to a fundamental change of the intestinal microbiota. 
It was shown in studies with volunteers that during the treatment one-third of the bacterial 
taxa changed and two years after the treatment the microflora was not reconstituted to the 
pre-treatment taxa 122–125. Further led the antibiotics to a reduction of the GIT barrier 
function by changing the microflora, reducing intestinal Muc-2, and the decline of the 
immune defense by the reduction of RegIIIγ and reduction of CD4+ T cells in the small 
intestine 126–130.  
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Gastro intestinal immunity 
 The GIT and its mucosal surface are fully competent in the generation of an innate 
and an adaptive immune response. The innate immune system provides cells for the 
uptake of antigens. Those cells after processing the antigens induce inflammation through 
secretion of pro-inflammatory signals. Whereas the adaptive immune system recognizes 
particular antigens, reacting specifically and generating immunological memory 131. The 
dendritic cells (DCs) and the microfold cells (M) are responsible for the capture, the 
transport, the processing and the presentation of the antigens. In the GIT, the DCs have 
transepithelial dendrites that enable the cell to sample antigens directly from the lumen of 
the GIT 132. The DCs can prime naïve B cells, which then cluster in the mucosal-
associated lymphoid follicles forming germinal centers or, migrate from lymph nodes to 
the germinal centers. In here, the primed B cells clonally expand, differentiate and 
undergo to affinity maturation. The pre-mature B cells can migrate to the lamina propria 
and differentiate into polymeric IgA-secreting plasma cells by two mechanisms: i) 
through activation of CD4+ T cells, DCs and the intestinal epithelial cells and ii) through 
a T cell-independent manner after direct activation of DCs loaded with commensal 
bacteria 133,134. The polymeric sIgA are secreted as a dimer, providing it an enhanced 
binding capacity to the antigen. In the GIT lumen, the polymeric sIgA prevent the binding 
of the pathogens to the mucosal surface by building large complexes that enable to the 
mucus to trap the pathogens 135,136. Furthermore, the sIgA can bind to pathogens that have 
bypassed the mucosal epithelium 135,137. 
 
Oral immunization and malnutrition - experiences from poliovirus 
The World Health Organization (WHO) used the oral poliovirus vaccine (OPV) 
in routine immunization throughout the polio eradication initiative. In industrialized 
countries with a single OPV dose the seroconversion rate was over 80%, and with three 
doses a protection close to 100% was reached 138. However, the lower mean frequencies 
of response to any poliovirus serotype were reached for South India (40%) and Northern 
India (20%) 18,139,140. Various hypotheses to explain these differences were raised 
including diarrhea cases, low zinc levels, low Vitamin A levels and malnutrition 141,142. 
For example, in 2011 about 44% of the Pakistani children were reported to be 
malnourished, in correlating areas to the majority of cases of paralytic poliomyelitis 18,143. 
A study conducted by Saleem et al. evaluated the efficacy of the vaccine depending on 
the nutritional status of the vaccinated children in a randomized control trial. They 
showed that among the malnourished children 13% were unprotected against polio 
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serotype 1, in which most of them suffered significantly more often of diarrhea in the 
seven days before the vaccination. However, this lack of immunity could be compensated 
by giving the combination of bivalent OPV + IPV which lead to protection against PV1 
(97.6%), PV2 (96.1%) and PV3 (91.7%) in parity to the protection of normally nourished 
children who had not received IPV. Therefore, it was concluded that the malnutrition has 
a major impact on the poliovirus eradication and vaccination regime needs to adapt 
towards injected IPV vaccines additional to the OPV in areas with high prevalence of 
malnutrition 18. 
The dog tapeworm Echinococcus granulosus  
The dog tapeworm Echinococcus granulosus (E. granulosus) is the causative 
agent of cystic echinococcosis (CE) in humans and other intermediate or accidental hosts. 
According to the World Health Organization (WHO), this parasitosis is considered as 
neglected tropical disease 144. Distributed nearly worldwide, but mainly prevalent in 
developing countries CE is responsible for considerable human morbidity, mortality and 
economic loss 145. Only in the United States of America (USA), the economic impact of 
CE is about 2 billion US-Dollars per year, and the worldwide infected population has 
been estimated to be close to 3 million people 144,146,147. The CE is caused by E. 
granulosus in its larval stage (metacestode), which is growing throughout the internal 
organs from the intermediate hosts (mostly ungulates like sheep and camels) and the 
accidental hosts (such as humans) forming cysts up to 20 cm in diameter 148. Cyst 
formation particularly occurs in the liver and the lung, leading to the clinical signs of the 
disease 149. Signs for a cyst located in the liver are abdominal pain, nausea, weight loss, 
general malaise and evidence of hepatic failure. If left untreated echinococcosis is 
progressive and fatal 150. 
 
The life cycle of E. granulosus 
In the E. granulosus life cycle, two kinds of hosts are involved (Figure 4), a 
definitive corresponding to the Canidae family as dogs and wolfs and an intermediate 
corresponding to ungulates as sheep and camels 151. The final host shed the E. granulosus 
eggs in feces, which subsequently can get ingested by the intermediate hosts. In the 
stomach of intermediate hosts, the eggs hatch and the oncosphere are released in the 
intestine, where the oncospheres get activated 152. After penetrating the intestinal 
epithelium and the lamina propria, the oncospheres are transported passively by the 
bloodstream or lymphatic fluid, reaching their final destinations, primarily the liver and 
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the lung. To protect itself the oncosphere develops into larvae, forming a hydatid cyst 
(metacestode) as shown in Figure 4. These unilocular fluid-filled bladders that develop in 
internal organs of the accidental and the intermediate hosts consist of two parasite-
derived layers, an inner nucleated germinal layer and an outer acellular laminated layer 
(LL), which is surrounded by the host-derived fibrous capsule generated during the 
immune response 147,153. The life cycle of E. granulosus closes when a definitive host eats 
the metacestodes of an intermediate host containing invaginated protoscolex. These settle 
in the small intestine after passing through the stomach fluid (pH 1.08 in fed and pH 2.05 
in fasted dogs 154). Once settled in the small intestine of definite hosts the protoscolex 
maturate, which take 4 to 5 weeks to reach sexual maturity. However, most canids do not 
show symptoms from the parasite 147. 
 
  
Figure 4. Schematic representation of the E. granulosus life cycle adapted from 
WHO/OIE.  
The eggs, the oncospheres, the metacestodes and the invaginated protoscoleces are the forms of 
E. granulosus found in the intermediate hosts. The evaginated protoscoleces and the adult 
worms are found in the definitive host. The length and diameter of the structures are indicated. 
Adapted from WHO 150. 
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The immune escape of the metacestode in the intermediate host 
 The first barrier of the immune system from the intermediate host against the E. 
granulosus oncosphere is the barrier of the GIT. After penetrating the epithelium a 
significant cellular response is detected mainly based on eosinophils, lymphocytes and 
macrophages 147. As consequence of the parasite implantation, the neutrophils and the 
macrophages infiltrate towards the E. granulosus oncosphere and mediate antibody-
dependent cell-mediated cytotoxicity 155,156.   
 
 
However, as soon as the oncosphere develops into a metacestode and the hydatid cyst is 
Figure 5. The human immune reaction against E. granulosus oncosphere and formed 
cyst adapted from WHO/OIE, Sjöberg et al, and Diaz et al. (I) The cyst laminated layer 
(LL) binds factor H (II) which is down regulating the complement system (III) by inhibiting 
C3b and its convertase (C3bBb). (IV) The LL components get recognized by B cells, which 
lead to its differentiation in plasmatic B cells resulting in the release of specific antibodies. 
(V) Whereas, specific IgM antibodies do not pass the LL but the IgG antibodies can penetrate 
the cyst. (VI) The parasitic proteins get screened by DCs. This screen is dependent on the 
ratio of activation factors (red arrows) and immune regulatory factors (blue arrows) secreted 
by the parasite. Immune regulatory factors lead to the formation of regulatory T cells (VII), 
which inhibit effector T cells. The effector T cells develop depending on surrounding stimuli 
into Th2 cells (VIII), that lead to a humoral immune response (IgG and IgE) effective against 
the parasite. Or into a Th1 cell response with a cellular immune response only partially 
effective and the Th17 cells which induce a tissue inflammation potentially inducing further 
anti-parasitic effects. Adapted from WHO 150,157,158. 
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formed, the binding of Factor H of the complement system to the LL is inhibiting the 
complement system of the host shown in Figure 5 157,158. Thus, the factor H is an inhibitor 
of the C3-convertase C3bBb, the C3b, and the C3bBbC3b C5-convertase. Through this 
inhibition, the LL gets covered by inhibited iC3b, which forms a physical barrier of host-
self components between the E. granulosus tapeworm and the host immune system 157,158.  
 
Further, the cells of the innate immunity as macrophages and mast cells lead to fibrosis, 
necrosis of cyst neighboring cells, vessel obstruction and bile duct 155,159. Also, the 
eosinophil cells degranulate at the interface of the Echinococcus cyst and the host, 
whereas cationic proteins reach high levels in the hydatid cyst fluid that are harmful to the 
parasite 160. Also, patients with a CE showed a significant number of NK cells in their 
peripheral blood mononuclear cells (PBMC) 161.  
As a second strategy, the E. granulosus oncospheres infecting the intermediate hosts can 
increase the immune responses significantly, which include both the cellular and the 
humoral immune response 155. In this case, the cellular immune response observed at an 
initial stage of the metacestode development led by a Th1 response that then shifts to a 
Th2 response in later chronic stages, characterized by high levels of IL-10 released by M2 
macrophages involved in parasite elimination 162–164. Nevertheless, E. granulosus can 
survive for many years in the intermediate hosts 165, due to the physical barrier of and by 
the cyst 166. When a metacestode "leaks" from a ruptured cyst into other tissues or organs 
secondary cysts can establish 155. A massive cellular infiltration towards the parasite takes 
place within three days, involving activated M2 macrophages, eosinophils and basophils 
and T regulatory cells that are recruited through chemokines 167,168, getting stimulated by 
parasitic immune modulators and evoking a Th2 response 147,169,170. However, the E. 
granulosus tapeworm can control for most extend the hosts immune system as described 
in Figure 5 and survives in the host’s body 171.  
The immune escape of the adult E. granulosus in the definitive host 
The weak and ineffective immune reaction to a primary infection from E. 
granulosus to dogs leads to the hypothesis of immunomodulation by the parasite 172. As 
described in Figure 6 once the tapeworm gets implanted in the intestine of dogs by 
strongly adhering to the crypts of Lieberkühn it is in close contact with the gut mucosa172. 
Interestingly in a study performed by Rossi et al. 172 primary E. granulosus infected dogs 
developed a strong polarization towards a Th2 response. After this first infection with E. 
granulosus parasites, the dogs treated with the antihelmintic, praziquantel. Such infection 
and eradication cycles were repeated 3 and 6 times respectively. The results obtained 
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from this analysis showed the development of a balanced Th1/Th2 response with a 
following lower number of worms detected in the intestine of the dogs. Therefore, it 
seems to be helpful for the dogs to develop a Th1 driven immune response to reduce the 
E. granulosus worm counts.  
 
The anti-E. granulosus vaccine 
Then, by considering the following three main points as i) a necessity to protect 
the intermediate and accidental hosts from E. granulosus infection 144, ii) based on a 
mathematical model showing the efficacy of reducing the E. granulosus burden by 
stopping dogs to spread E. granulosus eggs 173 and  iii) the ability of the dogs to develop 
an immune reaction against E. granulosus 172 could lead to the bases for the development 
of an effective vaccine targeting E. granulosus protoscoleces in the definitive host like 
dogs.  
Figure 6. Schematic model of the immune reaction induced by E. granulosus in the dog 
infected small intestine adapted from Zhang et al. Antigens actively screened by M cells 
and DCs in the small intestine lumen. DCs process the antigens by then presenting them to the 
B cells, which can differentiate into plasmatic cells able to produce specific antibodies against 
E. granulosus. IgA transcytosis occurs in the epithelial cells by binding to the Ig-Receptor. 
The IgA are exported into the small intestine lumen and are effective against the parasite. 
Alternatively, the T cells can be activated releasing pro-inflammatory cytokines able to attract 
neutrophils, eosinophils, basophils and mast cells inducing a local inflammation with limited 
effects against the E. granulosus. Adapted from Zhang et al 155. 
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E. granulosus tropomyosin and paramyosin as identified antigens  
Up to now, some E. granulosus antigens as tropomyosin and paramyosin have 
been identified as possible targets for the development of a vaccine 174. In a first instance, 
Esteves et al. characterized the E. granulosus tropomyosin (EgTrp), showing its 
expression in the suckers and the subtegument of the protoscoleces but also in the muscle 
of the tapeworm 175. The mammalian orthologous for tropomyosin correspond to four 
highly conserved genes that by alternative splicing can rise to over 40 isoforms 176. 
However, Alvite et al. 177 had reported only three isoforms of tropomyosin in the E. 
granulosus generated by the splicing of a unique gene. Further tropomyosin was also 
identified as potent antigens and therefore considered as vaccine candidates 178–180. 
Also, Mühlschlegel et al. 181, identified the E. granulosus paramyosin (EgA31) which 
consists of a 97 kDa protein, localized in the tegument and subtegumental parenchyma in 
the protoscoleces. However, also mainly localized in the region of the suckers where it 
rapidly accumulates at the time of the head evagination 181,182.  
    
EgTrp and EgA31 successfully tested for antigenicity in dogs 
In a trial performed, using Salmonella typhimurium expressing EgA31 and 
EgTrp, Pétavy and collaborators 13 were able to immunize dogs which lead to more than 
70% reduction in the worm counts after a challenge infection with E. granulosus when 
compared with the non-vaccinated dogs. Further, the worms from vaccinated dogs were 
smaller and less developed when compared to the worms extracted from the non-
vaccinated dogs. However, the systemic humoral immune response showed no difference 
between the immunized and non-immunized group 13.  
Based on these results, EgTrp and EgA31 will be considered as antigens for the vaccine 
strategy.  
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PhD Project 
 
AIM. The aim of this Ph.D. project is to investigate the possibility of using B. subtilis to 
immunize hosts against enteric infections through an intestinal establishment of B. 
subtilis biofilm. For this purpose, the extracellular matrix protein TasA will be fused with 
selected antigens, derived from the enteric tapeworm E. granulosus. Mice as a model and 
dogs as the major host of the tapeworm will then be inoculated with recombinant B. 
subtilis spores to characterize the development of immune reactions against E. 
granulosus.  
 
WORKING HYPOTHESIS. With this PhD proposal, I intend to answer fundamental 
questions related to the development of enteric immunity due to oral administration of B. 
subtilis spores followed by formation of an intestinal biofilm as the main factor for 
immunization. The model target used for this purpose is the tapeworm E. granulosus. To 
achieve these goals, the spores from recombinant bacteria need to retain their tenacity, 
which is necessary to bypass the stomach. Then, they must maintain their ability to 
germinate and replicate in the gut. Finally, they need to express enough antigen of interest 
in an immunizing form to stimulate a local immune response. To address these issues, I 
have subdivided my work into the following steps, each of which can be tested by a 
formal hypothesis: 
 
Hypothesis 1: Recombinant B. subtilis spores, compared to wild type spores, are not 
altered in their tenacity and shelf life at room temperature. 
Hypothesis 2: Recombinant B. subtilis spores can bypass the stomach of mice and dogs.  
Hypothesis 3: Recombinant B. subtilis spores can germinate in the intestine of mice and 
dogs and can express the TasA-antigen fusion protein, forming an intestinal biofilm.  
Hypothesis 4: Mice and Dogs develop, after oral administration of recombinant B. 
subtilis spores, a specific humoral and cellular immune response against selected E. 
granulosus antigens (EgTrp and EgA31) fused to TasA. 
Hypothesis 5: The oral administration of combined dose of recombinant B. subtilis 
spores for EgTrp and EgA31 will induce an exacerbated humoral and cellular immune 
response.  
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Materials and Methods 
B. subtilis strains 
A list with the B. subtilis strains used in this study and its origins is showed in 
Table 1.  
Table 1. B. subtilis strains used in this thesis 
Strain Genotype Reference/source 
168 Wild type domesticated Kolter Lab. Harvard 
Medical School 
NCIB3610 Wild type undomesticated Kolter Lab, Harvard 
Medical School 
∆tasA (CA017) tasA::KmR Vlamakis et al., 2008 183 
∆sinR (DS92) sinR::SpcR Romero et al., 2010 52 
∆tasA/∆sinR tasA::KmR; sinR::SpcR This study 
TasA-mCherry(CA113) AmyE::yqxM-sipW-tasA-mCherry ; 
CmR 
Romero et al., 2010 52 
∆tasA/TasA-mCherry tasA::KmR; AmyE::yqxM-sipW-tasA-
mCherry ; CmR 
This study 
∆sinR/TasA-mCherry sinR::SpcR; AmyE::yqxM-sipW-tasA-
mCherry ; CmR 
This study 
∆tasA/∆sinR/TasA-mCherry tasA::KmR; sinR::SpcR; AmyE::yqxM-
sipW-tasA-mCherry ; CmR 
This study 
∆tasA/∆sinR tasA-sinR::KmR This study 
∆tasA/∆sinR/TasA-(102-
207)EgTrp 
tasA-sinR::KmR; AmyE::yqxM-sipW-
tasA-(102-207)EgTrp; SpcR 
This study 
∆tasA/∆sinR/TasA-(102-
278)EgTrp 
tasA-sinR::KmR; AmyE::yqxM-sipW-
tasA-(102-278)EgTrp; SpcR 
This study 
∆tasA/∆sinR/TasA-(170-
369)EgA31 
tasA-sinR::KmR; AmyE::yqxM-sipW-
tasA-(170-369)EgA31; SpcR 
This study 
∆tasA/∆sinR/TasA-(370-
583)EgA31 
tasA-sinR::KmR; AmyE::yqxM-sipW-
tasA-(370-583)EgA31; SpcR 
This study 
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Antibiotic concentration for B. subtilis strains 
The final concentration of antibiotic used for the B. subtilis strains are the 
following: spectinomycin (Spc) (100 µg/ml), kanamycin (Km) (10 µg/ml), erythromycin 
(MLS) (1 µg/ml), lincomycin (25 µg/ml) and chloramphenicol (Cm) (5 µg/ml).  
Plasmid constructions 
The plasmids pDG-TasA-(102-207)EgTrp, pDG-TasA-(102-278)EgTrp, pDG-
TasA-(170-369)EgA31 and pDG-TasA-(370-583)EgA31 were obtained by digestion of 
the plasmids pBS-TasA-(102-207)EgTrp, pBS-TasA-(102-278)EgTrp, pBS-TasA-(170-
369)EgA31 and pBS-TasA-(370-583)EgA31 with XhoI and BamHI to obtain the 
fragments TasA-(102-207)EgTrp, TasA-(102-278)EgTrp, TasA-(170-369)EgA31 and 
TasA-(370-583)EgA31, respectively. The fragments were ligated into pDG1730 184 
between XhoI and BamHI restriction sites. The plasmids pBS-TasA-(102-207)EgTrp, 
pBS-TasA-(102-278)EgTrp, pBS-TasA(170-369)EgA31 and pBS-TasA-(370-583) were 
obtained by PCR amplification of EgTrpA and EgA31 fragments from the constructs 
pQIA-EgTrp and pQIA-EgA31 185 using specific primers containing flanking NotI, 
BamHI and Smal restriction sites, followed by ligation between NotI and SmaI in pBS-
TasAop(SSSN). The plasmid pBS-TasAop(SSSN) was obtained by PCR amplification of 
TasAop fragment from pBS-TasA-mCherry 52 using specific primers containing XhoI and 
NotI restriction sites, followed by ligation between XhoI and NotI in pBS(SSSN). The 
plasmid pBS-MCS(SSSN) was obtained ligation of the annealed oligonucleotides (Fwd.: 
5'-ATGCCTCGAGGGATCCTCAGAGTTAAATGGTA-TTGCT-3' and Rev.: 5'-
GCATGCGGCCGCATTTTTATCCTCGCTATGCGC-3') between SalI and NotI 
restriction sites in pBluescript-KSII(+) (Stratagene).   
The plasmid constructs pQE32-mCherry, pQE32-EgA31, pQE32-EgTrp and pQE32-
TasA were obtained by PCR amplification of the fragments mCherry, EgA31 and EgTrp 
from pRSET-mCherry (Tsien lab), pQIA-EgA31, pQIA-EgTrp 175, and pET-TasA 52 
using specific primers containing flanking BamHI and HindIII restriction sites and ligated 
in frame between BamHI and HindIII in pQE32 (Qiagen). 
 
The long-flanking homology PCR (LFH–PCR) technique was used for creating deletion 
mutation, tasA-sinR	Kmr genes replacement, as described by Vlamakis et al., 2008 183. 
For this purpose, a joining PCR to create tasA-KmR-sinR was prepared from genomic 
DNA from B. subtilis NCIB3610 to amplify tasA with FtasAUP (5’-
ACAATAAGTCATGGCCGGA-3’) and RtasADO (5’-CCTATCACCTCAAATGG 
TTCGCTGGTTCGCTGGTTTAATACGCTGGCCAA-3’) and sinR with FsinRUP (5’-
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CGAGCGCCTACGAGGAATTTTATCGGCTCCC-CTTTTATTGAATG-3’) and 
RsinRDO (5’-TATGCCGGCTATATGCTT-3’). The KmR gene was obtained by 
amplification of genomic DNA from B. subtilis ∆tasA (CA017) strain 183 using the 
following primers FKmrUP (5’-CAGCGAACCATTT-GAGGTGATAGG-3’) and 
RKmrDo (5’-CGATACAAATTCCTCGTAGGCGCT-CGG-3’). B. subtilis 168 tasA-
sinR::KmR was used as donor strain for transferring the mutant allele into the B. subtilis 
strain NCIB3610 using SPP1-mediated generalized transduction 186. 
Oligonucleotides 
The primers utilized for the construction of the different plasmids are signaled in Table 2.  
 
Table 2: Primers used for plasmid construction. 
 
Transformation of B. subtilis  
B. subtilis strain 168 was transformed routinely as follow 187, bacteria were 
inoculated in 10 ml of LB medium and grown overnight at 37°C with agitation. After 
centrifugation (2000 x g) the bacterial pellet was resuspended in transformation medium 
Amplified segment Oligonucleotide sequences 
pBS-TasAop (SSSN) Fwd.: 5’-ATGCCTCGAGGGATCCTCAGAGTTAAATGGTATTGCT-3’ 
Rev.: 5’-GCATGCGGCCGCATTTTTATCCTCGCTATGCGC-3’ 
pBS-TasA-(102-
207)EgTrp 
Fwd.: 5’ ATGCGCGGCCGCCGAAACATCTACTAAGCTTGAC-3’ 
Rev.: 5’ GATCCCCCGGGGGGATCCTTACTCTTGCTCGGAGACTTC-
GAG-3’ 
pBS-TasA-(102-
278)EgTrp 
Fwd.: 5’ ATGCGCGGCCGCCGAAACATCTACTAAGCTTGAC-3’ 
Rev.: 5’ GATCCCCGGGGGATCCTCAGAAGGAAGTGAGCTCCGC-3’ 
pBS-TasA-(170-
369)EgA31 
Fwd.: 5’ ATGCGCGGCCGCCGCAGCT5GAAAAACAAGCCATG-3’ 
Rev.: 5’ GATCCCCGGGGGATCCTCACCTTGTTTCAAGCATTTCAAT-3’ 
pBS-TasA-(370-
583)EgA31 
Fwd.: 5’ ATGCGCGGCCGCCGCTGAGACTAAAGAAATTAAT-3’ 
Rev.: 5’ GATCCCCGGGGGATCCTCAATCTCTTTCGAGCTGTTTGAT-3’ 
pQE32-mCherry Fwd.: 5’ GATCGAATTCATGGTGAGCAAGGGCGAGGAG-3’ 
Rev.: 5’ GATCGCGGCCGCTTACTTGTACAGCTCGTCCATGCC-3’ 
pQE32-EgTrp-(102-
278) 
Fwd.: 5’ GATCGGATCCTTGAAACATCTACTACTAAGCTTGAC-3’ 
Rev.: 5’ GATCCTGCAGTCAGAAGGAAGTGAGCTCCGC-3’ 
pQE32-EgA31 Fwd.: 5’ ATGCGCGGCCGCCGCTGAGACTAAAGAAATTAAT-3’ 
Rev.: 5’ GATCCCCGGGGATCCTCATAATGCGTCCTTTTCTTTTTT-3’ 
pQE32-TasA Fwd.: 5’ CGAGCGCCTACGAGGAATTTGTATCGGCTCCCCTTTTATTG-
AAT-3’ 
Rev.: 5’ TATGCCGGCTATAGCTT-3’ 
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(6 mM K2HPO4, 4 mM KH2PO4, 10 mM D-glucose, 100 mg/l casamino acids, 1.5 mM L-
glutamate, 300 mM sodium citrate, 4 mM ferric ammonium citrate, 0.3 mM MgSO4, 
0.025 mM tryptophan and 0.025 mM phenylalanine) to OD600 nm of 0.085 and let grow to 
early stationary phase until reaching OD600 nm of 1.25. Then, 1 ml of bacteria were mixed 
with 5 ng of plasmid DNA, and the tubes were rolled for 40 min at 37°C. The cells were 
plated on LB agar medium supplemented with antibiotics. The transformants were 
selected with the appropriate antibiotics for a double crossover recombination at 
the amyE locus 184. Thus, the positive clones were analyzed by direct PCR of the selected 
colonies. For this, each colony was resuspended in 15 µl lysis buffer (50 mM KCl, 0.1 % 
Tween20, 10 mM Tris-HCl pH 8.3) The PCR reaction was performed using the following 
primers for designated for pDG1730 plasmid constructions, pDG5’-F (5’-
ATAATTTTAAATGTAAGCGTT-3’) and pTasop-R (5’-CTGTAAAAGAAGC 
AAAAAAAAA-3’). The PCR was performed using the following ingredients in a total 
volume of 50 µl: 0.2 mM dNTPs, 150 µg of the forward and reverse primer, 0.3 µl Taq 
DNA polymerase, 1 µl DMSO, supplemented with ddH2O. The PCR was performed 
under the following conditions: 5 min at 95°C followed by 40 cycles of 30 s 95°C, 60 s at 
50°C and 90 s at 72°C and then followed by 10 min at 72°C and storage at 4°C until 
analysis by agarose electrophoresis. TapA operon-tasA-fusions were then transferred to 
NCIB3610 by SPP1-mediated generalized transduction 186. Briefly, B. subtilis 168 was 
inoculated in 3 ml of TY media (tryptone (10 g/l), yeast extract (5 g/l), NaCl (5 g/l), 10 
mM MgSO4, 100 µM MnSO4, pH 7.2) supplemented with antibiotics and incubated for 5 
hours at 37°C. Then, 200 µl of the culture was mixed with 100 µl of diluted SPP1 phage 
in TY media (10-3, 10-4 and 10-5), incubated for 15 min at 37°C and mixed with 3 ml TY 
top agar (TY media, 0.5 % agar), poured over TY agar plates (TY media, 1.5 % agar) and 
incubated overnight at 37°C. The plaques were collected, filtered (0.45 µm) and stored at 
-80°C. Then, 30 µl SPP1 lysed use to transduce 1 ml recombinant donor B. subtilis 168 
strain in 9 ml of TY media and incubated for 30 min at 37°C. Then, the culture was 
centrifuged for 7 min at 2000 x g, and the pellet was resuspended in 300 µl of TY media, 
seeded in LB-agar plates supplemented with antibiotics and incubated overnight at 37°C. 
Positive clones were selected as described above. The recombinant B. subtilis strains 
were stored at -80˚C in 15% glycerol in LB media. 
B. subtilis biofilm formation 
For experiments using biofilms of B. subtilis, a single colony from semi-solid LB 
agar with selective antibiotics was resuspended in LB media with antibiotics and grown 
to an OD600 nm to 1. Then, 2 µl were spotted on 25 ml MSgg (5 mM potassium phosphate 
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(pH 7), 100 mM morpholine propane sulfonic acid (MOPS; pH 7), 2 mM MgCl2, 700 µM 
CaCl2, 50 µM MnCl2, 50 µM FeCl3, 1 µM ZnCl2, 2 µM thiamine, 0.5% glycerol, 0.5% 
glutamate, 50 µg/ml tryptophan, 50 µg/ml phenylalanine, and 50 µg/ml threonine, 1.5% 
agar 50) semi-solid agar plates, let dry at RT and incubated at 30°C for the indicated times. 
 
Quantification of fluorescence in B. subtilis biofilms  
The strains B. subtilis wild type, TasA-mCherry, ∆tasA/TasA-mCherry, and 
∆tasA/∆sinR/TasA-mCherry were allowed to form biofilms as described above. At 24, 
48, and 72 h post-inoculation, the biofilms fluorescence (photon/sec) and area (mm2) 
were measured using Synergy HT, Biotek, Germany. The data correspond to the mean ± 
SEM from three different biofilms for each tested B. subtilis strain. The plot was 
performed using Microsoft Excel for MAC: 2011, version 14. 5. 8 software. 
 
B. subtilis spore preparation 
B. subtilis spores were prepared following an adapted protocol from Nicholson 
and Setlow 188. Briefly, a colony of B. subtilis was inoculated in 3 ml LB media 
supplemented with antibiotics (spectinomycin (Spc) (100 µg/ml), kanamycin (Km) (10 
µg/ml) and MLS: erythromycin (1 µg/ml) and lincomycin (25 µg/ml) and 
chloramphenicol (Cm) (5 µg/ml)) and incubated at 37°C for 18 h on a horizontal shaker 
at 180 rpm. The inoculum was expanded in 500 ml LB media in a 2 L Erlenmeyer flask 
and let grow for 12 h at 37˚C in a shaker at 180 rpm. Afterward, 50 ml of the culture were 
diluted in 500 ml Difco sporulation media (DSM) contained in a 2 L Erlenmeyer Flask 
(bacto nutrient broth 8 g/L, KCl 1 g/L and MgSO4 0.25 g/L, autoclaved and allow to cool 
down to 50°C. To 1 L of this solution, 1 ml of each of the following filter sterilized 
solutions were added: 1 M Ca(NO3)2, 10 mM MnCl2 and 1 mM FeSO4 188. As a routine, 4 
L of DSM were prepared for each spore stock. The culture was incubated for 72 h at 37°C 
on a horizontal shaker at 180 rpm. The spores were harvested by centrifugation at 14'000 
x g, for 10 min and 4˚C; further, the supernatant decanted and the pellet heated for 30 min 
at 80°C. The pellet was resuspended in ten volumes of 1 M KCl / 0.5 M NaCl and 
centrifuged at 14'000 x g, for 10 min and 4˚C. The supernatant was decanted and the 
pellet resuspended in ten volumes of 50 mM TrisCl pH 7.2 and lysozyme [50 µg/ml], 
incubated for 60 min at 37°C and centrifuged at 14'000 x g, for 10 min and 4˚C. The 
pellet was resuspended in ten volumes of 1 M NaCl and centrifuged at 14'000 x g, for 10 
min and 4˚C. Next, two turns of centrifugation and pellet resuspension were washed in 
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ten volumes of deionized water. Finally, the pellet was resuspended in 3 ml deionized 
water and stored at -80°C until use. The spores were titrated by diluting 20 µl of spore 
resuspension in 180 µl PBS (AccuGene, Lonza) and further serially diluted from 10-1 to 
10-12. A 10 µl drop from each spore dilution was inoculated over an LB media agar with 
antibiotics plate and let disperse vertically in the dish. The plates were incubated for 18 
hours at 37˚C, and the number of colonies for each dilution was determined. The spore 
titer was determined as the colony forming units (CFU) per ml and calculated using the 
following formula: 
 !"# $% = ((°	+,%,(-./×1-%23-,(45) 7,%2$.	-(	$% 
Determination of the sporulation ability from B. subtilis biofilm 
The ability of recombinant B. subtilis to sporulate in a biofilm was determined as 
described by Vlamakis et al., 2008 183. Briefly, B. subtilis cultured in LB media were 
diluted to OD600 nm of 1, and 10 µl of the suspension (in duplicated) were inoculated over 
2.5 ml of MSgg media in 12 well plates. The plates were incubated at room temperature 
with no agitation.  Samples of cells were taken after 48 h and subjected to mild sonication 
conditions (10 sec at 14 m Amplitude) to obtain single cells. The optical density of each 
preparation was normalized to OD600 nm of 1 after sonication. The normalized preparations 
were incubated for 20 min at 80°C to kill vegetative cells. The viable spore counts were 
determined by serial dilutions plated from the normalized preparation after the 80°C 
incubation.  
 
 
Immunoblotting 
Protein detection was performed by immunoblotting 189,190. Biofilm in MSgg agar 
was harvested at 72 h into in 500 µl deionized water followed by homogenization by 
sonication. Samples were normalized to OD600 nm to 1. Then, 20 µl of normalized sample 
was mixed with 5 µl sample buffer (8% SDS, 40% Glycerol, 200 mM Tris pH 6.8, 4% 2-
mercaptoethanol, 0.4% Bromophenol blue) and heated for 5 minutes at 95°C. Samples 
were loaded on an SDS-polyacrylamide gel (SDS-PAGE) 191. The proteins were 
transferred to the nitrocellulose membrane (Amersham Protran 0.45 µm NC, GE 
Healthcare, #10600002) at 200 mA for 2 h in a wet tank Trans-Blot® cell (BioRad) 
containing Laemmli transfer buffer (for 1 L, pH 8.3: 3 g Tris Base, 14.4 g Glycine and 
200 ml ethanol in deionized H2O). The membrane was blocked for 30 min at room 
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temperature in blocking buffer (PBS, + 5 % nonfat milk). The primary and secondary 
antibodies were incubated at the indicated dilutions (Table 3) in blocking buffer for 2 h at 
room temperature on a teeterboard. The membrane was washed three times with blocking 
buffer between the antibodies and developing. The membrane was cleared with PBS and 
developed by using ECL western developing solution (Pierce™ ECL Western Blotting 
Substrate, ThermoScientific) and films (Lumi-Films, Roche, #11 6666 657 001). The 
exposed films were then developed using an RGII Fuji X-ray film processor and scanned 
for figure preparation. 
 
Table 3: List of antibodies 
Antibody name Dilution Used in Origin 
Rabbit polyclonal anti-TasA 1:20’000 WB, ELISA A.F. Pétavy, Lyon 
Rabbit polyclonal anti-TasA 1:1000 IF A.F. Pétavy, Lyon 
Mouse polyclonal anti-EgTrp 1:4000 WB, ELISA A.F. Pétavy, Lyon 
Mouse polyclonal anti-EgA31 1:3000 WB, ELISA A.F. Pétavy, Lyon 
Rat anti-CD4 mouse conjugated 
to PE 
1:800 FC BioLegend, #116005 
Rat anti-CD8 mouse conjugated 
to PE/CY7 
1:600 FC BioLegend, #100721 
Rat anti-CD4 canine conjugated 
to PE/CY 7 
1:800 FC eBioscience, #25-5040-41 
Rat anti-CD8 canine conjugated 
to PerCP-eFluor710 
1:300 FC eBioscience, #46-5080-41 
Mouse anti-CD25 canine 
conjugated to FITC 
1:800 FC eBioscience, #11-0250-41 
Goat anti-Rabbit Alexa 594 1:500 secondary AB IF sigma, #A-11037 
Goat anti-mouse IgA-HRP 1:10’000 secondary AB ELISA sigma, #A-4789 
Goat anti-rabbit IgG-HRP 1:10’000 
secondary AB WB, 
ELISA 
sigma, #A0545 
Goat anti-canine IgG HRP 1:600 secondary AB ELISA sigma, #A6792 
Goat anti-canine IgA HRP 1:600 secondary AB ELISA Bethyl Lab., #A40-104P 
 
 
Preparation of recombinant proteins 
His6 tagged proteins were produced in E. coli M15[pREP14], as described by the 
manufacturer protocol. Briefly, pQE32 constructs were transformed into E. coli M15 
[pREP14], the isolated colonies were inoculated in 3 ml LB media supplemented with 
100 µg/ml ampicillin and incubated overnight in a shaker. After that 900 µl of fresh LB 
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media with 100 µg/ml ampicillin were incubated with 100 µl of the overnight culture for 
30 min at 37°C. Then the protein expression was induced by 1 µM Isopropyl β-D-1-
thiogalactopyranoside (IPTG, for 4 h at 37°C).  The bacteria were centrifuged (14'000 x 
g, 4°C) and the pellet was kept at 4°C and suspended in 6 ml freshly prepared lysis buffer 
(PBS, lysozyme 1 mg/ml, protease inhibitor (cOmplete® Roche, #04 693 159 001)). 
Then the suspension was incubated for 15 min on ice. After the incubation lauryl 
sarcosine (0.15 v/v %) and dithiothreitol (final concentration 5 mM) was added and the 
suspension was sonicated 6 times for 10 sec in ice. The lysate was centrifuged for 15 min 
and 14’000 x g at 4°C. The His6-tagged protein was then extracted using the PerfectPro 
Ni-NTA Agarose (5 Prime, #2400000), 0.5 ml of PerfectPro Ni-NTA was equilibrated 
with 2.5 ml (5 vol) of equilibration buffer (20 mM imidazole in PBS) and centrifugated at 
800 g for 2 min. The resin was loaded with the bacterial lysate and incubated for 2 h in a 
wheel at 4°C. The resin was washed once with 10 volumes of the following solutions: 
washing buffer 1 (50 mM NaH2PO4, 300 mM NaCl, 0.1% Triton100, 20 mM Imidazole), 
washing buffer 2 (50 mM imidazole in washing buffer 1) and washing buffer 3 (100 mM 
imidazole in washing buffer 1). Each washing step was performed for 30 min in a turning 
wheel at 4°C. The His6-tagged protein was eluted from the resin with 2 volumes of 
elution buffer (50 mM NaH2PO4, 400 mM NaCl, 0.1% Triton100, 250 mM Imidazole) for 
1 h at 4°C. The purified protein was dialyzed using snake skin® (Dialysis Tubing, 
Thermo Scientific, #88242). Every 2 h, the dialysis buffer was changed by dialysis buffer 
1 (50 mM NaH2PO4, 400 mM NaCl, 0.1% Triton 100), dialysis buffer 2 (50 mM 
NaH2PO4, 350 mM NaCl) and dialysis buffer 3 (50 mM NaH2PO4, 300 mM NaCl) in 200 
volumes and 4˚C. The dialyzed protein was stored in 30 % glycerol at 4°C. The purity 
and the concentration of the recombinant protein were assessed by Coomassie blue 
staining in SDS-PAGE and confirmed by immunoblot using specific antibodies. 
The Coomassie blue stained SDS-PAGE were digitalized using the transilluminator 
(BioRad), and the bands were analyzed by densitometry using ImageJ64 (version 1.48v, 
NIH, USA). A calibration curve was performed using known amounts of BSA. 
For further confirmation of the selected proteins (H6-EgA31 and H6-EgTrp) were 
analyzed by mass spectrometry at the functional genomics center of the University of 
Zurich. 
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Characterization of the spore stability 
Shelf life of spores 
B. subtilis spores were diluted in deionized water to 107 CFU/ml, aliquoted in 300 
µl into screw lid tubes and stored at room temperature in the dark until analysis. A first 
aliquot was directly analyzed (sample day 0). For each measurement, an individual 
aliquot was used at the indicated time point (4, 8, 12, 16, 20 weeks). The CFU was 
determined as described above (B. subtilis spore preparation). The CFU for each time 
point was compared to the sample from day 0. The experiment was repeated three times 
independently, and an average number of CFU was determined. 
 
 
Heat stability test for spores 
B. subtilis spores were diluted in deionized water to 108 CFU/ml and aliquoted in 
300 µl into screw lid tubes. The reference sample was not heat-treated and remained at 
room temperature for further analysis. The samples were heated 30 min to the following 
temperatures: 85°, 95°, 99°, 121°C. The spores serially diluted and CFUs were counted 
on semi-solid LB agar plates after incubation at 37˚C. The experiment was repeated three 
independent times, and an average of the percentage of germinated spores compared to 
the untreated samples was determined.  
 
PH resistance test for spores 
B. subtilis spores were diluted in deionized water to 105 CFU/ml and aliquoted in 
300 µl into screw lid tubes. The reference sample was treated as the other samples but 
with PBS at pH 7. The samples were treated with different pH 3, 2 and 1. The spores 
were suspended in a phosphate buffered saline solution adapted by HCl to the indicated 
pH. For this, the samples were centrifuged for 5 min 10'000 x g, and the supernatant was 
removed. The samples were then resuspended in 500 µl of PBS HCl with the 
corresponding pH. The samples were kept for 2 h at 37°C. After the samples had been 
washed twice with 500 µl PBS and suspended in 300 µl PBS, the spores were serially 
diluted and determined the CFU on semi-solid LB agar plates. The pH stability was 
expressed as the percentage of CFU compared to the corresponding pH 7 sample. The 
experiment was repeated for three independent times and the average percentage of CFU 
compared to the samples treated at pH 7.  
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Transmission electron microscopy of spores 
Freshly prepared B. subtilis spores were frozen by high-pressure freezing, freeze 
substituted (FS 7500, Boeckler Instruments) with acetone containing 0.25 % 
glutaraldehyde and 0.5 % osmium tetraoxide at temperatures between -30°C and + 2°C as 
described in detail by Wild et al. 192 and then embedded in epon. The sections of 50–60 
nm thickness were stained with uranyl acetate and lead citrate. The samples were 
analyzed by the transmission electron microscope (CM12, Fei) equipped with a CCD 
camera (Ultrascan 1000, Gatan) at an acceleration voltage of 100 kV. The pictures were 
analyzed using Fiji software 193–196. 
 
 
 
 
Biofilm immunohistochemistry 
Biofilms were grown for 72 h in MSgg-agar media. The biofilm was excised 
from the agar vertically using a surgical blade. The biofilm was oriented in the paraffin 
embedding in a manner that later semi-thin cuts of the biofilm in the paraffin block were 
vertical cuts of the biofilm. The semi-thin cuts were mounted on glass slides and then 
deparaffinized using two changes in xylene, 5 min each followed by transfer of the slides 
to xylene: alcohol (1:1) for two changes of 3 min each. Then the slides were transferred to 
successive washes of 95%, 70% and 50% alcohol, rinsed in PBS and blocked in 5% BSA-
PBS (Bovine serum albumin fraction V, AppliChem) in a humid chamber. The samples 
were incubated with 100 µl of the primary antibody (rabbit anti-tasA, 1:1000) for 90 min 
a humid chamber at room temperature. Next, the samples were washed twice for 3 min in 
PBS-0.025 % TritonX-100, followed by two washes of 3 min in PBS. Then, the samples 
were incubated with 100 µl of 300 nM DAPI (4',6-diamidino-2-phenylindole) for 10 min 
in a humid chamber at room temperature and washed for two times (3 min) using PBS. 
The samples were incubated with the secondary antibody diluted in 150 µl (anti-rabbit 
Alexa Fluor 488, 1:500 in PBS-BSA 1%) for 60 min in a humid chamber at room 
temperature. The samples were washed twice with PBS, mounted in Prolong Diamond 
(Molecular Probes) and covered by a cover glass-slide. The histological samples were 
analyzed within 6 h after mounting, and images were acquired using a fluorescent 
microscope (LEICA DMI 6000B).  
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Animal experiments 
Mouse experiments 
All the mouse experiments were performed according to the guidelines of the 
animal experimentation law (SR 455.163; TVV) of the Swiss Federal Government. The 
protocols were approved by the Cantonal Veterinary Office with the following animal 
experimentation number 104/2012 (Annex I). 
 
Schedule of mouse experiments 
Mice were treated three times by oral gavage on days 1, 21 and 42 of the 
experiment. The experiments were terminated on day 50 through mice euthanasia by 
isoflurane sedation and neck dislocation. Mice were dosed intragastrically with 5 x 1010 
spores diluted in a final volume of 0.2 ml of saline solution (PBS). Each mouse 
experiment had the following experimental groups: placebo (0.2 ml saline solution), 
background B. subtilis spores (∆tasA/∆sinR) and recombinant B. subtilis spores. Blood 
and feces samples were collected before each oral gavage and on day 50. The feces 
samples were collected for 6 days after the first immunization, during the antibiotics 
treatment and before each of the subsequent immunizations and in day 50. Blood samples 
were collected by tail bleeding the day before each immunization and at day 50. When 
terminating the experiments on day 50 T cells were isolated from the spleen, mesenteric 
lymph nodes, and Peyer's patches. During the experimental procedure, mice were 
grouped by six animals per cages, with food and drinking water ad libitum. The mice 
were kept exclusively in company with animals receiving the same treatment. For the 
collection of feces of a single mouse, animals were kept in single cages during the 
harvesting period. The mice health status was monitored by following their body weight 
during the experimental period.  
 
Antibiotic treatment for microflora eradication 
When indicated, mice were treated an antibiotic cocktail for the elimination of the 
gut microflora and performed as described by Shan et al.197. Briefly, the following 
antibiotics were diluted in the autoclaved drinking water: ampicillin [0.5 mg/ml] 
(Panreac), gentamycin [0.5 mg/ml] (Panreac), vancomycin [0.25 mg/ml] (Alfa Aesar), 
metronidazole [0.5 mg/ml] (Alfa Aesar), sucrose [20mg/ml] (Sigma). The duration and 
frequency of the antibiotics administration were set to 7 days for the first experiment and 
reduced for the further experiments to 3 days. 
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Blood analysis in mouse experiments 
The blood was collected using micro trainer SST tubes (Beckton, Dickinson and 
Company, NJ USA) and processed according to the manufacturer's protocol. In brief, the 
blood was incubated at room temperature for 30 min to allow coagulation. The serum was 
separated from the clot by centrifugation (1000 x g, 3 min) and transferred into new tubes 
(1.5 mL Eppendorf) for storage at -20˚C until analysis. 
  
Detection of specific humoral immune response by ELISA 
Specific antibody content in blood serum was detected using indirect enzyme-
linked immune absorbent assay (ELISA). Briefly, 100 ng of purified recombinant 
proteins histidine-tagged Echinococcus granulosus tropomyosin (H6-EgTrp), histidine-
tagged Echinococcus granulosus paramyosin (H6-EgA31), histidine-tagged TasA (H6-
TasA), histidine-tagged mCherry (H6-mCherry). Alternatively, homogenates (OD600 nm = 
2*10-4) of biofilms (72 h incubated) from recombinant B. subtilis strain 
∆tasA/∆sinR/TasA-(102-207)EgTrp and ∆tasA/∆sinR/TasA-(370-583)EgA31 in coating 
buffer (30 mM Na2CO3, 70 mM NaHCO3 adjusted to pH 9.6) were used to coat immune 
absorbent 96-well plates (MaxiSorp Polystyrene ThermoScientific) for 16 h at 4°C. Plates 
were washed three times with 400 µl PBS with 0.05 % Tween 20 and then blocked for 2 
h with 200 µl blocking solution (1 % bovine serum albumin (BSA) in PBS). Blood serum 
(100 µl diluted to 1:100 in 1 % BSA-PBS) were incubated for 2 hours at 37°C in a humid 
chamber. Then, the plates incubated with 100 µl secondary antibody conjugated to 
peroxidase for 30 min at 37°C in a humid chamber (Table 3). After, each incubation with 
antibodies (primary and secondary) the plates were washed three times as described 
above. To reveal the plates using colorimetric substrate as is the TMB reagents (Pierce™ 
TMB Substrate Kit, ThermoFisher) by adding 50 µl per well. The colorimetric reaction 
was monitored by reading absorbance at OD600 nm, and the reaction was stopped when the 
highest value reached OD600 nm to 1.5 with 50 µl H2SO4 1 M. The OD450 nm was read out 
using a multi-spectrometer (SLT 340 ATTC Tecan). The obtained data were analyzed 
using Excel software (Mac2011, 14.5.8, Microsoft). The average value of two 
independent ELISA plates with the same loading was determined and plotted using Prism 
software (%.0d for Mac, GraphPad). For the statistical analysis see the corresponding 
section.   
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Detection of humoral immune response from mouse feces 
Feces were collected over periods of 24 h from mice isolated in single cages and 
stored at -20°C until analysis. The feces were resuspended in PBS (5 ml PBS/ g feces) 
and homogenized 30 s by vortex to analyze the spore content and the specific IgA 
immune response. The resuspended samples were centrifuged (800 x g, 10 min) and the 
supernatant was recovered for further analysis. For the testing, the IgA content in feces, 
360 µl of the supernatant was mixed with 40 µl feces buffer (1 % BSA, 0.01 % 
Triton100, 0.1 % 2-mercaptoehtanol and one tablet for each 7 ml PBS protease inhibitor 
(cOmplete™ EDTA-free protease inhibitor cocktail tablets, Roche)) and stored in ice. 
100 ng of purified recombinant proteins H6-EgTrp, H6-EgA31 and H6-TasA or 
homogenates (OD600 nm = 2*10-4) of biofilms (incubated for 72 h) from B. subtilis strains 
TasA-(102-207)EgTrp or TasA-(370-583)EgA31 were used to coat immune absorbent 
plates, as described above. The plates were washed three times with 200 µl 0.05 % Tween 
20 in PBS and blocked for 2h with 200 µl blocking solution (1% bovine serum albumin in 
PBS). 100 µl per well of feces supernatant were incubated for 2 hours at 37°C in a humid 
chamber. The plates were washed for three times as above and then incubated with 100 µl 
per well of goat anti-mouse IgA conjugated to peroxidase (Sigma, #A4789), diluted in 
1:600 in 1% BSA-PBS, for 60 min at 37°C in a humid chamber. Plates were developed 
using TMB substrate and data analyzed as described above (Detection of specific 
humoral immune response by ELISA).  
Spores from mouse feces analysis  
To analyze the spore content in feces and to eliminate vegetative cells 300 µl of 
the feces supernatant were heated 20 min at 80°C. Then, samples were serially diluted 
and plated on selective semi-solid LB-agar Kanamycin as described by Vlamakis et al. 
183. The obtained colonies were counted for the two highest dilutions containing colonies. 
The following formula was used to determine the number of spores per feces weight in 
grams. !"#8.+./	[:] = ((°	+,%,(-./×1-%23-,(45) 8.+./	[:] 
T cell proliferation assay by CFSE dilution 
For the isolation of T cells from fresh spleen and a mixture of mesenteric lymph 
nodes (MLN) and Peyer's patches (PP), the tissues were dissected in pieces and mashed 
through a cell strainer into a petri dish (100 µm, BD Falcon #352360) to obtain single 
cells suspension. 
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The isolated mixture of MLN and PP cells were negatively sorted using magnetic 
EasySep™ Mouse T Cell Isolation Kit (StemCells # 19851). Thus, negative cells for the 
following cell surface markers: CD11b, CD11c, CD19, CD24, CD25, CD44, CD45R, 
CD49b, TCRγ/δ, and TER119 were selected using the manufacturer's instructions. 
Briefly, the cells were diluted in RPMI 1640 media to 1 x 108 cells/ml, and 50 µl/ml of rat 
serum were added to reduce unspecific binding of the antibody cocktail. 100 µl of the cell 
suspension were added to 400 µl of RPMI1640 media. Next, the antibody cocktail was 
added (25 µl) and incubated for 7.5 min at room temperature. Subsequently, a depletion 
cocktail (25 µl) consisting of specific anti-mouse conjugated antibodies against the cell 
markers CD11b, CD11c, CD19, CD24, CD25, CD44, CD45R, CD49b, TCRγ/δ, and 
TER119 was added and incubated for 2.5 min at room temperature. Finally, the magnetic 
beads (50 µl) binding to the conjugated antibodies were added and incubated for 2.5 min 
and placed over a magnetic plate for to 2.5 min to accelerate sedimentation of non-T cells 
previous to the supernatant collection. Then, the cells obtained from the supernatant were 
washed once with 5 ml RPMI 1640 followed by two washes with 5 ml PBS. Each 
washing step included the cell suspension in the solution by pipetting 5 times the 
suspension up and down followed by the centrifugation (10 min at 800 x g) and the 
removal of the supernatant by pipette.  
The spleen cells were washed once with 5 ml RPMI 1640 (Gibco) and density selected 
for T cells using a HistopaqueR 1077 (Sigma) density cushion. For that, 5 ml of cell 
suspension were loaded over 5 ml of HistopaqueR 1077 and centrifugated for 10 min at 
800 x g with no brakes. The cells from the top fraction were collected and washed once 
with 5 ml RPMI 1640 and two times with 5 ml PBS. 
The T cells isolated from spleen, MLN and PP were stained with 1 ml of 1 µM of 
Carboxyfluorescein succinimidyl ester (CFSE) in PBS for 10 min at 37°C. Afterward, the 
cells were washed three times. Suspension of the cells with 5 ml RPMI1640 10% FCS, 
penicillin (50 units/ml), and streptomycin (50 µg/ml) (Gibco) and centrifugation for 10 
min at 800 x g. Then the cells were seeded in a 96 multiwell with low adherence U-
bottom plates (Falcon) at a density of 5x104 cells per well. Each experimental point was 
seeded in triplicate and stimulated with one of the following reagents: 50 ng/well of 
PMA, 100 ng/well of purified H6-TasA, 100 ng/well of purified H6-EgTrp or 100 ng/well 
H6-EgA31. All the stimulating agents were diluted in cell culture medium (RPMI 1640, 
10% FCS, penicillin (50 units/ml), and streptomycin (50 µg/ml)). The cells were 
incubated for four days (37°C, 5% CO2) and then analyzed by flow cytometry as 
described below. 
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Flow cytometry 
Previous to the acquisition, the proliferating T cells were stained with the surface 
markers anti-CD4 and anti-CD8 antibodies directly conjugated to PE and PE/CY7, 
respectively (Table 3) and incubated for 15 min at 4°C in the dark. The cells were 
transferred to 5 ml analysis tubes (Greiner Bio-one), washed with 2 ml of PBS, 
centrifuged for 10 min at 800 x g and resuspended in 500 µl of PBS. The samples were 
kept at 4°C until acquisition. Thus, the samples were acquired using a Gallios flow 
cytometer (Beckmann Coulter) with the following settings: Forward Scatter Excitation 
(FSC) [(Ex): 488 nm, 862 Volt (V), gain 7.5]; Side Scatter (SSC) [Ex: 488 nm, 650 V, 
gain 2]; FL1 [Ex: 488 nm, 450 V, gain 1]; FL6 [Ex: 638 nm, 647 V, gain 1] and FL9 [Ex: 
405 nm, 572 V, gain 1]. The obtained data were analyzed using the Kaluza analysis 
software (Beckmann Coulter) by setting gates in the manner to get single cell populations 
and that in the further gates the 99 % of negative control cells remained outside for the 
gated CD4+ CD8+ T cells populations. Thus, the gated cells were analyzed for 
proliferation monitoring CFSE signal intensity.  <.=+.(3>:.	,8	?=,%-8.=>3-(:+.%%/ = />$?%.	?=,%-8.=>3-(:	+.%%/<@A	/3-$2%>3.1	?=,%-8.=>3-(:	+.%%/ ∗ 100 
So then the result plotted in Prism (5.0d for Mac, GraphPad). 
Statistics of mouse experiments 
Statistical analyses were performed by Prism software (5.0d for Mac, GraphPad) 
or Microsoft®Excel for Mac 2011, version 14.6.0 where indicated. The statistical 
differences with p-value < 0.05 were considered as significant. For the ELISA analysis, a 
Friedman-Test was applied followed by a Dunns post-test in inner group comparisons. 
Also, Kruskal-Wallis-Test followed by a Dunns post-test was used when the mean of the 
same time point but two different groups were compared. 
The statistical analyses for body weight of the mice and the cellular immune response 
were obtained using one-way ANOVA followed by Tukey's post-test multiple 
comparison tests from Prism software. 
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Dog experiments 
All the dog experiments were performed according to the guidelines of the animal 
experimentation law (SR 455.163; TVV) of the Swiss Federal Government. The protocols 
were approved by the Cantonal Veterinary Office with the following animal 
experimentation number 100/2010 (Annex II). 
 
Schedule of dog experiments 
The dogs were immunized through oral administration with recombinant spores 
of B. subtilis on days: 1, 21 and 42. Blood samples were collected weekly starting one 
day before the first oral gavage. A total of eight animals were included in this experiment. 
The animals were euthanized on day 50 for the collection of the spleen, the mesenteric 
lymph nodes, the Peyer's patches, the intestinal fractions, and the intestinal content. For 
identification, the animals were tagged before weaning through the implantation of a 
transponder, as denoted by their identification number showed in Table 4. The dogs were 
kept in groups of three animals per cage. During the whole experimental procedure, the 
animals were provided water and food in amounts appropriated to their age and size. 
According to the Swiss schedule for dogs vaccination, all the dogs were vaccinated at the 
age of 13 weeks against leptospirosis, canine distemper, canine hepatitis, parvovirus 
infection and parainfluenza viruses (Canigen L Virbac and Canigen SHA2PPi). 
The eight dogs were distributed in four experimental groups receiving (details in Table 
4): i) placebo (saline solution), ii) 2.5x1010 CFU recombinant spores B. subtilis (102-
207)EgTrp and 2.5x1010 CFU recombinant spores B. subtilis (102-278)EgTrp, iii) 5x1010 
CFU recombinant spores B. subtilis (370-583)EgA31 and iv) mixture containing 2.5x1010 
CFU recombinant spores B. subtilis (102-207)EgTrp and 2.5x1010 CFU recombinant 
spores B. subtilis (370-583)EgA31.  
The dog experiment was performed in two separate rounds, having in the first round the 
two dogs receiving spores of the EgTrp strain and one of the placebo included. The 
remaining dogs were included in the second experiment round. This because of the 
insufficient number of dogs available at the first starting time point. 
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Table 4: Dogs identification numbers, gender, room localization and spores assignment 
Transponder N˚ Gender Treatment Room N˚ 
756 0981 0061 6715 female Placebo 1 
756 0981 0061 7019 male EgTrp 1 
756 0981 0061 7005 female EgTrp 1 
756 0981 0055 6689 male Placebo 2 
756 0981 0055 6696 male (370-583)EgA31 3 
756 0981 0055 6674 female (370-583)EgA31 2 
756 0981 0055 6710 male mix 3 
756 0981 0055 6720 female mix 2 
 
Additionally, the dog's health status (body weight, body temperature, and general health 
signs as the gingiva, behavior and feces consistence) was monitored daily or weekly by 
the animal caretakers or a veterinarian physician, respectively. 
Oral administration 
The recombinant B. subtilis spores were diluted in 1 ml of cat milk (Whiskas® 
Mars, Virginia USA) to facilitate the dog swallow. The control group received only 1 ml 
of cat milk. The oral gavage with the B. subtilis spores was performed in morning hours 
after feeding the dogs.  
Blood collection and purification of serum and peripheric lymphocytes 
Blood samples were collected weekly from the jugular vein using CPT™ 
Vacutainer® blood collection tube (BD), according to manufacturer's instructions. Thus, 
permitting the separation of lymphocytes and monocytes from plasma and erythrocytes to 
be used for CFSE proliferation assay. Also, the collected plasma was used for detection 
of systemic humoral response and stored at -20°C until analysis. 
 
Detection of specific humoral immune response by ELISA 
For the analysis 100 ng of purified recombinant proteins H6-EgTrp, H6-EgA3, H6-
TasA, H6-mCherry or homogenates (OD600 nm = 2*10-4) of biofilms (72 h incubated) from 
recombinant B. subtilis strain ∆tasA/∆sinR/TasA-(102-207)EgTrp and 
∆tasA/∆sinR/TasA-(370-583)EgA31 in coating buffer (30 mM Na2CO3, 70 mM NaHCO3 
adjusted to pH 9.6) were used to coat for 16 h at 4°C immune absorbent 96-well plates 
(MaxiSorp Polystyrene ThermoScientific). The plates were washed three times with 400 
µl 0.05 % Tween 20 in PBS and blocked for 2 h with 200 µl of blocking solution (1 % 
BSA in PBS). Next, the blocking solution was discarded, and the wells were incubated 
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with 100 µl serum diluted 1:10 in blocking solution during 2 h at 37°C in a humid 
chamber. The plates were washed three times with 0.05 % tween20 in PBS and incubated 
with the anti-canine IgG HRP and anti-canine IgA HRP respectively (Table 3) for 60 min 
at 37°C in humid chamber. After washing three times the plates with 0.05 % tween20 in 
PBS, the ELISA was developed by adding 50 µl per well TMB substrate (Pierce™ TMB 
Substrate Kit, ThermoFisher). The colorimetric reaction was monitored by reading 
absorbance at OD600 nm, and the reaction was stopped when the highest values were 
reaching OD600 nm to 1.5 with 50 µl H2SO4 1 M. The OD450 nm was read out using a multi-
spectrometer (SLT 340 ATTC Tecan). The data obtained were analyzed using 
Microsoft®Excel for Mac 2011, version 14.6.0. The background absorbance was 
subtracted from all values. An average was obtained for two independent identical plates 
for each of the measured samples. The PI for each animal was considered as a threshold 
and hence, subtracted from each measurement per dog. Only obtained values from plates 
coated with the recombinant proteins and the biofilm homogenate that were higher than 
those values obtained from plates coated with H6-mCherry were considered as positives.  
 
Dog necropsy 
The dogs were euthanized by the veterinarian physician. The procedure was 
performed through intravenous administration of acepromazine 0.1 ml/10 kg 
(Prequillan™, AROVET AG) and second three overdosed of intravenous barbiturate 
(sodium pentobarbitone) at 80 mg/kg of dog 198.  
The following samples were collected at necropsy: blood for the analysis of the cellular 
immune response analysis. Further samples of the duodenum, jejunum, ileum, cecum and 
colon were knotted using a thread in sections of 2 cm in length and knotted on both sides 
to prevent the loss of intestinal content. For each section of the intestine, one sample was 
frozen in liquid nitrogen and stored for further analysis at -80°C. Another sample was 
collected and stored in formalin 4% and further processed for paraffin semi-thin 
sectioning for histological analysis. The remaining parts of the small intestine of the two 
dogs receiving the mixtures of spores were flushed with PBS for analysis of the content 
of recombinant bacteria as described below. Samples from the spleen, MLN and Peyer's 
patches were collected into RPMI 1640 and kept on ice and processed for analysis within 
3 hours. 
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Analysis of the intestinal content for the detection of recombinant Spores  
The small intestine was dissected in duodenum, jejunum, and ileum. Each section 
was perfused by vigorous flushes with PBS to collect the intestinal content in a flask. 
Then, the intestinal content was centrifuged at 14'000 x g and 20°C for 15 min. The 
supernatant was discarded, and the pellet resuspended in 20 ml PBS and centrifuged at 
1'500 x g for 10 min at 20˚C. The supernatants were collected and centrifuged at 14'000 x 
g for 15 min and 20˚C. The pellet was resuspended in 3 ml of PBS. Then, 20 µl of each 
suspension were used for serial dilution in PBS from 1 to 10-6. 10 µl of each dilution were 
plated on selective semi-solid LB-kanamycin plates (10 µg/ml) and incubated for 36 h at 
37°C. The colonies were counted, and the amount of CFU/mL was calculated as 
described in the mouse section. 
To characterize the colonies isolated from the intestinal content specific PCR was 
performed. Thus, the colony was resuspended in 15 µl lysis buffer (50 mM KCl, 0.1 % 
Tween20, 10 mM Tris-HCl pH 8.3) and were heated to 99°C for 10 min. Next PCR mix 
(0.2 mM dNTPs, 150 ng of the forward and reverse primer, 0.3 µl Taq DNA polymerase, 
1µl DMSO) was added over 5 µl of the lysate of the bacteria. The used internal primers 
were for detection B. subtilis recombinant EgTrp strains: forward 5’-
ATGCGCGGCCGCCATTATGATGGCAATGAAATTG-3’ and reverse 5’-
GATCCCCGGGGGGATCCTTACTCTTGCTCGGAGACTTCGAG-3’, and for B. 
subtilis recombinant strains EgA31: forward 5’-ATGCGCGGC 
CGCCGCAGCTGAAAAACAAGCCATG-3’ and reverse 5’-GATCCCCGGGGG 
ATCCTCACCTTGTTTCAAGCATTTCAAT-3’. The PCR was performed with the 
following conditions: 5 min at 95°C followed by 40 cycles of 30 s at 95°C, 30 s at 52°C 
and 1 min at 68°C and conducted with 10 min of elongation at 68°C. The PCR samples 
were analyzed in an agarose electrophoretic gel for migration pattern. 
 
T cell proliferation Assay 
The tissue samples were dissected into pieces and passed through a cell strainer 
(100 µm, BD Falcon #352360) to obtain a single cell suspension. The cells were next 
density selected using a histopaque 1077 (Sigma) density cushion. The cell suspension 
was loaded over 5 ml of histopaque 1077 and centrifuged for 10 min at 800 x g without 
brakes. The top fraction above the histopaque 1077 was collected and twice washed using 
7 ml RPMI 1640 media and centrifuged at 800 x g for 10 min. Then the pelleted cells 
were twice washed using 5 ml PBS 1x and centrifuged (800 x g for 10 min). Next, the 
cells were stained with 1 µM of Carboxyfluorescein succinimidyl ester (CFSE) in 2 ml 
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PBS for 10 min at 37°C in the dark. Then the cells were washed three times with 5 ml 
media (RPMI 1640, 10% FCS, penicillin (50 units/ml) and streptomycin (50µg/ml))and 
centrifuged at 800 x g for 10 min. The cells were seeded in a 96 multiwell with low 
adherence U-bottom plates (Falcon) at a density of 5x104 cells per well. Each 
experimental point was seed in triplicate and stimulated, with 50 ng/well of PMA, 100 
ng/well of purified H6-TasA, 100 ng/well of purified H6-EgTrp, 100 ng/well of purified 
H6-EgA31 or 100 ng/well of purified H6-mCherry diluted in cell culture medium (RPMI 
1640, 10% FCS, penicillin (50 units/ml), and streptomycin (50 µg/ml). The cells were 
incubated for four days (37°C, 5% CO2) and then analyzed by flow cytometry.  
Blood-derived PBMC were collected weekly using the CPT Vacutainer. Followed by 
centrifugation at 1500 x g for 30 min. 1 ml of blood serum was removed before 
resuspending the PBMC. After the transfer of the suspension to a 15 ml plastic tube cells 
were centrifuged (800 x g, 10 min) and suspend using 5 ml of PBS. After another 
centrifugation (800 x g, 10 min) the cells were suspended in 1 ml PBS + CFSE (1 µM 
final concentration) and incubated for 10 min at 37°C. The cells were then washed three 
times with 5 ml RPMI1640, 10 % FCS, penicillin (50 units/ml), and streptomycin (50 
µg/ml). Moreover, then the cells were platted in a U-bottom of low adherence plate with 5 
x 104 cells per well. The blood-derived PBMC were stimulated and incubated as 
described above for the T cells derived from solid tissues of the dogs followed by flow 
cytometry.  
 
Previous to the acquisition, the stimulated cells were stained with the following surface 
markers anti-CD4, anti CD8, anti-CD25, anti-CTLA4 using FC antibodies (Table 3). For 
this, the cells were incubated for 10 min at 4°C in 5 ml analysis tubes (Greiner Bio-one) 
and kept at 4°C until acquisition. Thus, samples were acquired using a Gallios flow 
cytometer (Beckmann Coulter) with the following settings: Forward Scatter Excitation 
(FSC) [(Ex): 488 nm, 786 Volt (V), gain 2]; Side Scatter (SSC) [Ex: 488 nm, 817 V, gain 
7.5];  FL1 [Ex: 488 nm, 368 V, gain 1]; FL2 [Ex: 488 nm, 443 V, gain 1] FL4 [Ex: 488 
nm, 608 V, gain 1], FL5 [Ex: 488 nm, 807 V, gain 1], FL6 [Ex: 638 nm, 762 V, gain 1] 
and FL9 [Ex: 405 nm, 486 V, gain 1]. The obtained data were analyzed using the Kaluza 
analysis software (Beckmann Coulter) by setting gates to get single cell populations and 
that in the further gates the 99 % of negative control cells remained outside for the gated 
T cell populations. Thus, the gated cells were analyzed for proliferation monitoring CFSE 
signal intensity. 
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Results 
Parts of the results presented in this thesis were already published in Microbial 
Cell Factories journal and entitles as "Heterologous expression of antigenic peptides in 
Bacillus subtilis biofilms” 199 and a second manuscript based on the results presented in 
here, is currently in preparation. 
 
Characterization of B. subtilis background mutant 
One of the aims of this thesis was to express an antigen of interest in the biofilm 
of B. subtilis using a fusion of the antigen to the matrix protein TasA. As described 
above, TasA was observed to be homogeneously distributed in the biofilm, as visualized 
using a TasA-mCherry protein fusion 52. The expression of TasA-mCherry in the biofilm 
was investigated using three different genetic backgrounds. First, in B. subtilis NCIB3610 
(wild type, wt) 200; second, in a deletion of the tasA gene (∆TasA) 183 and third, in a 
double mutant for tasA and the repressor of the tapA promoter, the sinR gene 
(∆tasA/∆sinR). The whole TapA operon with TasA fused to mCherry (Figure 7A) was 
phage transduced into these three strains. The working hypothesis was that the TasA-
mCherry fusion is functional as a component of the biofilm matrix, suggesting that TasA 
could be fused to an antigen of interest. To test this hypothesis, the phenotypes of 72 hpi 
biofilms from different strains (wt, ∆tasA, and ∆tasA/∆sinR) were compared in the 
absence or the presence of TasA-mCherry. As depicted in Figure 7B, the TasA-mCherry 
fusion was able to partially complement the defective biofilms of the mutants ∆tasA and 
∆tasA/∆sinR, as observed by the worm-like structures and the wrinkles in the center and 
the edge of the biofilm. The expression of the TasA-mCherry fusion in the biofilm was 
monitored by immunoblotting (Figure 7C) using equivalent amounts of biofilm extracts 
and using anti-TasA or anti-dsRed (against mCherry) antibodies for detection. When 
incubating with anti-TasA, the biofilms formed by the strains transduced with TasA-
mCherry (lanes 2, 5, 6, 8, 11 and 12) showed two bands of approximately 30 and 60 kDa, 
corresponding to the predicted molecular weights for TasA and TasA-mCherry, 
respectively.  
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A band of approximately 25 kDa was observed in samples expressing the TasA-mCherry 
fusion protein. As the band is a defined band, it was rather a by-product of the TasA-
mCherry expression than a degradation product. Also, when incubating the membrane 
with anti-mCherry, it was possible to detect a unique band of 60 kDa corresponding to the 
predicted molecular weight for TasA-mCherry. 
To elucidate which of the B. subtilis backgrounds showed the strongest expression of 
TasA-mCherry, the mCherry fluorescence (Figure 7D) was measured in the formed 
biofilms at 24, 48 and 72 h post-inoculation and normalized by the biofilm area. The 
results showed that the strongest expression of TasA-mCherry was obtained with the B. 
subtilis strain ∆tasA/∆sinR/tasA-mCherry, displaying five times higher fluorescence than 
the B. subtilis wt background. Interestingly, the best expression of TasA-mCherry was 
obtained at 24 and 48 h post-inoculation, declining at 72 h post-inoculation. These 
temporal expression levels were explained by changes in the different cell-type 
populations in the biofilm community 183. Since it was intended to administrate 
recombinant B. subtilis spores to the animals orally, we next investigated the ability of 
these strains to sporulate when compared to B. subtilis wt strain. For this purpose (Figure 
7E), 48 h incubated biofilms from the B. subtilis strains ∆tasA/tasA-mCherry or 
∆tasA/∆sinR/tasA-mCherry both expressing TasA-mCherry, were harvested and the 
number of spores was determined and compared to the spores obtained from biofilms 
formed by B. subtilis wt. The results showed that a biofilm of B. subtilis 
∆tasA/∆sinR/tasA-mCherry had 25% of sporulation ability compared with a biofilm from 
B. subtilis wt but similar to the B. subtilis strain ∆tasA/tasA-mCherry. Even if reduced by 
percentage the number of spores obtained from ∆tasA/∆sinR/tasA-mCherry showed only 
Figure 7. Comparison of the biofilm architecture and sporulation capacity of recombinant 
B. subtilis strains expressing the TasA-mCherry fusion. 
 (A) Schematic representation of the operon of tapA wild type and carrying tasA-mCherry. Black 
arrow; tapA promoter; the secretory protein (tapA); signal peptidase (sipW); extracellular matrix 
protein (tasA); TasA repressor (sinR); TasA inducer (sinI), the terminator (black pin). The 
mCherry gene represented by the red box replace the terminator, the SinR, and SinI gene. (B) 
Visualization of 72 h incubated biofilm grown on semi-solid MSgg-agar. Strains incubated are 
indicated, each either with –(TasA-mCherry) in the construct or without. (C) Immunoblotting of 
biofilm grown for 72 h. Homogenized biofilm (OD600 nm = 1; 20 µl) of the strain wt (lanes 1, 3, 7, 
9), ∆tasA/tasA-mCherry expressing TasA-mCherry (lanes 2, 5, 8, 11), ∆sinR (lane 4, 10), 
∆sinR/∆tasA/tasA-mCherry expressing TasA-mCherry (lanes 6, 12). The blots were analyzed 
with specific anti-TasA and anti-dsRed antibody respectively. The red arrow is indicating the 
TasA-mCherry fusion, and the blue arrow is indicating TasA.  (D) The ability to express 
mCherry of indicated strains analyzed by analysis of the fluorescence of a biofilm at the 
indicated time points. (E) The sporulation ability of the indicated B. subtilis strains. Strains were 
inoculated for 48 h to develop biofilms before harvesting and analyzing the formed spores. Spore 
formation of the wild-type strain is shown as 100 %. The analyzed strains are indicated as the 
percentage of spores compared to the wild type strain. *  ; p-value < 0.05. 
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a significant difference to the wt but not to the ∆tasA/tasA-mCherry strain. Therefore, the 
chosen background for the high expression of the desired antigen corresponded to the one 
provided by B. subtilis ∆tasA/∆sinR. 
The studies presented above were performed using a double mutant B. subtilis 
∆tasA/∆sinR obtained by replacement of the specific genes with two antibiotic resistances 
kanamycin and spectinomycin, respectively. Engineering of B. subtilis strains in a 
∆tasA/∆sinR background with the aim to facilitate the preparation was obtained by 
introducing a single antibiotic resistance gene for kanamycin. The biofilm developed by 
this newly engineered strain, hereafter named ∆tasA/∆sinR, was phenotypically compared 
to the biofilms produced by B. subtilis wt, ∆tasA and ∆sinR strains (Figure 8B). The 
results indicated that the biofilm phenotype was, as expected, defective as well as similar 
to the one obtained in the B. subtilis ∆tasA/∆sinR with the two separate antibiotic 
resistances from Figure 7B. The biofilm formed by ∆tasA/∆sinR with a single antibiotic 
resistance gene for kanamycin was flattened and slimy in the edges, like the one brought 
by the ∆tasA, and with a worm like structuring central zone as the ∆sinR biofilm 
phenotype. The absence of TasA in B. subtilis ∆tasA and ∆tasA/∆sinR with a single 
antibiotic resistance gene for kanamycin was assessed by immunoblotting using a specific 
anti-TasA antibody (Figure 8C, lanes 2 and 4). The results were then compared with the 
expression of TasA in biofilm extracts from B. subtilis strains wt and ∆sinR (Figure 8C, 
lanes 1 and 3). Based on the collected data, it was decided to continue using the B. 
subtilis strain ∆tasA/∆sinR with a single antibiotic resistance gene for kanamycin as the 
background strain for the construction of a B. subtilis carrying TasA fused to an antigen 
of interest. 
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Figure 8 Characterization of the B. subtilis biofilm phenotype when deleted tasA or/ and 
sinR genes. (A) Schematic representation of the operon of tapA. black arrow: TapA 
promoter; Secretory protein (tapA); signal peptidase (sipW); extracellular matrix protein 
(tasA); TasA repressor (sinR); TasA inducer (sinI); the position of the antibiotics resistance is 
indicated as blue box (Kanamycin (Km)) and purple box (Spectinomycin (Spc))]; the 
terminator (black pins). (B) Biofilm top view of the indicated B. subtilis strains at 72 hpi on 
semi-solid MSgg. Scale bar, 5 mm. (C) Immunoblotting of biofilm extracts of indicated B. 
subtilis strains at 72 hpi. Bands were detected using a specific anti-TasA antibody stained for 
the TasA expression. The blue arrow indicates TasA. The molecular weights (kDa) of the 
proteins are indicated. The lanes are numbered corresponding to the loaded biofilm 
homogenate; B. subtilis wt (1), ∆tasA (2), ∆sinR (3), ∆tasA/∆tasA (4).  
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Expression of TasA fused to tropomyosin E. granulosus antigen peptides in B. 
subtilis biofilms 
To test the expression of E. granulosus tropomyosin peptides (EgTrp) in B. 
subtilis, various TasA-EgTrp fusions were phage transduced into the ∆tasA/∆sinR B. 
subtilis strain. A schematic representation of the different constructs for the TasA-EgTrp 
fusions is depicted in Figure 9A. Two new recombinant B. subtilis strains were generated 
after that abbreviated as (102-207)EgTrp and (102-278)EgTrp, respectively. The 
recombinant operon was inserted by homologous recombination in the genome of B. 
subtilis by replacing the non-essential gene amyE (α-amylase) 201. Clones growing on 
spectinomycin selective semi-solid media were tested for the phenotype of their formed 
biofilms. Biofilms showing a wrinkled and worm-like phenotype were selected (Figure 
9B), homogenized, suspended and 10 µl of equal optical density was loaded in 
immunoblotting. 
The immunoblotting (Figure 9C), when incubated with a specific anti-TasA (lanes 1 to 
4) or anti-EgTrp (lanes 5 to 8) antibodies, showed a band of ≈ 30 kDa (lanes 1, 3 and 4) 
corresponding to the expected molecular weight of TasA. Also, it was possible to detect a 
band of ≈ 42 kDa (lanes 3 and 7) and one of the ≈ 48kDa (lanes 4 and 8) corresponding to 
the predicted molecular weight for the fusion protein TasA-(102-207)EgTrp and TasA-
(102-278)EgTrp, respectively.  
Based on its biofilm phenotypes and the detection in immunoblotting of the engineered 
TasA-EgTrp fusion proteins the two new B. subtilis strains, (102-207)EgTrp and (102-
278)EgTrp we decide to include these two strains for further experimentation.  
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Figure 9. Expression of the fusion protein TasA-EgTrp in the biofilm of recombinant B. 
subtilis (102-207)EgTrp and (102-278)EgTrp strains.  
(A) Schematic representation of the organization of the TasA-EgTrp operon transduced into the 
α-amilase locus of the B. subtilis DsinR/∆tasA strain. Black arrow TapA promoter; secretory 
protein (tapA), signal peptidase (sipW); extracellular matrix protein (TasA); fusion protein 
(green arrow). (B) Top view pictures of 72 hpi biofilms of the indicated B. subtilis recombinant 
strains on semi-solid MSgg-agar. Scale bar, 5 mm. The incubated strains are indicated in the 
pictures. (C) Immunoblotting from homogenized biofilms at 72 hpi on semi-solid MSgg. The 
red and blue arrows indicate TasA-EgTrp fusion proteins and TasA protein, respectively. The 
protein molecular weights marker is indicated (kDa). 
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Expression of TasA fused to E. granulosus paramyosin antigenic peptides in B. 
subtilis biofilm 
E. granulosus paramyosin (EgA31) was fused in frame to the C-terminus of TasA 
to test the expression in the B. subtilis deletion mutant (∆tasA/∆sinR). A scheme 
representing the engineered TasA-EgA31 fusion constructs is shown in Figure 10A. The 
main antigenic peptide for EgA31 (aa 170 to 583 182) was divided into two different 
amino acidic regions (170-369) and (370-583) and fused in frame to the C-terminal 
region of TasA. Analogous as described for the TasA-EgTrp strains (see also Material 
and Methods), two recombinant B. subtilis strains for TasA-EgA31 were generated 
named as (170-369)EgA31 and (370-583)EgA31, respectively. To determine the ability 
to form in vitro biofilms, the two recombinant B. subtilis strains, (170-369)EgA31 and 
(370-583)EgA31, were inoculated on semi-solid MSgg and let grow for 72 h as depicted 
in the Figure 10B. Under the tested conditions, the (370-583)EgA31 strain was forming 
structural complex biofilms with the central zone and wrinkles in the outer zone. 
Furthermore, the (170-369)EgA31 strain was forming a partially complemented biofilm 
showing fine worm-like structures in the central area and smooth wrinkles in the biofilm 
edges. Moreover, the presence of TasA-EgA31 antigenic peptides in biofilms extract was 
determined by immunoblotting of biofilms, using specific antibodies for TasA and 
EgA31. As depicted in Figure 10C, when incubating the membrane anti-TasA (lanes 1 to 
6), it was possible to detect a smaller band of ≈ 30 kDa corresponding to the calculated 
molecular weight of TasA (lanes 2, 3, 5 and 6). In addition, a band of ≈ 50 kDa (lane 3) 
and one of ≈ 52 kDa (lanes 6 and 12) was detected when incubating with both anti-TasA 
and anti-EgA31, which corresponded to the predicted molecular weight for the fusions of 
TasA-(170-369)EgA31 and TasA-(370-583)EgA31, respectively. However, the strain 
(170-369)EgA31 was not expressing an amount of EgA31 detectable by the used anti-
EgA31 antibody (lane 9) even having shown the expression in the analysis by the anti-
TasA antibody (lane 3). Therefore the strain (170-369)EgA31 was excluded from further 
experiments. 
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Figure 10. Expression of the fusion protein TasA-EgA31 in biofilm of recombinant B. 
subtilis (170-369)EgA31 and (370-583)EgA31 strains.  
(A) Schematic representation of the organization of the TasA-EgA31 operon transduced into 
the α-amilase locus of the B. subtilis DsinR/∆tasA strain. Black arrow TapA promoter; 
secretory protein (tapA), signal peptidase (sipW); extracellular matrix protein (TasA); fusion 
protein (green arrow). (B) Top view pictures of 72 hpi biofilms of the indicated B. subtilis 
recombinant strains on semi-solid MSgg-agar. Scale bar, 5 mm. (C) Immunoblotting from 
homogenized biofilms at 72 hpi on semi-solid MSgg. To detect TasA an anti-TasA and EgA31 
an anti-EgA31 antibody were used. The red and blue arrows indicate TasA-EgA31 fusion 
proteins and TasA protein, respectively. The protein molecular weight marker is indicated 
(kDa). 
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Visualization of TasA in recombinant B. subtilis biofilms 
To localize the fusion of TasA-E. granulosus antigenic peptides of the 
recombinant B. subtilis strains in their biofilms, an immunohistochemistry analysis was 
performed within 72 h post-inoculation. The biofilms were embedded and semi-thin 
vertical sections of the biofilms were prepared. Then, to localize TasA, the biofilm-
sections were stained with a specific anti-TasA antibody followed by a secondary 
antibody conjugated to Alexa 594(red). As depicted in Figure 11, the obtained results 
showed that TasA fused to the antigen localize in the biofilm extracellular matrix.  
 
Recombinant B. subtilis spores expressing E. granulosus antigens displayed 
unaltered heat, pH resistance, shelf life durability and spore structures 
The resistance of the recombinant B. subtilis spores was analyzed upon four 
different parameters, as temperature, shelf-life viability, high pH and the structure of the 
spore outer layer and compared to the wt spores. 
Figure 11. Immunohistochemistry of semi-thin paraffin cuts of 72 hpi biofilms from 
recombinant B. subtilis strains expressing EgTrp and EgA31 antigens, respectively. 
Vertical thin sections of biofilms. The name of each B. subtilis recombinant strain is indicated. 
Sections were stained for TasA (anti-TasA, red). Merge with the bright field. Scale bars, 50 µm. 
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Figure 12. Recombinant B. subtilis spores exposed to different conditions. 
 (A) heat, the spores were incubated for 15 min at RT, 85°C, 95°C or 99°C, respectively. (B) 
shelf life store capacity in weeks at RT in the dark and (C) acidic pH variations. RT; room 
temperature (23°C) prior to inoculation on LB-agar to determine the CFU. Statistical analysis 
by one-way ANOVA, Tukey’s multiple comparison test. Statistical significant is considered as 
a p-value < 0.05 for the differences between spores at a specific condition.  
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In a first instance, I compared the resistance of spores to different temperature by ranking 
from room temperature (23˚C) to 99˚C. The obtained results (Figure 12A) showed that 
all the tested recombinant spores had a similar amount of CFU and therefore a similar 
resistance to heat as the wild type spores. In addition, in the specific experimental setting, 
the recombinant spores got inactivated as the wild type spores did when treated with 
steam pressure for 30 min at 121°C. 
Secondly (Figure 12B), I determined the shelf-life of the spores by analyzing the ability 
to germinate of the wild type and the recombinant spores after been stored in dark at 
room temperature for 0, 4, 8, 12, 16 and 20 weeks, which turned to be identical between 
wild type ant the tested recombinant B. subtilis spores.  
Third, the resistance of the 
spores in an acidic environment 
was tested. The spores were 
exposed for 2 h to different pH 
conditions as are pH 7, 3, 2 and 
1. Further, the spores were 
washed, and the number of 
spores counted for each sample 
was compared to samples 
exposed to pH 7. The analysis of 
the obtained data showed that 
the recombinant spores were 
able to germinate in a number as 
the wild type spores did after 
being exposed to pH as low as 
pH 1 (Figure 12C).  
Lastly, the purified spores from 
the recombinant B. subtilis 
strains were analyzed by 
transmission electron 
microscopy (TEM) for 
determining the outer structures 
of the spores, as are the outer 
coats and the inner cortex 
peptidoglycan. The recombinant 
 Figure 13. Transmission electron micrographs of 
freshly purified B. subtilis spores of the indicated 
strains.  
Spores were frozen with liquid nitrogen, fixed with 
glutaraldehyde, counterstained and photographed. The 
star is marking the overview micrograph. In the 
magnification the open arrow is pointing the cortex 
peptidoglycan and the black arrow is pointing the spore 
coats. Scale bar, 100 nm for the magnified and 50 nm for 
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spores, visualized in Figure 13, were compared to the spores purified from the wild type 
B. subtilis NCIB3610. The outer coat appeared as thick electron dense layer surrounding 
the whole spore. When using higher magnification, a layered structure was observed 
corresponding to the outer coat. Also, I observed in the inner coat the multi-layered 
structures in the recombinant spores analyzed. The inner coat was less-electron dense 
than the outer coat and the layered structure was clearly defined. All compared spores 
showed a similar coat of peptidoglycans at the inner site of the layered structure, as well 
as a similar layered structure. Thus, all the B. subtilis spores, wild type and recombinant 
TasA-antigens, showed to be similar when compared by TEM in the structures of both the 
outer and the inner coats, analyzing for each indicated strain spores of one purification. 
In conclusion, I stated that the generated recombinant B. subtilis mutants for (102-
207)EgTrp, (102-278)EgTrp and (370-583)EgA31 when fused in frame to the C-terminal 
of TasA, were enabling the partial complementation of the defective B. subtilis 
∆tasA/∆sinR background by forming biofilm in vitro that were phenotypically similar to 
the B. subtilis NCIB3610 wild type. Additionally, as demonstrated by specific 
immunoblotting and immuno-histochemistry, TasA fused to E. granulosus antigens was 
located in the biofilm matrix. Lastly, I showed that the recombinant spores possessed the 
same ability to germinate as wild type spores after experiencing harsh conditions 
(temperature, shelf life and extreme pH) and as denoted by TEM showed a similar 
structure of organization of the outer most spore structures.  
Based on the obtained results, I was able to generate recombinant strains of B. subtilis 
expressing antigenic peptides for E. granulosus when forming biofilms, while keeping the 
characteristic of the resistant spores formed.  
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Trial in mouse and dogs model to determine the capacity of recombinant B. subtilis 
spores to develop an enteric immune response. 
 
A further aim of this Ph.D. thesis was to test the ability of the recombinant B. subtilis 
spores to generate specific cellular and humoral immune responses in mice and dogs. For 
this purpose, an immunization schedule was designed in which each animal (mice or 
dogs) was orally administered with recombinant B. subtilis spores carrying the antigen of 
interest for three times on days 1, 21 and 42. Due to its nature, it was hypothesized that 
the spores would be able to bypass the stomach barrier and be able to germinate in the 
small intestine of the inoculated animal. Thus, having the capacity to develop a biofilm, 
which would expose the antigens of interest. In this manner, the antigen could stimulate 
the gut-associated lymphoid tissue (GALT). In this context, it was also hypothesized that 
E. granulosus antigens (EgTrp and EgA31), when fused to TasA would be able to 
generate a specific humoral and cellular immune responses against the parasite. Therefore 
and based on the above-presented results, I decided to test the recombinant B. subtilis 
spores carrying the following E. granulosus antigens (102-207)EgTrp, (102-278)EgTrp 
and (370-583)EgA3 to investigate their ability to stimulate GALT in the gastrointestinal 
tract of both mice and dogs.  
Evaluation of the ability of recombinant B. subtilis spores carrying (102-278)EgTrp 
and (102-207)EgTrp to induce humoral and cellular immune responses in mice 
 
The mouse immunization schedule (Figure 14A) for the first mouse experiment, 
correspond to the oral gavage of 5 x 1010 CFU spores per dose on days 1, 21 and 42. In 
this trial, the following experimental groups were proposed: i) placebo (saline solution), 
ii) control spores (∆tasA/∆sinR), iii) recombinant spores of the (102-207)EgTrp strain 
and iv) recombinant spores of the (102-278)EgTrp strain. Each group contained six, six 
weeks old female Balb/c mice. Before each oral gavage and before euthanasia, blood and 
feces samples were collected to analyze the humoral immune response and quantifying 
the spores shed in the feces. On day 50, mice were euthanized and harvested mesenteric 
lymph nodes (MLN), Peyer's patches and spleen for studying the cellular immune 
response against EgTrp. The mice health was monitored by weighing them before each 
oral administration, on a daily base for seven days following the first oral gavage, and 
previous to each oral gavage and the euthanasia. As observed in the Figure 14B, the mice 
body weight development for all tested groups was unaltered, independently of the type 
of spores administrated. Thus, the data suggests that B. subtilis spores had no detrimental 
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effect on the mice health. Additionally, the ability of the spores to germinate after the 
passage of the GIT of the gavaged animals was determined. For this purpose, feces 
samples were collected from days 1 to 5 after the first immunization, before each oral 
gavage and the euthanasia. The obtained results (Figure 14C) show that the spores 
administered were shed in feces within 4 Days post-administration of the spores. Also, in 
the feces collected on day 21 and 42, from mice of the (102-207)EgTrp group contained 
spores, but on day 50 none of the animals were shedding spores. The total number of 
spores detected in feces was close to 109 CFU (Figure 14D), suggesting that a 
considerable number of spores get retained in the gastrointestinal tract of the mice.  
 
Figure 14. Mice were not hindered in development and spores were able to germinate 
after the passage through mice. (A)  
Schematic representation of the experimental design. Recombinant B. subtilis strains (102-
207)EgTrp and (102-278)EgTrp were administered. Six female, nine weeks old Balb/c mice 
per group received by oral gavage (é) 5 x 1010 spores or saline solution (Placebo) on days 1, 
21 and 42 of the experiment. Before each oral gavage, blood (ê) and feces () samples were 
collected from each mouse. On day 50 mice were euthanized (í), and mesenteric lymph 
nodes, Peyer's patches, and spleen were harvested for analysis. (B) Plot showing the mouse 
health status. The data corresponding to the group body weight represented as mean ± SEM 
[g]. (C) A number of spores detected in the feces of mice resolved in 24 h. Data points 
correspond to the number of colonies forming units (CFU) of spores formed on selective 
media, represented as group mean ± SEM [in CFU / g feces]. (D) The total number of spores 
detected in the feces of mice within the seven days after the first oral gavage. Bars represents 
the total amount of colony forming units (CFU) as group mean ± SEM. For the plots from (B) 
and (C), each dot corresponds to the group average by  for 207EgTrp, n for 278EgTrp, ¢ 
for Placebo and • for ∆tasA/∆sinR. DPI, days post immunization; PI, pre-immune. Error bars 
show the standard error of the arithmetic means of each group. indicates a p-value < 0.05, 
ns indicates a not significant difference; one-way ANOVA with Tukey's multiple comparison 
tests. 
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The humoral immune response of mice administrated with recombinant spores carrying 
(102-207)EgTrp and (102-278)EgTrp was analyzed by indirect ELISA. For this purpose, 
different kind of antigens, such as biofilm extract from recombinant B. subtilis (102-
207)EgTrp and ∆tasA/∆sinR, purified recombinant proteins H6-EgTrp, H6-TasA, and H6-
mCherry as well as homogenized E. granulosus protoscoleces were used to coat the 
plates.  
 
In Figure 15A, on days 42 and 50 post-inoculation the level of sIgA against complete 
biofilm of the (102-207)EgTrp strain raised significantly for the group of mice receiving 
(102-278)EgTrp spores when compared with pre-immunized conditions within the same 
group. However, the measured values in the ELISA (Figure 15A) of serum of mice of the 
∆tasA/∆sinR group against the biofilm of the (102-207)EgTrp strain were on a similar 
level as the values for the (102-207)EgTrp group. Therefore, the antigen to which the 
sIgA bind remains not-elucidated. Further does the signal from two mice of the (102-
207)EgTrp group against the biofilm of the ∆tasA/∆sinR strain (Figure 15B) underline 
that other components than the TasA-(102-207)EgTrp is recognized by the sIgA detected. 
Further, the level of specific IgA in serum against biofilm of the (102-207)EgTrp strain 
did not show any significant variations, independently of the spores received by the mice 
(Figure 15C).  
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Figure 15. Humoral immune response against components of the B. subtilis biofilm.  
(A) Plot showing secretory IgA in feces detected by ELISA against homogenate of (102-
207)EgTrp biofilm. Each dot represents the mean OD450 nm of one mouse in duplicate and 
normalized by the analyzed feces weight. (B) Plot showing secretory IgA in feces detected 
by ELISA against homogenate of ∆tasA/∆sinR biofilm. Each dot represents the mean OD450 
nm of one mouse in duplicate. (C) Plot showing IgA in serum detected by ELISA. Each dot 
represents the average at OD450 nm of one mouse in duplicate. 
For the plots from (A) to (C): The coated antigens are indicated at the y-axis. The group of 
mice is shown below the x-axis. Each dot corresponds to one mouse by  for 207EgTrp, n 
for 278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. DPI, days post immunization. Error 
bars show the standard error of the arithmetic means of each group. indicates a p-value < 
0.05, ns indicates a not significant difference; one-way ANOVA with Tukey's multiple 
comparison tests. 
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Additional ELISAs were performed for the detection of specific IgA extracted from feces 
(Figure 16A), and serum (Figure 16B) directed against purified recombinant proteins 
H6-EgTrp, H6-mCherry and H6-TasA, biofilm extract from ∆tasA/∆sinR as well as crude 
homogenized E. granulosus that showed no difference when compared to the placebo 
Figure 16. Humoral immune response against purified recombinant components of the B. 
subtilis biofilm.  
(A) Plot showing secretory IgA in feces detected by ELISA at 50 dpi. Each dot represents the 
mean OD450 nm of one mouse in duplicate and normalized by the analyzed feces weight. (B) Plot 
showing IgA in serum detected by ELISA at 50 dpi. Each dot represents the mean OD450 nm of 
one mouse in duplicate.  
For the plots (A) and (B): The coated antigens are indicated at the bottom below the x-axis 
[horizontal text]. The group of mice is shown below the x-axis. Each dot corresponds to one 
mouse by  for 207EgTrp, n for 278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. DPI, days 
post immunization. Error bars show the standard error of the arithmetic means of each group. 
indicates a p-value < 0.05, ns indicates a not significant difference; one-way ANOVA with 
Tukey's multiple comparison tests. 
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samples. Moreover, the cellular immune response, obtained from T cell proliferation 
analysis, showed no significant differences when stimulating with purified H6-EgTrp 
CD4+/CD8+ T cells derived from spleen, MLNs and Peyer’s patches (Figure 17). 
In summary, within the performed experiments no adverse effects of the recombinant B. 
subtilis have been detected. Furthermore, the oral inoculation with recombinant spores led 
to a significant increase of sIgA of the (102-207)EgTrp group against components of the 
biofilm of the (102-207)EgTrp strain. However, it remains not elucidated to which 
antigenic components in specific as the level of the sIgA from the ∆tasA/∆sinR group 
detected against the biofilm of the (102-207)EgTrp strain was on a comparable level as 
the sIgA detected for (102-207)EgTrp. Further did the analysis of the humoral immune 
response against purified proteins and crude E. granulosus remain negative. The results 
of the analysis of the cellular immune response showed no significant difference between 
the groups. Hence, upon these conditions, it was not possible to detect a specific humoral 
or cellular immune response against recombinant E. granulosus antigens.  
Figure 17. Cellular immune response 
detected in mice immunized with 
(102-207)EgTrp and (102-278)EgTrp 
recombinant spores.  
(A) Plot showing proliferating 
CD4+/CD8+ cells derived from the 
spleen after stimulation with purified 
recombinant H6-EgTrp. Each dot 
represents the mean percentage of 
maximal stimulated cellular 
proliferation of one mouse measured in 
triplicate. (B) Plot showing 
proliferating CD4+/CD8+ cells derived 
from the MLN and Peyer’s patches 
after stimulation with purified 
recombinant H6-EgTrp. Each dot 
represents the mean percentage of 
maximal stimulated cellular 
proliferation of one mouse measured in 
triplicate. For the plots from (A) and 
(B) each dot corresponds to one mouse 
by  for 207EgTrp, n for 278EgTrp, 
¢ for Placebo and n for ∆tasA/∆sinR. 
Error bars show the standard error of 
the arithmetic means of each group. 
indicates a p-value < 0.05, ns indicates 
a not significant difference; one-way 
ANOVA with Tukey's multiple 
comparison tests. 
 
   Page 72 
Oral treatment with antibiotics reduced mice microflora 
The gut microflora could inhibit the germination of the administered recombinant 
B. subtilis by a different mechanism, as is the lack of an appropriate niche in the gut or 
commensalism and thereby, reducing a potential humoral immune response 102. Thus, to 
test if an altered microflora would allow a specific immune response against recombinant 
E. granulosus antigens I decided to change the mice original gut microflora by treating 
the mice with antibiotics. For this purpose, an antibiotic cocktail containing ampicillin, 
gentamicin, metronidazole and vancomycin was added to the mice drinking water 202. In a 
first instance, the effect of the antibiotics treatment on the gut microflora was determined 
in a pre-test using three mice. In this case, the antibiotic cocktail was provided in the 
drinking water for six days (Figure 18A), in which the mice were weighed, and the feces 
were harvested on a daily base, respectively. The body weight was monitored as an 
indicator of the health status of the animals (Figure 18B). The weight of mice treated 
with antibiotics was compared with the untreated mouse. The body weight data shows a 
loss of weight during days 1 to 3 of the antibiotics treatment, but followed by a 
stabilization and a regain of weight.  
The bacteria content in isolated feces isolated from the mice treated with antibiotics was 
determined by feces extracts incubated in nutritious, rich agar media as Luria-Bertani 
(LB), Heart-Brain Infusion (HBI) and Nutrient Broth (Figure 18 C, D, and E). The 
number of colony forming units (CFU) was determined and compared with the feces from 
the untreated mouse. The data show that CFU of mice treated with antibiotics dropped 
undetectable levels on day 2 when compared with the untreated mouse. In fact, the 
number of detected bacteria in feces was not incremented until day 6 of treatment. Same 
kinds of results were obtained using LB, HBI and NB agar media. Thus, based on these 
results, the following experiments the mice would receive antibiotics in the drinking 
water before the oral gavage of recombinant spores. 
   Page 73 
 
Figure 18: Antibiotics in the 
drinking water reduce the number 
of detectable bacteria in the feces. 
Two mice received antibiotics added 
to the drinking water (ampicillin, 
gentamicin, metronidazole, 
vancomycin), one mouse got normal 
drinking water. Every 24 h feces () 
was collected and analyzed for 
bacteria cultivable on different 
media. (A) Scheme of the experiment 
for each tested mouse. In green () 
indicated the time of antibiotics in the 
drinking water. The ticks () 
represent the daily feces collection, 
and the red arrow (í) shows the 
euthanasia of the mice. (B) Health 
status of the mice. The graph 
represents the body weight [g] of the 
mice. Every dot shows one 
measurement of one mouse. (C) 
Colony forming units of bacteria 
cultivable on lysogeny broth-agar 
semi-solid plates. (D) Colony 
forming units of bacteria cultivable 
on brain heart infusion-agar semi-
solid plates. (E) Colony forming units 
of bacteria cultivable on nutrient 
broth-agar semi-solid plates.  
For the graphs B to E each dot 
represents the log10 of CFU extracted 
of 24 hours of feces collected and 
analyzed. The dots represents each 
mouse by m for the control receiving 
normal drinking water, p for one 
mouse receiving antibiotics within 
the drinking water and the for the 
other antibiotics receiving mouse.  
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Evaluation of immune response of mice administrated with recombinant B. subtilis 
spores carrying EgTrp after eradication of the gut microbiota.  
In this preliminary schedule (Figure 19A), the mice were treated for six days 
with the antibiotic cocktail in the drinking water. Then, mice receive three doses of 
5x1010 CFU of spores on days 1, 21 and 42. The mice were organized in the following 
groups: i) placebo (saline solution), ii) control spores ∆tasA/∆sinR iii) recombinant 
spores of the (102-207)EgTrp strain and iv) recombinant spores of the (102-278)EgTrp 
strain. Each group was composed of six female Balb-c mice, six weeks old. The feces and 
serum were collected to study the humoral immune response and to monitor spores shed 
in feces. On day 50 post-immunization, mice from all groups were euthanized for the 
analysis of cellular immune responses from isolated T cells from spleen, mesenteric 
lymph nodes, and Peyer's patches. The mice body weight was measured daily during the 
antibiotic treatment and one week after the first immunization to evaluate if the 
concomitant administration of the antibiotic cocktail and the recombinant spores would 
have an effect on the mice health. As depicted in Figure 19B, no differences in the body 
weight were observed between mice treated with spores and the control group. However, 
the treatment with antibiotics had to be interrupted on the fifth day of therapy because the 
body weight dropped in average more than 20% from the initial body weight in all 
groups. Hence, mice were provided for one night of drinking water without antibiotics to 
allow their rehydration. This treatment permits a normalization of the body weight in the 
next morning and hence the treatment with antibiotics was continued for another two 
days. 
The feces samples were collected from individual animals to determine if the antibiotic 
treatment disabled the recombinant spores to germinate after the passage through the GIT 
and to determine the passage time of the recombinant spores. The spores administered 
were detected in the collected feces within the first four days’ post-inoculation for all the 
animals (Figure 19C). In the feces collected on day 21, no spores were detected. 
Interestingly, when checking the spores shed in the feces from the day 42 (after 21 days 
from previous oral gavage), one mouse of the (102-207)EgTrp group was shedding 6.41 x 
105 spores within one day of feces collection. Moreover, in day 50 all animals that have 
received recombinant spores showed to shed recombinant spores into its feces. 
Furthermore, the total number of shed spores in feces (Figure 19D) after the first oral 
gavage was determined as 0.2% (∆tasA/∆sinR), 31.7% (102-207EgTrp) and 11.3% (102-
278EgTrp) from the oral administered dose of spores. 
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To determine the specific humoral immune response against the antigenic peptide from E. 
granulosus, sIgA extracted from feces, and IgA from serum were analyzed by indirect 
ELISA. As depicted in Figure 20A, mice inoculated with recombinant spores of both 
strains, (102-207)EgTrp and (102-278)Egtrp, were able to respond specifically against 
homogenized biofilm. Mice of the (102-207)EgTrp group showed an increased signal on 
days 42 and 50 post-immunization represented by specific sIgA isolated from feces.  The 
mice group immunized with spores carrying (102-278)EgTrp showed on 42 days post-
Figure 19: Antibiotics administration lowered the body weight and did not hinder 
recombinant spores to be able to germinate after the passage through the gastrointestinal 
tract.  
(A) Schematic representation of the spores administration schedule. Recombinant B. subtilis 
strains (102-207)EgTrp and (102-278)EgTrp were administered. Six female, nine weeks old 
Balb/c mice per group received by oral gavage (é) 5 x 1010 spores or saline solution (Placebo) 
on days 1, 21 and 42 of the experiment. The mice received antibiotics in the drinking water 
before the first oral gavage (___).  Before each oral gavage, blood (ê) and feces () samples 
were collected from each mouse. On day 50 mice were euthanized (í), and mesenteric lymph 
nodes, Peyer's patches, and spleen were harvested for analysis. (B) Plot showing the mice body 
weight. Data corresponding to the group body weight represented as mean ± SEM [g]. (C) 
Detection of spore amounts in mice feces at 24 h. Data points correspond to the number of 
colony forming units (CFU) of spores formed on selective media, represented as group mean ± 
SEM [in CFU / g feces]. (D) Total number of spores detected in the feces of mice within seven 
days after the first oral gavage. Bars represents the total amount of colony forming units (CFU) 
as group mean ± SEM. 
For the plots from (B), and (C) each dot corresponds to the group average by  for 207EgTrp, 
n for 278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. DPI, days post immunization; PI, pre-
immune. Error bars show the standard error of the arithmetic means of each group. 
indicates a p-value < 0.05, ns indicates a not significant difference; one-way ANOVA with 
Tukey's multiple comparison tests. 
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inoculation a significant increase of sIgA against the homogenized (102-207)EgTrp 
biofilm compared to the preimmune sample. Meanwhile, the control groups (placebo and 
∆tasA/∆sinR) were unable to generate such a response against the biofilm extract. 
However, the difference between the response on day 50 of the EgTrp spores receiving 
groups was not significantly different from the signal detected testing the day 50 serum of 
the placebo group. Importantly, no signal was obtained from biofilm extract from B. 
subtilis ∆tasA/∆sinR (Figure 20B), pointing into the direction that mice responded 
specifically against the TasA-EgTrp fusion protein. When analyzing the specific antibody 
response in serum from the gavaged mice, in particular for IgA (Figure 20C), it was 
possible to observe a significant increase of IgA against (102-207)EgTrp biofilm for all 
three groups receiving recombinant B. subtilis spores. The results indicate a non-specific 
immune response against other components of the biofilm than TasA-(102-207)EgTrp. 
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Figure 20: Specific secretory IgA of mice immunized with (102-207)EgTrp and (102-
278)EgTrp recombinant spores detected after treatment of the mice with antibiotics before 
the first oral gavage. 
(A) Plot showing secretory IgA in feces detected by ELISA coated with homogenized biofilm 
expressing TasA-(102-207)EgTrp. Each dot represents the mean OD450 nm of one mouse in 
duplicate and normalized by the analyzed feces weight. (B) Plot showing secretory IgA in feces 
detected by indirect ELISA coated with 72h homogenized biofilm from B. subtilis ∆tasA/∆sinR 
strain. Each dot represents the mean OD450 nm of one mouse in duplicate and normalized by the 
analyzed feces weight. (C) Plot showing serum IgA detected by ELISA coated with 72h 
homogenized biofilm from B. subtilis TasA-(102-207)EgTrp strain. Each dot represents the 
mean value at OD450 nm for one mouse in duplicate.   
For the plots from (A) to (C) each dot corresponds to one mouse by  for 207EgTrp, n for 
278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. DPI, days post immunization; PI, pre-
immune. Error bars show the standard error of the means of each group. , p-value < 0.05; ns, 
not significant; one-way ANOVA with Tukey's multiple comparison tests. 
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Interestingly, sIgA isolated from feces (Figure 21A) of mice gavaged with recombinant 
spores carrying EgTrp antigenic peptides were able to recognize (ns) wild-type biofilm 
extract, possibly pointing to recognize TasA in the biofilm. However, no signal was 
detected from other substrates as recombinant proteins for H6-EgTrp and H6-mCherry and 
also crude E. granulosus. Thus, no sera IgA were detected against homogenate of the 
biofilm of the ∆tasA/∆sinR strain, and also no significant increase in serum IgA against 
homogenized biofilm of the wt strain was detected (Figure 21B). The sera IgA against 
H6-EgTrp, H6-mCherry, and crude E. granulosus did not change detectable.  
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The cellular immune response from isolated CD4+/CD8+ T cells from spleen, MLN and 
Peyer’s patches was determined by dilution of incorporated CFSE in proliferative T cells. 
Unfortunately, as depicted in Figure 22, no significant specific cellular immune response 
was observed for all the groups tested when stimulating with purified recombinant H6-
EgTrp or crude homogenized E. granulosus antigens. 
Figure 21: 50 DPI Intestinal humoral immune response of mice immunized with (102-
207)EgTrp and (102-278)EgTrp recombinant spores detected against homogenate of wt B. 
subtilis biofilm 
(A) ELISA plot is showing secretory IgA in feces at 50 dpi. Each dot represents the mean OD450 
nm of one mouse in duplicate and normalized by the analyzed feces weight. (B) Plot showing 
serum IgA at 50 doi detected by ELISA. Each dot represents the mean at OD450 nm for one mouse 
in duplicate.   
For the plots (A) and (B); the coated antigens are indicated at the bottom [horizontal text]. The 
group of mice is shown below the x-axis. Each dot corresponds to one mouse by   for 
207EgTrp, n for 278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. DPI, days post 
immunization. Error bars show the standard error of the arithmetic means of each group. 
indicates a p-value < 0.05, ns indicates a not significant difference; one-way ANOVA with 
Tukey's multiple comparison tests. 
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Thus, a specific humoral response of sIgA against homogenized (102-207)EgTrp biofilm 
for both groups of EgTrp spore receiving mice was observed. Based on the obtained 
results it was concluded that a local intestinal humoral immune response, particularly 
Figure 22: Cellular immune response remains unaltered independent of the group of the 
mice. 
(A) Plot showing proliferating CD4+/CD8+ cells derived from the spleen after stimulation with H6-
EgTrp or homogenized crude E. granulosus indicated below x-axis [horizontal text]. Each dot 
represents the mean percentage of maximal stimulated cellular proliferation of one mouse 
measured in triplicate.  
(B) Plot showing proliferating CD4+/CD8+ cells derived from the MLN and Peyer’s patches after 
stimulation with H6-EgTrp or homogenized crude E. granulosus indicated below x-axis [horizontal 
text]. Each dot represents the mean percentage of maximal stimulated cellular proliferation of one 
mouse measured in triplicate.  
For the plots from (A) to (B), each dot corresponds to one mouse by  for 207EgTrp, n for 
278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. Error bars show the standard error of the 
arithmetic mean of each group.  indicates a p-value < 0.05, ns indicates a not significant 
difference; one-way ANOVA with Tukey's multiple comparison tests. 
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with the (102-207)EgTrp group could be detected when treating the mice with antibiotics 
previous to the first oral gavage with recombinant spores. However, it remains 
unenlightened against which components of the B. subtilis biofilm the immune response 
was directed. 
Results of the mouse experiment of mice treated previously to each oral gavage with 
antibiotics 
With the previous experiments, I had shown that modeling the intestinal 
microflora before the first inoculation improved the detected local humoral immune 
response against the EgTrp antigenic peptides. Due to the role of the antibiotics in 
eradicating the gut microflora, I questioned the effect that it would have to the immune 
response when mice were treated with antibiotics before each immunization boost with 
the recombinant spores. For this purpose, an experiment including the following schedule 
was performed (Figure 23A).  
 
The mice were grouped into four groups of 6 mice each: i) placebo (saline solution), ii) 
control spores ∆tasA/∆sinR, iii) recombinant spores of the (102-207)EgTrp strain and iv) 
recombinant spores of the (102-278)EgTrp strain. Mice were immunized by oral gavage 
on days 1, 21 and 42 of the schedule. Besides, the mice received the antibiotic cocktail for 
Figure 23: Mouse experiment with animals receiving antibiotics before each oral gavage 
of recombinant spores expressing EgTrp in the ECM of biofilms.  
(A) Schematic representation of the inoculation schedule. Recombinant B. subtilis strains 
(102-207)EgTrp and (102-278)EgTrp were administered. Six female, six weeks old Balb/c 
mice per group received through oral gavage (é) 5 x 1010 spores or saline solution (Placebo) 
on days 1, 21 and 42 of the experiment. The mice received antibiotics in the drinking water 
before each oral gavage (-). Before each oral gavage, blood (ê) and feces () samples were 
collected from each mouse. On day 50 mice were euthanized (í), and mesenteric lymph 
nodes, Peyer's patches, and spleen were harvested for analysis. (B) Plot showing mouse body 
weight. Data corresponding to the group body weight represented as mean ± SEM [g]. Each 
dot corresponds to the group average by  for 207EgTrp, n for 278EgTrp, ¢ for Placebo and 
n for ∆tasA/∆sinR. DPI, days post immunization; PI, pre-immune. é, oral gavage. Error bars 
show the standard error of the arithmetic means of each group.  indicates a p-value < 0.05. 
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six days prior the first oral gavage and three days previous the 2nd and third immunization 
(days 21 and 42). Feces and blood samples were collected as indicated in the 
immunization schedule. At day 50, mice were euthanized for collection of spleen, MLN 
and Peyer’s patches. As expected during each treatment with antibiotics the mice had lost 
weight but always less than 20% of their initial weight (Figure 23B). Additionally, they 
recovered within a short time once the antibiotic treatment was interrupted. 
 
Indirect ELISA measured the local immune response from sIgA isolated from feces in 
plates coated with biofilm from B. subtilis (102-207)EgTrp strain (Figure 24A). The 
mice of the (102-278)EgTrp group showed to have a significant higher sIgA level on day 
50 when compared to the Placebo mice. However, the level of sIgA was similar to the 
level of sIgA that ∆tasA/∆sinR receiving mice showed on day 42. Further showed the 
mice of all the groups gavaged with spores a higher level of sIgA at day 42 when 
compared to the placebo when coating with biofilm extract from B. subtilis ∆tasA/∆sinR 
or wild type (Figures 24B and 25A). Furthermore, the serum IgA (Figures 24 C and 25 
B), showed a specific response of both EgTrp spores receiving groups against biofilm 
extracts of B. subtilis (102-207)EgTrp but not against ∆tasA/∆sinR strains and to purified 
recombinant proteins H6-EgTrp, H6-TasA and H6-mCherry. However, it remains not-
elucidated to what component of the B. subtilis biofilm the mice developed an immune 
response detected by high sIgA and IgA levels. 
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Figure 24: Specific secretory IgA and serum IgA humoral immune response of mice 
gavaged with (102-278)EgTrp recombinant spores detected after treatment of the mice with 
antibiotics before each oral gavage. 
(A) Plot showing secretory IgA in feces detected by ELISA coated with homogenized biofilm 
expressing TasA-(102-207)EgTrp. Each dot represents the mean OD450 nm of one mouse in 
duplicate and normalized by the analyzed feces weight. (B) Plot showing secretory IgA in feces 
detected by ELISA coated with 72 h homogenized biofilm from B. subtilis ∆tasA/∆sinR strain. 
Each dot represents the mean OD450 nm of one mouse in duplicate and normalized by the analyzed 
feces weight. (C) Plot showing serum IgA detected by ELISA coated with 72h homogenized 
biofilm B. subtilis TasA-(102-207)EgTrp strain. Each dot represents the mean OD450 nm of one 
mouse in duplicate.  
For the plots from A to C each dot corresponds to one mouse by   for 207EgTrp, n for 
278EgTrp, ¢ for Placebo and n for ∆tasA/∆sinR. DPI, days post immunization; PI, pre-immune. 
Error bars show the standard error of the arithmetic means of each group. indicates a p-value 
< 0.05, ns indicates a not significant difference; one-way ANOVA with Tukey's multiple 
comparison tests. 
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The cellular immune response of T cells derived from the spleen (Figure 26) and pooled 
MLN and Peyer’s patches (Figure 27) was determined by a proliferation assays using for 
stimulation purified H6-EgTrp, H6-TasA and homogenized crude E. granulosus antigens. 
The analysis of CD4+, CD8+, and CD4+/CD8+ T cells did not show any significant 
differences between the analyzed groups.  
 
 
Figure 26: Cellular immune response of 
spleen-derived cells remains unaltered for 
all groups. 
(A) Plot showing proliferating spleen cells 
after stimulation with purified recombinant 
H6-EgTrp. The group of mice is indicated 
under the x-axis. Each dot represents the 
mean percentage of maximal stimulated 
cellular proliferation of one mouse 
measured in triplicate. (B) Plot showing 
proliferating spleen cells after stimulation 
with purified recombinant H6-TasA. The 
group of mice is indicated below the x-axis, 
and the cell type is indicated at the bottom 
[horizontal text] of the plot. Each dot 
represents the mean percentage of maximal 
stimulated cellular proliferation of one 
mouse measured in triplicate. (C) Plot 
showing proliferating spleen cells after 
stimulation with crude E. granulosus 
homogenized. The group of mice is 
indicated below the x-axis, and the cell type 
is indicated at the bottom [horizontal text] of 
the plot. Each dot represents the mean 
percentage of maximal stimulated cellular 
proliferation of one mouse measured in 
triplicate.  
For the plots from A to C each dot 
corresponds to one mouse by  for 
207EgTrp, n for 278EgTrp, ¢ for Placebo 
and n for ∆tasA/∆sinR. Error bars show the 
standard error of the arithmetic means of 
each group. indicates a p-value < 0.05, 
ns indicates a not significant difference; 
one-way ANOVA with Tukey's multiple 
comparison tests. 
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Thereby by treating the mice with antibiotics previous to each oral gavage 
seemed not to increase the humoral immune response. The obtained data suggest that for 
an enhancement of the humoral immune response it is sufficient to provide a unique 
treatment with antibiotics at the beginning of the enteric immunization. Furthermore, after 
Figure 27: Cellular immune response of 
MLN and Peyer’s patches derived cells 
remains unaltered for all groups. 
(A) Plot showing proliferating MLN and 
Peyer's patches cells after stimulation with 
purified recombinant H6-EgTrp. The group 
of mice is indicated below the x-axis, and 
the cell type is indicated at the bottom 
[horizontal text| of the plot. Each dot 
represents the mean percentage of maximal 
stimulated cellular proliferation of one 
mouse measured in triplicate. (B) Plot 
showing proliferating MLN and Peyer's 
patches cells after stimulation with purified 
recombinant H6-TasA. The group of mice 
is indicated below the x-axis, and the cell 
type is indicated at the bottom [horizontal 
text] of the plot. Each dot represents the 
mean percentage of maximal stimulated 
cellular proliferation of one mouse 
measured in triplicate. (C) Plot showing 
proliferating MLN and Peyer's patches 
cells after stimulation with homogenized 
crude E. granulosus. The group of mice is 
indicated below the x-axis, and the cell 
type is indicated at the bottom [horizontal 
text] of the plot. Each dot represents the 
mean percentage of maximal stimulated 
cellular proliferation of one mouse 
measured in triplicate.  
For the plots from A to C each dot 
corresponds to one mouse by   for 
207EgTrp, n for 278EgTrp, ¢ for Placebo 
and n for ∆tasA/∆sinR. Error bars show 
the standard error of the arithmetic means 
of each group.  indicates a p-value < 
0.05, ns indicates a not significant 
difference; one-way ANOVA with Tukey's 
multiple comparison tests. 
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repeated antibiotics treatment its favor the antigenicity of the (102-278)EgTrp spores over 
the (102-207) spores.  
 
Evaluation of the immune response in mice orally administrated with recombinant B. 
subtilis spores carrying EgA31 antigenic peptide.  
 
Parallel to the testing of E. granulosus tropomyosin (EgTrp) antigens by enteric 
immunization: I tested if the recombinant B. subtilis expressing (370-583)EgA31, would 
be able to promote a specific local humoral immune response. For this purpose, two 
mouse experiments were performed. In the first experiment using TasA-Paramyosin (370-
583)EgA31 a schedule was organized that includes an antibiotics treatment before the 
first and the third oral gavage of recombinant spores. In the second experiment, the 
schedule includes an antibiotics treatment before each of the three oral gavages. All other 
parameters were unaltered compared to the previously described experiments using 
recombinant B. subtilis strains expressing EgTrp (Data not shown). 
The results showed that the mice receiving spores of the B. subtilis (370-583)EgA31 
strain had a similar behavior as EgTrp strains with a loss of body weight accordingly to 
the antibiotics treatment but not due to the oral administration of B. subtilis spores. The 
analysis of the local immune response by indirect ELISA of sIgA isolated from the feces 
revealed no significant difference in the response among the different immunized groups 
in plates coated with B. subtilis biofilm extract from (370-583)EgA31, ∆tasA/∆sinR or 
wild-type strains. Also, the systemic humoral response, denoted by serum IgA showed no 
significant difference between the immunized groups independently of the tested 
antigens. Also, no difference was observed when stimulating T cells derived from the 
spleen, MLN and Peyer’s patches with purified recombinant H6-EgA31 or crude E. 
granulosus homogenate. These observations were independent of the experimental setup, 
therefore independent of giving before the first and third oral gavage or before each oral 
gavage antibiotics to the mice. 
In summary, the spores carrying (370-583)EgA31 were not able to induce a detectable 
local humoral response even if mice were treated with antibiotics previous to each 
immunization. The results suggest that these particular recombinant spores were non-
immunogenic or induced tolerance.   
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Use of recombinant B. subtilis expressing E. granulosus antigens for enteric 
immunization of dogs  
 
Canidae, like dogs, are the definitive host for the E. granulosus tapeworm 203. 
Hence, it is of priority to determine if recombinant B. subtilis spores carrying E. 
granulosus antigens can induce a local humoral or cellular immune response in orally 
immunized dogs. For this purpose, an experimental trial was performed in dogs to 
determine the local and systemic humoral as well as a cellular immune response in dogs 
orally administered with spores of the recombinant B. subtilis strains expressing the E. 
granulosus antigenic peptides, EgA31 and EgTrp.  
Schedule of the dog experiment 
The tentative schedule was based on the oral administration of recombinant B. subtilis 
spores carrying (102-207)EgTrp, (102-278)EgTrp and (370-583)EgA31 antigenic 
peptides. Thus, eight animals included in the experiment were separated into four groups 
of two dogs each. The groups were the following: i) placebo (saline solution), ii) EgTrp 
(receiving (102-207)EgTrp and (102-278)EgTrp spores), iii) EgA31 (receiving (370-
583)EgA31 spores), iv) Mixture (receiving (102-207)EgTrp and (370-583)EgA31 
spores). As depicted in the experiment schedule (Figure 28A), the dogs were orally 
administered with a total 5x1010 CFU / dose of spores for three times on days 1, 21 and 
42. Additionally, the animals were weighed (Figure 28B) and examined by a veterinarian 
before every treatment to ensure their health. Blood samples were collected weekly to 
determine the humoral and the cellular immune response. Furthermore, on day 60 the 
dogs were euthanized for the collection of spleen, MLN and Peyer’s patches for the 
analysis of the cellular immune response. Samples from duodenum, jejunum, ileum, 
caecum and colon were collected for detection of recombinant B. subtilis as well as 
inflammatory cells by histological analysis. 
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Humoral immune response of the dogs 
The humoral immune response (IgA and IgG) against the recombinant spores was 
analyzed by indirect ELISA using plates coated with biofilm extracts from B. subtilis 
(102-207)EgTrp or (370-583)EgA31 strains, and purified recombinant proteins H6-
EgTrp, H6-EgA31, H6-TasA or H6-mCherry, respectively. The results are presented as bar 
charts showing the delta OD, as the pre-immune value was subtracted from the measured 
OD to determine the specific humoral immune response developed during the 
experiment. The immunological profiles obtained by the ELISAs of the purified 
recombinant proteins H6-EgTrp, H6-EgA31 and H6-TasA were compared to the immune 
response profile of a complete exogenous antigen as is H6-mCherry. Thereby, the animals 
that responded positively for H6-mCherry with an immune profile similar to the other 
tested recombinant antigens (H6-EgTrp, H6-EgA31, H6-TasA) were considered as not 
showing specific IgG and or IgA against the tested recombinant antigens. Further, were 
indirect ELISAs performed against homogenate of complete biofilms from the B. subtilis 
(102-207)EgTrp strain and compared to the immune profile obtained when tested against 
homogenate of complete biofilms from B. subtilis (370-583)EgA31 strain, and vice versa. 
Thereby, animals that showed a response against the homogenate of biofilm of both 
strains were considered as responding to more antigens in the biofilm than the specific 
expressed (102-207)EgTrp and (370-583)EgA31, respectively. 
Figure 28: Healthy development of the dogs included in the oral gavage experiment 
(A) Schematic representation of the dog immunization schedule with recombinant B. subtilis 
spores (102-207)EgTrp and (102-278)EgTrp or/and (370-583)EgA31 strains. Two beagle dogs 
per group received by oral gavage (é) 5 x 1010 spores or saline solution (Placebo) on days 1, 
21 and 42 of the experiment. Before each oral gavage, blood (ê) samples were collected. On 
day 60 the dogs were euthanized (í), and mesenteric lymph nodes, Peyer’s patches, spleen 
and intestinal samples were collected for analysis. (B) Plot showing the dog body weight [kg]. 
Each dot corresponds to one dog bright blue (circle) and dark blue (square) for EgTrp; bright 
yellow (circle) and dark yellow (square) for EgA31; bright green (circle) and dark green 
(square) for spores mixture and bright red (circle) and dark red (square) for the placebo. 
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In a first attempt, the serum samples were tested against the purified recombinant 
protein H6-mCherry to control for the potentially recognized E. coli cell debris from the 
purification process (Figure 29). In a second attempt, the serum samples were tested 
against the purified recombinant proteins H6-EgTrp, H6-EgA31, and H6-TasA (Figure 
30). The bar charts are showing the delta OD of the measured value subtracted the value 
measured for pre-immune samples. 
 
 
 
The delta OD presented in Figure 29 A and B for one of the dogs receiving EgTrp spores 
(bright blue bars) increased from seven weeks post-immunization (IgG and IgA). 
However, one of the dogs receiving (370-583)EgA31 spores (dark yellow bars) showed a 
decreasing IgG and IgA signal against H6-mCherry in the ELISA. Further, one of the 
mixed group dog (dark green bars) show low IgG reaction (< 0.1 ∆OD450), and the other 
Figure 29: ELISA analysis of the detectable immunoglobulins against the purified 
recombinant H6-mCherry  
Bar charts are showing the humoral immune response (total IgG and IgA) detected by indirect 
ELISA. The results were calculated by subtraction of the individual PI level of each dog. In 
blue (bright and dark) the EgTrp group, in yellow (bright and dark) the EgA31 group, in green 
(bright and dark) the Mixed group and in red (bright and dark) the Placebo group. (A) serum 
total IgG specific against H6-mCherry. (B) serum IgA specific against H6-mCherry.  
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dog of the mixed group (bright green bars) and the control dog of the Placebo group 
(bright red bars) showed reactive IgA against H6-mCherry. 
 
In a next attempt, the detectable IgG and IgA in the blood serum samples of the dogs 
were analyzed in an ELISA against recombinant H6-EgTrp. The one dog EgTrp 
inoculated (dark blue bars) and the dog inoculated with mixed spores (dark green bars) 
showed increasing IgG and IgA response against purified H6-EgTrp in the ELISA 
(Figure 30 A and B). Further, one of the dogs receiving EgTrp spores (bright blue bars) 
show a response for IgG at 3, 7 and 9 weeks post-immunization and for IgA at weeks 7, 8 
and 9. But, one of the (370-583)EgA31 spores receiving dogs (dark yellow bars) showed 
a decrease of IgG and IgA against purified H6-EgTrp.  
When analyzing the ELISA against purified H6-EgA31 (Figure 30 C and D), it was 
observed that EgTrp spores receiving dogs (bright and dark blue bars) had an increasing 
response as well as one from mixed spores group (dark green bars) that also had shown 
previously low response against purified H6-EgA31. However, (370-583)EgA31 spores 
receiving dog (dark yellow bars) showed a decreased level of  IgG and IgA against H6-
EgA31. 
Next, the dog’s serum samples were tested against H6-TasA (Figure 30 E and F). A 
sharp increase of the signal for IgG was detected for the dog receiving spores of the 
EgTrp strains represented by dark blue bars. Further showed the same dog to have at 
week nine an increased IgA delta OD against H6-TasA. Similar to that but only starting 
from 7 weeks post-immunization and later showed the second EgTrp spore receiving dog 
(bright blue bars) an increased IgG as well as an IgA delta OD against H6-TasA. Different 
from the two (102-207)EgTrp dogs did one of the mixed group dogs (dark green bars) 
showed a decrease of the signal over time for IgG as well for IgA. 
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Figure 30: Testing of the 
humoral response of 
dogs inoculated with 
recombinant B. subtilis 
spores against purified 
recombinant E. 
granulosus proteins.  
Bar charts are showing 
the humoral immune 
response (total IgG and 
IgA) detected by indirect 
ELISA. The results were 
calculated by subtraction 
of the individual PI level 
of each dog. In blue 
(bright and dark) the 
EgTrp group, in yellow 
(bright and dark) the 
EgA31 group, in green 
(bright and dark) the 
Mixed group and in red 
(bright and dark) the 
Placebo group.  
(A) serum total IgG 
specific against H6-
EgTrp.  
(B) serum IgA specific 
against H6-EgTrp.  
(C) serum total IgG 
specific against H6-
EgA31.  
(D) serum IgA specific 
against H6-EgA31.  
(E) serum total IgG 
specific against H6-TasA. 
(F) serum IgA specific 
against H6-TasA 
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To interpret the results of the ELISA experiment the observed results against purified 
recombinant H6-mCherry antigen was compared to the signal profile obtained in the 
ELISAs against H6-EgTrp, H6-EgA31 and H6-TasA. As the H6-mCherry was achieved by 
the same purification process as the other recombinant proteins but was an entirely 
exogenous antigen for the dogs, the ELISA against H6-mCherry was expected to show 
signals from antibodies binding to proteins of E. coli remaining from the purification. For 
one dog receiving spores of the EgTrp strains (dark blue bars) the ELISA analyzing IgG 
against H6-EgTrp, H6-EgA31 and H6-TasA showed a sharp increase over time of the 
experiment, whereas the ELISA against H6-mCherry didn't show a signal apart from a 
peak on week 9 post-immunization. However, this dog showed a signal in the ELISA for 
IgA and IgG against H6-EgA31, which is also an exogenous antigen as H6-mCherry. Then 
the dog (dark blue bars) inoculated by (102-207) EgTrp spores was probably not showing 
a specific response against the recombinant H6-EgTrp, H6-EgA31, and H6-TasA. 
However, an increase of the signal over time was detected, which could not be 
differentiated against what component it was directed. Different to that, one dog receiving 
the mixture of B. subtilis spores of the (102-207)EgTrp and the (370-583)EgA31 strain 
(dark green bars) showed an increase of signal of IgG against H6-EgTrp, H6-EgA31 and 
H6-TasA detectable by ELISA. The other dogs had shown an ELISA signal profile 
against H6-EgTrp, H6-EgA31 and H6-TasA comparable to the ELISA signal profile for 
H6-mCherry or no signal at all and were therefore counted as not having developed a 
detectable humoral immune response specific against H6-EgTrp, H6-EgA31 and H6-TasA 
but probably against debris of E. coli lasting from the purification process.  
 
Next, the serum samples were tested first against biofilm from (102-207)EgTrp and 
second against biofilm of the (370-583)EgA31strain in an ELISA analysis (figure 31). 
The dog receiving spores of the EgTrp strains (dark blue bars) as well as the dog 
receiving the mixture of spores (dark green bars) showed a positive IgG delta OD from 
week two post-immunization on against the homogenate from the (102-207)EgTrp 
biofilm. For the IgA response, the dark green dog showed from seven weeks post-
immunization on an increased delta OD, and the dark blue dog showed nine weeks post-
immunization a peak of IgA against the homogenate from the (102-207)EgTrp biofilm. 
Further, did the two dogs receiving spores of the (370-583)EgA31 strain show a delta OD 
in the IgG and IgA ELISA, against the (102-207)EgTrp biofilm, one-week post-
immunization until the fifth-week post-immunization. The Placebo dogs showed to have 
some IgA detectable in the ELISA against the (102-207)EgTrp biofilm. When analyzing 
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the serum samples in an ELISA against the (370-583)EgA31 biofilm, the delta OD for 
IgG revealed that the dog of the EgTrp group (bright blue bars) developed an IgG 
response in the last four weeks of the experiment.  
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Further, did the dog of the EgA31 group (bright yellow bars) show an IgG response from 
one to five weeks post-immunization. When analyzing the IgA level detected in one dog 
of EgTrp group (light blue bars) showed from two till nine weeks post-immunization an 
elevated IgA level, peaking at seven weeks post-immunization. Whereas the IgA level of 
one of the dogs of the EgA31 group (light yellow bars) had a decreasing level of IgA 
from one-week post-immunization till four weeks post-immunization, reaching an 
undetectable level of IgA at five weeks post-immunization. When the results of the 
ELISA, against homogenates of the biofilms of the B. subtilis (102-207)EgTrp and the 
(370-583)EgA31 strains, were combined in an analysis that a signal in one ELISA but not 
in the other would represent a probably specific detection of the fusion protein. The 
results revealed that one dog of the EgTrp group (dark blue bars) developed an increasing 
IgG signal against the (102-207)EgTrp fusion protein, as no signal was detected when 
analyzing the serum samples of this dog in an ELISA against (370-583)EgA31. Further, 
did one dog of the mixed group (dark green bars) show an IgG response against the 
fusion protein TasA-EgTrp in the homogenized (102-207)EgTrp biofilm, as the serum 
sample did not contain a detectable amount of IgG against the homogenized biofilm (370-
583)EgA31. However, one dog of the EgA31 group (bright yellow bars) showed an IgG 
and IgA reaction within both ELISA. Therefore, this detected IgG and IgA reaction could 
be against other antigenic proteins of the biofilm than only the TasA-fusion protein, or 
against the TasA component of the fusion protein and was counted therefore as non-
specific against the TasA-(370-583)EgA31 antigen. 
 
In summary, the result obtained in the ELISA testing blood serum samples of the dogs 
indicate that one of the immunized dogs (dark blue bars) with single spore for EgTrp 
antigen resulted positive for the tested recombinant antigens (H6-TasA, H6-EgTrp, and 
Figure 31: Humoral response of dogs immunized with recombinant B. subtilis spores, 
(102-207)EgTrp / (102-278)EgTrp, against recombinant B. subtilis biofilm. 
Bar charts are showing the humoral immune response (total IgG and IgA) detected by indirect 
ELISA. The results were calculated by subtraction of the individual PI level of each dog. In 
blue (bright and dark) the EgTrp group, in yellow (bright and dark) the EgA31 group, in green 
(bright and dark) the Mixed group and in red (bright and dark) the Placebo group. (A) serum 
total IgG specific against homogenized (102-207)EgTrp biofilm. (B) serum IgA specific 
against homogenized (102-207)EgTrp biofilm. (C) serum total IgG specific against 
homogenized (370-583)EgA31 biofilm. (D) serum IgA specific against homogenized (370-
583)EgA31 biofilm. 
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H6-EgA31) but not against H6-mCherry. Further was an increasing signal against 
homogenized (102-207)EgTrp biofilm detected and no signal against the homogenized 
(370-583)EgA31 biofilm. Therefore, it remains unlighted against what component of the 
recombinant proteins the immune reaction was developed, but it is indicated that 
immunization against B. subtilis TasA-EgTrp could be detected in this dog. However, the 
other immunized dog (light blue bars) for EgTrp spores was not responding specifically 
due that similar immune response for this dog was observed for the control antigen H6-
mCherry. Also, the IgA immune response in those dogs was very low at late time post-
immunization, which was consistent with the maturation of the constant region of the 
heavy chain from the immunoglobulin. On the other hand, when analyzing the immune 
response of one dog immunized with single spores for EgA31 (light yellow bars), the dog 
was responding either specifically against the TasA protein or other components of the B. 
subtilis biofilm as the dog showed a response against both tested homogenates of 
biofilms. In the case of the dogs immunized with the mixed spores for both antigens 
(EgTrp and EgA31), one of them (dark green bars) was responding specifically to the 
antigens from the biofilm extract from B. subtilis (102-207)EgTrp but not against the 
(370-583)EgA31 biofilm. 
 
Blood-derived PBMC cellular immune response of the tested dogs  
Further, to study the immunological state induced in these dogs, their cellular 
immune response was examined in the course of the immunization by stimulating T cells 
from peripheral blood monocyte cells (PBMC) derived from the weekly blood samples. 
In particular, CD4+ cells and CD8+ cells and Treg cells (CD4+, CD25hi, CTLA4+) 
populations were analyzed by flow cytometer after stimulation with recombinant H6-
EgTrp and H6-EgA31 purified from E. coli.  
This analysis was performed with the dogs of the EgA31, the mixed group, and one 
placebo dog.  
Blood-derived T cells were stimulated using purified recombinant H6-EgTrp and H6-
EgA31. The delta percentage of T-cells proliferating after being stimulated with the 
indicated antigen compared to the proliferation of the T cells stimulated by PMA as the 
positive control at the week post-immunization minus the values obtained pre-immune 
are presented in figure 32. The results revealed that the dog of the mixed group 
represented by the dark green bars developed an increased proliferation of CD4+ cells 
when stimulated by H6-EgTrp and H6-EgA31. Whereas the CD8+ cells were showing an 
increased proliferation when boosted by H6-EgTrp after six weeks post immunization but 
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when excited by H6-EgA31 an increased proliferation was detected from one-week post-
immunization till eight weeks post-immunization. However, the values were inconsistent 
from week to week and showed to have a high variability. The second dog of the mixed 
group (bright green bars) showed an increased proliferation of CD4+ cells when 
stimulated by H6-EgTrp but not when the cells were boosted by H6-EgA31. However, the 
CD8+ cells were showing an increased proliferation when boosted by H6-EgTrp and H6-
EgA31 but as well for this dog a high variability from week to week was detected. The 
dog receiving spores of the (370-583)EgA31 strain showed (dark yellow) to have CD4+ 
and CD8+ cells increasing the proliferation rate when stimulated by H6-EgA31 but not 
when boosted by H6-EgTrp.  
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Figure 32: Cellular immune response tested for blood-derived PBMC of immunized dogs.  
Bar charts are showing the cellular immune response of blood derived PBMC detected by 
CFSE dilution and flow cytometer analysis. The results were calculated by subtraction of the 
individual PI level of each dog. In green (bright and dark) the Mixed group, in yellow (bright 
and dark) the EgA31 group and bright red the tested Placebo dog. 
(A) CD4+ PBMC stimulated by H6-EgTrp. (B) CD4+ PBMC stimulated by H6-EgA31. (C) 
CD8+ PBMC stimulated by H6-EgTrp. (D) CD8+ PBMC stimulated by H6-EgA31 
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Further, it is to mention that the dog receiving the placebo did also show to have CD4+ 
and CD8+ cells increasing the proliferation rate when stimulated by H6-EgTrp or H6-
EgA31. But for the CD4+ cells stimulated by H6-EgTrp or H6-EgA31 and the CD4+ cells 
boosted by H6-EgTrp the proliferation was at a low level when comparing it to the cells 
derived from the other dogs. However, as the placebo dog was showing such a high 
response of CD8+ cells when having stimulated the cells by H6-EgA31, the response of 
CD8+ cells of the other dogs shown in Figure 32 D was considered as background. Based 
on the inconsistent values measured for each dog and the partially high reactivity of the 
cells derived from the placebo dog it remains not-elucidated if the analysis is showing the 
particular reaction of the tested cells or the inconsistent reaction were an effect of an 
uncontrolled parameter of the experiment.  
 
Additional were the blood derived Treg PBMC cells (CD4+, CD25hi, CTLA+) analyzed. 
Only in one of the EgA31 spore receiving dogs an increased proliferation of the Treg cells 
was detected when having stimulated them by H6-EgA31 (Figure 33 B). The increase in 
Treg cell proliferation was detected four weeks post-immunization, which was coincident 
Figure 33: T regulatory cell proliferation induced by recombinant H6-EgA31 of one of the 
EgA31 receiving dogs. 
Bar charts are showing the cellular immune response of blood derived PBMC (CD4+, CD25hi, 
CTLA+ Treg cells) detected by CFSE dilution and flow cytometer analysis. The results were 
calculated by subtraction of the individual PI level of each dog. In yellow (bright and dark) the 
EgA31 group, in green (bright and dark) the Mixed group and bright red the tested Placebo dog. 
(A) Treg cells PBMC stimulated by H6-EgTrp. (B) Treg cells PBMC stimulated by H6-EgA31 
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with the detected decrease of the CD4+ T cells proliferation when being stimulated by H6-
EgA31. 
As a manner to detect local cellular immunity, the derived T cells from the spleen, MLN 
and Peyer’s patches were stimulated with recombinant purified H6-EgTrp and H6-EgA31. 
The results obtained were presented as a percentage of proliferation of the cells 
stimulated by the positive control (PMA induced). Therefore, rates of proliferation below 
100 % were considered as non-responding. Remarkably CD4+ cells derived from 
mesenteric lymph nodes (MLN) of dogs receiving spores of the EgTrp strain (bright blue 
and dark blue) were vigorously proliferating when stimulated by recombinant H6-EgTrp, 
but only cells from one dog (bright blue) when the cells were derived from Peyer’s 
patches. Different to that were CD4+ cells derived from the spleen of the dogs receiving 
(370-583)EgA31 strain spores (yellow bright and dark) showing an increased 
proliferation when stimulated by H6-EgA31. For the CD8+ cells derived from MLN 
independent of the recombinant protein used and independent of the dog (placebo, EgTrp, 
and EgA31) showed an increased proliferation. However, CD8+ spleen-derived cells of 
one dog of the mixed group (bright green) showed an increased proliferation for both 
stimuli (H6-EgTrp and H6-EgA31). However, the dog (dark green square) of the same 
group showed to have CD8+ cells proliferating when derived from PP (H6-EgTrp and H6-
EgA31 stimulated) and when stimulating by H6-EgA31 also spleen-derived CD8+ cells 
showed an increased proliferation for this dog. Interestingly one dog receiving EgTrp 
spores (dark blue) had an increase CD8+ proliferation derived from the spleen, whereas 
the other dog from the same group (bright blue) showed an increased CD8+ proliferation 
from +Peyer Patches derived cells stimulated by H6-EgTrp. Similarly to the dogs 
receiving (370-583)EgA31 spores (bright yellow) that have an increased CD8+ 
proliferation of spleen-derived cells. Thus, the other dog of the same group (dark yellow) 
showed an increased CD8+proliferation Peyer Patches derived cells when H6-EgA31 
stimulated. 
Based on the observation that the two dogs of the same group often appear to have 
different cellular immune response profiles (Figure 34) the interpretation of the results 
remains difficult and is further discussed in the discussion of this thesis. 
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Figure 34: Cellular response of 
cells derived from the spleen, 
mesenteric lymph nodes and 
Peyer's patches of dogs 
immunized with recombinant B. 
subtilis spores carrying (102-
207)EgTrp or (370-583)EgA31 
antigen. 
(A) Plot showing 
CD4+proliferation induced by 
purified recombinant H6-EgTrp. 
Each dot represents the mean 
percentage of maximal 
proliferation of one dog in 
triplicate. (B) Plot showing CD4+ 
cellular proliferation induced by 
purified recombinant H6-EgA31.  
(C) Plot showing CD8+ cellular 
proliferation induced by purified 
recombinant H6-EgTrp. (D) Plot 
showing CD8+ cellular 
proliferation induced by purified 
recombinant H6-EgA31. Each dot 
represents the mean percentage of 
maximal proliferation of one dog 
in triplicate. 
For the plots (A) to (D) each dot 
corresponds to one dog by bright 
yellow (circle) and dark yellow 
(square) for EgA31, bright green 
(circle) and dark green (square) for 
the Mix bright red (circle) and dark 
red (square) for the Placebo. DPI, 
days post immunization; PI, pre-
immune.  
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B. subtilis mutant bacteria extracted ex vivo of the intestine of immunized dogs 
The small intestine from the dogs receiving the mixed spores for EgA31 and EgTrp was 
divided in duodenum, jejunum, and ileum. The intestinal content of each part was 
collected by perfusion and then cultivated in selective semi-solid media for the detection 
of recombinant B. subtilis. As denoted in Table 5, it was possible to isolate from the 
duodenum and the jejunum from one the dogs (corresponding to light green), 3200 and 
12200 CFU/ml of the recombinant B. subtilis, respectively.  
 
Dog Intestinal section Estimated amount of of  
bacteria 
Mix (light green) Duodenum 3200 CFU/mL 
 Jejunum 12200 CFU/mL 
 Ileum  
Mix (dark green) Duodenum  
 Jejunum  
 Ileum  
Table 5: CFU of recombinant B. subtilis detected in the small intestine of dogs 
receiving the mixture of EgTrp and EgA31 spores. 
 
These colonies were analyzed by PCR using specific primers for detection of the B. 
subtilis EgTrp and EgA31 strains (Figure 35 A and B). The results showed the presence 
of both recombinant B. subtilis strains in duodenum and jejunum. Thereby, suggesting 
that spores from B. subtilis germinated and got establish in the small intestine of the 
inoculated dogs, in particular in the duodenum and jejunum. However, this analysis was 
performed with the mix group dogs but not with the other dogs. Further, as only one of 
both dogs showed to have a detectable amount of recombinant bacteria in the duodenum 
and the jejunum, this observation is left as a single result and not extrapolated any further. 
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In conclusion of the dog experiment, I state that the body weight of the dogs was not 
influenced by the oral administration of B. subtilis recombinant spores. I observed 
indicators for a humoral immune response but also indicators for non-specific responses. 
Therefore, the humoral and cellular immune response do not give a clear answer if the 
recombinant spores would in a bigger population of dogs induce an immune response or 
not. Further, it is important that in at least one dog of the mixed group recombinant B. 
subtilis in the jejunum and ileum lumen were detected 18 days after the last 
administration of spores. Therefore, for this experimental setup performed with the 
analytical methods shown, revealed that one dog receiving recombinant B. subtilis (102-
207)EgTrp (dark blue) most probably developed a humoral immune response specific 
against the B. subtilis (102-207)EgTrp biofilm. 
 
 
  
Figure 35: Intestinal content of one dog receiving the mixture of (102-207)EgTrp and 
(370-583)EgA31 showed to be for one dog recombinant EgA31 and EgTrp positive 
End-point PCR analysis of the found bacteria in the intestine of the dog. The left panel is 
showing (102-207)EgTrp specific PCR and right panel showing (370-583)EgA31 specific 
PCR. D, J1, J2 describe the position of the found sample (D = duodenum, J = jejunum). 
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Discussion 
Why do we need an affordable vaccine against E. granulosus? 
A successful vaccine needs to be effective in inducing a specific neutralizing 
immune response against the pathogen of interest, and furthermore, meet conditions as 
safety, production feasibility, affordable storage and stability over a reasonable time 22,204.  
The E. granulosus is a significant burden in developing countries due to the absence of a 
licensed vaccine protecting the intermediate or the definitive host. A mathematical model 
developed by Torgerson et al. 173 suggested that targeting tapeworms in dogs could 
substantially decrease the parasite population. This model partially corroborated by 
treating dogs monthly with Praziquantel® (an antihelmintic drug), which reduced the 
rates of E. granulosus infection significantly in sheep being in close contact with the 
treated dogs 205. However, due to the high frequency and the long duration of the 
eradication process for the E. granulosus tapeworms in a defined geographic area, the 
drug treatment resulted to be highly expensive and hard to manage. Therefore the use of a 
vaccine that could provide a long lasting protection in dogs would be highly 
advantageous 146,206,207. However, a vaccine administrated subcutaneously or 
intramuscularly demands trained staff that restrains the animals 208, and also the vaccine 
has to be sterile and pH and osmolarity controlled, and be free from residual host proteins 
and DNA 209.  
Previous studies demonstrated the ability of dogs to develop a specific immune response 
against E. granulosus, particularly against the protoscoleces membrane 177,210 and the 
secretory antigens 211,212. Additionally, it has also been shown that the use of paramyosin 
13,213–215 and tropomyosin 216,217 in immunization trials induced protective immunity 
against helminths infection. Thus, the paramyosin (EgA31) and tropomyosin (EgTrp) are 
detectable in the metacestodes and the protoscoleces states of E. granulosus 174. When 
administrated to dogs in an immunization trial using a carrier as Salmonella typhimurium 
expressing EgTrp and EgA31 antigens, a 70% reduction in tapeworm number after 
challenging with the parasite is observed 13. These promising results suggested that 
EgA31 and EgTrp could represent the antigens required for the eradication of E. 
granulosus in endemic areas. However, the use of attenuated S. typhimurium as carrier for 
enteric immunization has some drawbacks as are i) the expression of heterologous 
antigens is based on an episomic system, which can be lost by the bacteria; ii) the limited 
acceptance by the community of a pathogenic vector 218 and iii) reasonable lack of 
precedents regarding loss of the generated immunity after a natural infection with S. 
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typhimurium 219. B. subtilis, in contrast to S. typhimurium, is in possession of a GRAS 
(generally regarded as safe) status. Also, recombinant B. subtilis spores had been already 
tested in several studies as a carrier for enteric antigens showing no adverse effect 23,220–
222. Thus, it suggests that B. subtilis is a good candidate for an enteric vaccine against E. 
granulosus. Also, numerous advantages are provided using spores of B. subtilis as an oral 
vaccine for human or veterinarian purposes. Some of these benefits correspond to general 
conditions of an oral vaccine as are: i) no special training of a specialized staff for the 
vaccine administration 223; ii) in a veterinarian context, the animals do not require to be 
restrained as the vaccine can be administered directly within the food 208. Additional 
specific features for this kind of vaccine are: i) the resistance to the stomach acidic 
environment 93; ii) the lower impact for less-purified antigens 24,209; iii) considered as safe 
224; iv) readily prepared and purified 27; v) no requirement of a cold chain 93 and vi) the 
genetics and the physiology of B. subtilis is well-known. These conditions permit the 
development of a safe vaccine with controllable gene expression systems 26. A major 
advantage of using spores of B. subtilis, as a carrier for an oral vaccine is the preparation 
and purification based in successive washes with distilled water (see Materials and 
Methods) that reduce the risk of chemical contamination. Also, the vaccines have a 
tendency to lose activity within a short time because of inactivation of the biological 
compounds, a process that is mainly temperature dependent 225. In fact, currently only 31 
of WHO licensed vaccines are stable enough to resist a longer exposure to room 
temperature 226. Thus, the spores of B. subtilis are stable at room temperature and even 
can be frozen or exposed to temperatures as high as 45°C for 17 months without 
significant loss of effectiveness when tested in immunization trials 227,228. The data 
presented in this thesis, clearly show that the recombinant B. subtilis spores that carry E. 
granulosus antigens EgTrp and EgA31 are succeeding all the resistance tests for spores 
(shelf-life, high temperatures, and low pH) (Figure 12). Thus, the working hypothesis 
that recombinant B. subtilis spores, compared to wild-type spores, would not be altered in 
their tenacity and shelf life at room temperature, was proven to be correct.  
However, even showing similar resistance as the B. subtilis NCBI3610 spores, the 
number of spores of the recombinant strains was significantly reduced (Figure 7E). 
Previously, Serrano et al. 229 were pointing towards a role of TasA in the spore assembly 
as they observed a lack of the proper coat assembly in B. subtilis spores in a tasA deleted 
strain. In contrast, we find any impairment of the resistance of recombinant spores when 
demonstrating tasA (∆tasA) or transducing it with TasA-E. granulosus antigens. Also, 
this observation is supported by transmitted electron microscopy images of the 
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recombinant B. subtilis spores showing no alterations of the spore coat structure. Thus, no 
change of the spore coat is observed neither in the absence of TasA (∆tasA) nor with 
TasA fused to any of E. granulosus antigens ( (102-207)EgTrp, (102-278)EgTrp or (370-
583)EgA31). Collectively, the data suggest that the unaltered tenacity of recombinant 
spores does not depend on the lack of TasA. Also, the modification of the TasA structure 
fused to an antigenic peptide at its C-terminus seems not to have a role in spores 
resistance. However, the difference in the number of spores harvested from the wild type 
strain compared to the ∆tasA/∆sinR strain is based on the impairment of the regulation of 
the spore formation, which is among other factors influenced by sinR 230.  
The observations, support the hypothesis that the TasA-antigen is expressed in vitro in the 
structure of biofilms. In this line of thought, the results presented by Vlamakis et al. 183 
showed that TasA is a major component of the ECM and influence on the biofilm 
phenotype. In this thesis, the presented immunization system contemplates that the 
antigen gets expressed on the surface of the biofilm, which in the gut intend to stimulate 
the GALT (Gut associated lymphoid tissue). By an in vitro system, we showed that TasA 
fused to E. granulosus antigen peptides gets expressed within the biofilm as denoted by 
antigen expression in immunoblotting using both anti-TasA and specific related peptidic 
antigen antibodies (Figure 9 C and 10 C). Also, immunohistochemistry of recombinant 
biofilms showed the localization of the antigen throughout the entire biofilm (Figure 11). 
The same results were obtained for all tested biofilm of the recombinant B. subtilis 
expressing E. granulosus antigenic peptides, EgTrp(102-207), EgTrp(102-278) and 
EgA31(370-583) strains. Moreover, the biofilm phenotype formed by the recombinant B. 
subtilis strains showed that the TasA-antigen fusion protein expression could compensate 
the phenotype architecture of the B. subtilis ∆tasA/∆sinR strain (Figure 9 B and 10 B).  
Are recombinant B. subtilis inducing an enteric immunity? 
The basic strategy of a vaccine is the presentation of a determined antigen to the 
immune system, which gets then recognized as non-self and processed to induce an 
immune response when challenging by encountering a particular pathogen 15. In the 
intestine, the antigen presenting cell (APC) are intestinal microfold (M) and dendritic 
cells (DCs), which are responsible for the capture, the transport, the processing and the 
presentation of the antigens 131. The naïve B cells recognize the presented epitope 
exposed on the APCs by a specific surface IgM that gets stimulated by the gut-homing 
integrin α4/β7 and CCR9. These two cytokines are specific for the expression of the gut-
associated mucosal directing cell adhesion molecule-1 (MAdCAM-1) and the 
TECK/CCL5 on T and B cells, respectively 132,231. Thus, B and T cells primed in the 
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intestine to acquire distinct migration patterns to be directed to secondary lymphatic 
organs and the site of intestinal priming 131. This immunological maturation leads to the 
generation of specific mature antibodies that recognize the first antigen, which can be 
detected in sera after 14 days and peak at 4 to 6 weeks from the primary immunization 232. 
Only very few vaccines induce after a single immunization a high and sustained antibody 
response due to the limited antigen availability. Therefore, the immunization schedules 
usually include two to three inoculations, repeated in an interval of 3-4 weeks 233,234. 
Consequently, the vaccination program used in this thesis was designed with three 
immunizations at day 1, 21 and 42 for both mice and dogs. Under these conditions in 
mouse experiments, the onset of detectable sIgA in feces started at day 42 post-
immunization and raised until day 50. In the trials performed by Duc et al. 100, the 
administration of B. subtilis spores, which expressed intracellular ß-galactosidase when 
germinating, provided a sIgA in feces that peaked at day 58. However, the results of Duc 
et al., were obtained after nine oral gavages of spores. The time point of the onset of the 
mounted humoral immune response for specific EgTrp sIgA in feces was consistent in all 
mouse experiments when testing B. subtilis strains expressing (102-278)EgTrp 
independently of the treatment of antibiotics. The generated humoral immune response is 
limited to the local sIgA intestinal secretion 235. The systemic humoral immune response 
was observed in the mouse experiments when administrating B. subtilis expressing (102-
207)EgTrp after the antibiotics treatment (Figure 20). The stated hypotheses that 
recombinant B. subtilis spores can bypass the stomach and further germinate in the 
intestine of mice and dogs by expressing TasA fused to an antigenic protein, forming an 
intestinal biofilm can be answered only partially based on the obtained results. The 
recombinant B. subtilis spores can pass through the stomach of mice and dogs as the 
spores extracted out of the feces of the animals were still able to germinate (e.g. Figure 
14 D and Table 5). Furthermore, the recombinant spores germinate in the intestine of 
mice and dogs as the humoral immune response against EgTrp(102-207), and EgTrp(102-
278). However, the data presented is still not sufficient to proof that the germinated 
spores are expressing all component to form a biofilm or are only expressing the fusion 
protein TasA-EgTrp. 
However, the detected humoral immune response was only significantly higher when 
compared to its pre-immune sample, but it was not significantly different from the 
detected humoral immune response in both placebo or B. subtilis background strain 
(∆tasA/∆sinR) groups. In contrast, the local humoral response of the (102-278)EgTrp 
mice group treated with antibiotics before each oral gavage (Figure 24). The antibiotics 
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treatment enable the humoral immune response against (102-207)EgTrp, likely by the 
opening of niches as result of a decrease in the taxonomic diversity in the intestinal 
microflora 125. Studies from Brandl et al. 117 showed that treatments with a combination of 
antibiotics as vancomycin, metronidazole, and neomycin in mice lowered the intestinal 
expression of the antimicrobial peptide RegIII-γ, which is part of the mucosal innate 
immune defense 117. Thus, through the reduction of the barrier function, it is possible that 
the B. subtilis (102-207)EgTrp strain enable the induction of a humoral immune response 
in mice. Also, the vancomycin treatment decrease the short intestinal chain fatty acids 
(SCFA) concentration, which correlates with a reduction of stimulated G-coupled 
receptor 43 (GPR43) in regulatory T (reg T) cells. Resulting in a reduction of Reg T cells 
population in the intestinal mucosa but not in other organs 236,237. In our experimental 
approach, mice also received vancomycin among other antibiotics, which could lead to a 
reduction of the protective immunity having consequently the allowance of the 
recombinant B. subtilis spore germination. Thereby, the effects of an appropriate 
environmental condition for the spore germination are the enhancement of the TasA-
EgTrp antigenic peptides that can be detected as a humoral immune response against the 
specific antigens. Also in mice, the systemic humoral response raised, as detect by the 
positive reaction of serum IgA against the EgTrp antigenic peptides presented by the 
recombinant B. subtilis strains. Meanwhile, the mice not receiving antibiotic treatment 
only developed a local humoral response (Figure 15 A). The humoral immune response 
obtained in the mouse model was consistent with the results obtained when testing the 
immune response in dogs to the recombinant B. subtilis spores. Thus, in mice a specific 
response against TasA-(102-207)EgTrp expressed in biofilm extract and from 
recombinant H6-EgTrp but not against homogenates of E. granulosus protoscoleces 
(Figure 16 and 21).  
The analysis the dog's serum showed an immune response against biofilm homogenized 
of two dogs (dark blue and dark green) immunized with recombinant B. subtilis spores 
carrying EgTrp anB. subtilisd (102-207)EgTrp strain, respectively (Figure 31 A). In a 
previous study performed by Zhang et al. 205, in which dogs were immunized three times 
subcutaneously with purified recombinant E. granulosus antigens in intervals of three 
weeks, showed a dog’s humoral immune response after four weeks and lasted until the 
end of the experiment at 16 weeks. However, the immunization performed by Zhang et al. 
205 raised a specific IgG response, whereas no IgA or IgE raise was detected. Even 
without the development of an IgA or IgE response, the dogs were protected (97 - 100%) 
concerning the suppression of growth and egg development in E. granulosus 205. In 
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contrast, the rise of the dog serum IgG levels in our experimental set-up was already 
observed at two weeks after the first oral administration with recombinant spores. The 
humoral immune response was increasing until the end of the experiment, and it 
developed in IgA response (Figure 31), indicating that the immunization through oral 
administration in dogs seemed to be faster in generating a detectable immune response 
than subcutaneous immunization. The data in this work demonstrated that the 
recombinant spores induce the development of a humoral immune response in mice and 
dogs. 
Another point was the absence of detectable humoral immune response against EgA31 
antigenic peptides. The dogs and the mice receiving (370-583)EgA31 recombinant spores 
did not develop any specific increase of antibodies against (370-583)EgA31 in serum or 
feces. The two mouse experiments, in which were tested EgA31, were performed treating 
mice two and even three times with antibiotics in the drinking water. Even this antibiotic 
cocktail improve the response to (102-207)EgTrp, does not improve the mice for the 
recombinant EgA31 spores. The same results were observed in both mice and dogs 
experiments in which the recombinant (370-583)EgA31 spores. The negative response of 
the dogs and the mice towards the stimulation with EgA31 was probably based in no 
germination in GIT of the EgA31 spores of the dogs and mice or the development of 
tolerance against the EgA31 antigenic peptide. The first point can be argued against 
because of the EgTrp strains, possessing the same genetic background as the EgA31 
strain, and can induce a humoral immune response in mice and hence germinated in the 
GIT. Also, the in vitro tests (biofilm phenotyping, expression by immunoblots, biofilm 
antigen localization by immunohistochemistry) did not show any particular impairment of 
the (370-583)EgA31 strain. Lastly, the spores detected in the duodenum and jejunum of 
one of the dogs which received a mixture of EgTrp and EgA31 spores, turned positive by 
PCR analysis when tested with the specific EgA31 primers, suggesting that (370-
583)EgA31 spores were settled in the intestine of the dogs. Collectively the data suggest 
that the induction of tolerance in mice and dogs by EgA31 antigenic peptides could be 
responsible for the lack of humoral immune response to this antigen. This observation is 
sustained by a decrease in CD4+ T cell proliferation, and an increase of regulatory T cell 
proliferation in one EgA31 immunized dogs (Figure 32 and 33). The results are 
consistent with previous reports, showing 238 that the T cell population is not only 
instructed by classic self/non-self discrimination mechanisms during thymic 
development, but is also educated in the periphery to accommodate the variety of non-self 
antigens derived from the commensal microbiota at mucosal sites. Thereby, leading to 
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tolerance by induction of T regulatory cells 238,239,240 Further, as the experimental results 
presented in this thesis pointed towards the stimulation of the regulatory T cells by TasA-
(370-583)EgA31 due that serum regulatory T cell isolated from the dogs receiving the 
spore mixture (EgA31 and EgTrp) proliferate after stimulation by H6-EgA31 indicating 
the development specific tolerance toward EgA31 antigenic peptide. On the other hand, 
the dogs receiving recombinant spores showed a higher level of T cells derived from 
PBMC, spleen, mesenteric lymph nodes and Peyer’s patches than placebo dogs. The dogs 
administered with the mixture of spores showed proliferation of CD8+ T cells derived 
from Peyer’s patches when stimulated with recombinant purified H6-EgTrp and H6-
EgA31. Commonly, the stimulation of CD8+ T cells is trigger by the presentation of 
intracellular antigens in an MHC class I context by the APCs, as are for example the viral 
proteins. However, exogenous antigens can also lead to a stimulation of CD8+ T cells 241. 
As CD8+ T cells need stimulation through antigen-presenting cells (APC), the APC when 
not directly infected need to acquire exogenous antigens from and present them on MHC 
class I molecules, by cross-presentation. Dendritic cells show to have a more regulated 
phagocytic pathway that serves antigen processing and presentation on MHC molecules 
compared to macrophages and neutrophils that mainly destroy antigens. Dendritic cells 
are capable of processing exogenous antigens and to cross-present them on MHC I to 
CD8+ cells 242.  
 
In conclusion of this work, recombinant B. subtilis spores were engineered to express 
within the biofilms the antigenic peptides TasA-EgTrp and TasA-EgA31 protein. The 
tenacity of the recombinant spores was not altered when compared to B. subtilis wild-type 
spores as denoted by their shelf-life, temperature resistance and resistance to low pH. The 
spores were able to germinate after the passage through the stomach, as the recombinant 
B. subtilis spores were detected after the oral gavage in the feces of mice and intestinal 
content of dogs. Even if a direct evidence for the intestinal germination and biofilm 
formation is not determined during the present work, indirect evidence suggests that this 
is the point. Thus, the mounted specific immune response in dogs and mice against the 
TasA-EgTrp, strongly indicating the presence of recombinant vegetative B. subtilis cells 
in the intestinal tract.  
The evidence presented in here also showed that the nature of the antigen exposed in the 
biofilm could possibly induce tolerance. As is the case for EgA31 antigenic peptide, 
which showed no proliferation of T cells in mice but was detected in the microflora of 
one dog but been unable to induce a humoral immune response in both dogs and mice. 
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Therefore, it remains the last working hypothesis of this work without proof. The oral 
administration of a combined dose of recombinant B. subtilis spores for EgTrp and 
EgA31 did not induce exacerbated humoral and cellular immune response detectable by 
the methods applied.  
 
A proof of principle for the successful oral vaccination of dogs against E. granulosus by 
recombinant B. subtilis would depend on a direct challenge of dogs with viable E. 
granulosus protoscoleces. It is expected to detect a significant reduction in the E. 
granulosus worm burden among the group of recombinant spores immunized dogs 
compared with the group of unimmunized dogs. Unfortunately, due to biosafety concerns, 
this kind of experiment cannot be performed at the animal facility of the University of 
Zurich. The UZH facility is not in possession of a BL-3 biohazard safety level for dog 
experimentation, as stipulated by the Swiss legislation when working with definitive host 
infected in a mature state or eggs from Echinococcus spp 243,244. However, a challenge is 
possible through our collaborators from Tunisia and Morocco. As described above, there 
are hints that recombinant spores carrying EgA31 antigenic peptide induce tolerance; it 
will be of general interest to corroborate the tolerogenic effect of this particular antigen 
through an in vivo challenge. Deplazes et al., 1995 245 described in a dog experimental 
trial that ovalbumin when orally administered in high amounts induces tolerance. Thus, to 
determine the tolerogenic potential of the B. subtilis vaccination system, dogs or mice 
immunized against ovalbumin (OVA) can be orally treated with recombinant spores 
expressing TasA-OVA to determine the immune reaction of the treated animals. 
Indicators for a tolerance would be downregulation of inflammation factors as are for 
example interleukin 4 (IL-4) (macrophage activation) 246 and interferon-γ (IFN-γ) 
(enhancing phagocytosis of neutrophils and the formation of reactive oxygen species) 247 
as well as an increase of regulatory T cells 248. The induction of tolerance is essential for 
the treatment of several autoimmune diseases (as Hashimoto's thyroiditis, Grave's disease, 
Type 1 diabetes, Primary biliary cirrhosis) making valuable the deepest insight in this 
research area. Perhaps the recombinant B. subtilis spores can be a good alternative for 
further treatments 249. 
On the other hand, recombinant spores carrying EgTrp antigenic peptides were able to 
stimulate, but it could not be elucidated how specific, the local immune response. This 
aspect of the stimulation of the local immune system of the GIT can be very 
advantageous. For example for when required of local anti-TNFα antibodies in the 
treatment of chronic granulomatous disease 250 or to generate protection against enteric 
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diseases as rotavirus, coronavirus or even norovirus. Thereby, a clear insight of each 
antigen used as immunogen has to be scrutinized to determine if it is carrying tolerogenic 
or stimulating properties  
An interesting approach could be to prolong the retention time of the recombinant spores 
within the GIT. Therefore, recombinant spores expressing epithelial or mucosal 
adherence factors on their surface, as recently developed by Batista et al. 222 could be 
useful.  
Finally, by developing a vaccine based in spores of recombinant B. subtilis has many 
advantages, in particular by the expression of the antigens as C-terminal fusions to the 
matrix protein TasA. This idea was developed for the first time during this thesis work, 
and it is a promising manner for antigen presentation to the host and induction of local 
immunity. 
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ANNEX I: Mouse Animal Experiment Permission 
 
  
ANNEX I 


 Version 1.4   (august  2011) 
Form-A No. ................................... 
 (to be completed by the authorities) 
Application for licence to perform animal experiments 
Article 18 Animal Welfare Act (TSchG), article 141 Animal Welfare Ordinance (TSchV), article 30 Animal Experimentation Ordinance (TVV) 
1 Address of resource manager (institute, company) 
Catherine Eichwald 
Institute of Virology, Vetsuisse Faculty, University of Zurich 
Wintherturerstrasse 266a, 8057 Zurich, Switzerland 
 E-mail; tel no. ceichwald@vetvir.uzh.ch; +41 44 635 8711 
2 Address of cantonal authority 
 Kantonales Veterinäramt 
Culmanstrasse 1 
8090 Zürich 
3 TITLE OF PROJECT  
 Use of recombinant Bacillus subtilis spores, as a safe carrier, for enteric immunization against Echinococcus 
granulosus in mice. 
31 Field of study or area of application:  
 Veterinary Medicine, Bacteriology, Immunology, Parasitology 
32  [N] new application 
 [F] application for renewal (no. 
 
) 
 [E] supplementary application (no. )  
In the case of supplementary applications, the requested amendments must be summarized in keywords, the scientific 
rationale must be indicated in §44.2  and it must be indicated which numbers in the application are affected. The 
amendments are described alongside the various numbers and must be clearly highlighted versus the existing text:  
 
The modification refers exclusively:   Animal number / species;   Personnel  
 Validity / extension  Method 
 
33 ANIMAL SPECIES (strain) Total number 
per application 
Origin* 
(a-c) 
 Balb-c 591 b 
    
    
    
*Origin: (a): from previous experiment, please specify licence number:  
 (b): licensed laboratory animal husbandry in Switzerland (incl. own husbandry): licence number:   
         or laboratory animal breeder or dealer abroad (art. 118 para. 1, TSchV); 
 (c): other origin, please specify:  
 
Names and addresses of suppliers:  
 
34.1 Location of animals: address, room number licence number of laboratory animal husbandry:  
Tierspital Zürich, Nagerzentrum, room B09  Nr. 147 
Winterthurerstrasse 260,8057 Zurich 
34.2 Location of the experiments: address, room number 
Tierspital Zürich, Nagerzentrum room B24 
Winterthurerstrasse 260, 8057 Zurich 
34.3 Intercantonal experiment:  yes  no  
if so, which other canton(s):   
34.4 Use of genetically modified animals* :  yes  no  
 *Data sheets for genetically modified lines and strained mutants must be enclosed 
  (additionally for  strained lines: decision number). 
35 Maximum prospective degree of severity:        (for details, see para 56.4) 
36 Duration of project: 3 years 
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  (to be completed by the authorities) 
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 Date of proposed start: Immediately 
37 List of persons who perform or lead measures and procedures in the context of the experiment: 
The annex to this application “Persons involved and certificates of education and training” must be duly filled and copies of education 
and trainings have to be joined.  
Persons who lead or perform experiments must satisfy the educational and further training requirements set forth in 
art. 132 and 134, para. 1 TSchV and Chapter 3 of the ordinance of the FDEA on qualifications in animal husbandry. 
 
 
38 The undersigned resource manager (art. 129, 130, TSchV) confirms that the persons named  in the appendix are familiar with the 
regulations of the TSchG and TSchV applicable to animal experiments and that they satisfy the educational and further training 
requirements (art. 130 para. d TSchV). 
Place and date Name and signature 
Zurich, January 30th 2012 Dr. Catherine Eichwald 
 
 
39 Study director: if several people perform this function, their areas of responsibility must be defined in the appendix. Signature of 
principal study director: (art. 131, 132 TSchV): 
Place and date Name and signature 
Zurich, January 30th 2012 Prof. Dr. Mathias Ackermann 
 
 
 
Deputy study director (requirements as stipulated in art. 129 para. 2 TSchV, art. 30e TVV) 
Place and date Name and signature 
Zurich, January 30th 2012 Prof. Dr. Peter Deplazes 
 
 
4 INFORMATION ON THE PURPOSE OF THE EXPERIMENT (for statistics art. 147 TSchV);  
sections 41 - 43 indicate one only in each case and, if applicable, add a further note or additional information in the case of detailed 
questions. 
41 The project is associated with 
 biological (including medical) studies in the field of basic research 
 discovery, development, and quality control (excluding safety testing) of products or devices for human and veterinary medicine 
 diagnosis of disease 
 education and training 
 protection of humans, animals and the environment by toxicological or other safety tests 
... for substances used or intended to be used mainly 
 as pharmaceutical products (including medical devices) 
 in agriculture 
 in industry 
 in private households 
 as cosmetics or toiletries 
 as food additives or 
 to determine potential or actual hazards of contaminants in the general environment, or 
 other uses. Please specify: 
 
 
 other studies. Please specify:  
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42 The project is associated with 
 human diseases 
 cancer (excluding carcinogenicity studies) 
 cardiovascular diseases 
 nervous and mental disorders 
 other human diseases. Please specify: Cystic echinococcosis 
 animal diseases. Please specify: Cystic echinococcosis 
 no association with human or animal diseases. 
43 The project is associated with procedures required by law (registration and licensing regulations): 
 for Switzerland only 
 for other countries only. Please specify: 
 
 
 Both. Please specify:  
 Mention the relevant guidelines or test methods: 
  
 The project has no association with procedures required by law. 
 
44.1 General description of the aim of the project, the status of knowledge and presentation of what is not yet sufficiently known (for 
example summary of National Science Foundation application, one page maximum) 
Cystic echinococcosis, also called hydatidosis, represents a worldwide severe public health and livestock 
problem. The causative agent of the disease is the cestode Echinococcus granulosus, which is known for its 
two-host life cycle. The adult tapeworm lives in the small intestine of its main host, i.e. carnivores, including 
dogs. Parasite eggs are shed via feces, a likely mechanism for contamination of plants used for human 
and/or animal consumption. This may lead to the infection of intermediate host (sheep, cattle, humans). In 
these animals, larval stages of the metacestode develop and start migrating, reaching internal organs where 
they persist and may cause the dreaded disease symptoms. To complete the cycle, carnivores are infected 
following consumption of such persistently infected organs, and the adult tapeworm re-emerges to the 
ecosystem from the carnivores. 
According to mathematical models, the parasite's cycle may be interrupted through successful vaccination of 
carnivores [Torgerson PR. 2006.Parasite Immunol. 28, 295-303]. An oral vaccination strategy using 
recombinant Salmonella typhimurium as carrier has previously been developed and tested in dogs. The 
recombinant bacteria were engineered to produce the E. granulosus antigens EgA31 and EgTrp. Upon 
immunization, the vaccine conferred only partial protection, i.e. the parasite burden in vaccinated dogs was 
reduced by 70-80% and the development rate in the remaining worms was also affected [Petavy A-F., et al. 
2008. Plos neglected tropical diseases, 2(1):e125]. These data suggest that the antigens used have the 
desired potential to create an immune response in the host. However, the antigen carrier (Salmonella) has 
three major drawbacks: (1) the number of live bacteria reaching the duodenum, where immunity is supposed 
to develop, is dramatically reduced upon passage through the stomach, making the effectiveness of the 
vaccine unreliable; (2) expression of the recombinant vaccine proteins is unstable because they are encoded 
on plasmids; (3) there is a general skepticism against Salmonella as vaccine carrier because other members 
of this genus are associated with disease in humans and animals.  
The gram-positive bacteria Bacillus subtilis is used as probiotic in both, humans and animals, and in contrast to 
Salmonella, it is considered safe for oral use in food supplements [Duc & Cutting. Expert. Opin. Biol. Ther., 
2003,3:1263-70; Tam et al., J. Bact. 2006,188:2692-700 and Hong et al. J.Appl. Microbiol, 2008, 160:134-
43]. The genetics of B. subtilis sporulation have been extensively studied. In a spore, the chromosome is 
condensed in the core spore, which is surrounded by layers of lipid membranes and modified peptidoglycan. 
The spore coat is a very important structure, laminated by a proteinaceous shell that provides resistance 
against harsh environmental conditions, including heat, acids, organic solvents and enzymes.  
TasA, an extracellular protein of B. subtilis, which is secreted but also found in association with both cells and 
spores, has recently stirred considerable scientific interest. TasA is essential for the formation and structural 
integrity of B. subtilis biofilms [Aguilar et al. Curr Opin Microbiol. 2007; 10:638-43; Vlamakis et al.Genes Dev, 
2008, 22:945-53; Lemon et al.Curr Top Microbiol Immunol. 2008, 322: 1-16 and Romero D et al.,Proc. Natl. 
Acad. Sci. USA. 2010, 107 (5):2230-4]. This is particularly interesting since there is evidence suggesting that 
B. subtilis strains could persist in the mouse gut, suggesting that they have adapted to carry out their entire 
life cycle within the gastrointestinal tract (GIT). This makes TasA an attractive candidate for both antigen 
presentation and continuous stimulation of immunity. Indeed, there is evidence suggesting that vegetative 
cells of B. subtilis play a primary role in the development of gut-associated lymphoid tissue (GALT) and 
somatic diversification of the Ig genes, when these cells were introduced into germ-free appendices of 
rabbits [Rhee et al. J Immunol. 2004, 172:1118-24]. Subsequent studies demonstrated that orally 
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administrated B. subtilis spores in mice were able to germinate, proliferate and then re-sporulate in the gut 
[Tam et al. J Bact. 2006, 188: 2692-700).  
B. subtilis is considered a safe probiotic. It may therefore be well accepted in the community; its spores are highly 
resistant against harsh conditions, which makes them well-suited for their use as oral vaccines; it may form 
biofilms in the gut, which may be a great advantage for generating a desired local immune response. Finally, 
a spore-based  vaccine would be inexpensive to produce and would not need a cold chain, making it very 
attractive for commercialization. B. subtilis spores may provide a prototype for generating specific immune 
responses against various enteric disease organisms.  
Mouse model is an excellent and inexpensive tool to detect a humoral response against specific antigens. With this 
permit, we would like to test in mice a serie of antigens variants (single and combined mixture) from E. 
granulosus as are: EgTrp, EgA31 and a recently new described candidate as is CRISP(cysteine-rich 
secreted protein) (Britos et al., Exp. Parasitol. 2007, 116:95-102) and therefore, select the best antigenic 
variants to be used for dogs oral vaccination (Recombinant B. subtilis: A safe carrier for oral vaccine 
administration in dogs; permit n˚ 100/2010). Resulting in a significantive reduction of the number of dogs 
required for the vaccine trials. 
Our experimental design in based in fusioning the E. granulosus antigens (EgTrp, EgA31 and CRISP) to the C-
terminal of TasA through molecular biology methodology. The obtained DNA plasmid constructions will be 
used to transform B. subtilis strain,from which will be obtained the recombinant spores from B. subtilis. 
These strains will be evaluated for correct expression of the desired antigen in vitro, biofilm formation in vitro 
and spore production and morphology. All these data must to be analyzed before starting any animal 
experimentation because is fundamental for certainity of our scientific conclusion. 
44.2 Actual question the experiment is designed to answer 
Identify through oral immunization of mice, potentially protective antigens of E. granulosus expressed by 
recombinant B. subtilis. Both qualitative and quantitative aspects of the potentials of individual antigens and 
antigen combinations will be addressed. 
 
 
5 INFORMATION ABOUT THE METHOD (descriptions and note on sections 51 - 58) 
51.1  Overview of the project (experimental design, overview of the method, name of animal model where applicable, the course of the 
project, flowchart showing sequence of events, biometric planning) (details of the method in para 54) 
Experiment #1: Evaluation of an immune response of Balb/C female mice treated with spores expressing 
peptides from E. granulosus tropomyosin (EgTrp). The aim of this experiment is to determine if mice treated 
with recombinant B. subtilis spores expressing different peptides of Egtrp are able to induce an immune 
response against these specific peptides. For this purpose, we will need a total of fourty-eight, six weeks-old 
Balb-c female mice, divided in 4 groups of six mice each. All the groups will be inoculated orally through 
gavage with an identical volume of a suspension of spores in saline solution (200µl). Animals will be 
immunized three times at days 1, 21 and 42 with  an amount of 5e10 spores per immunization ( Hoang et al., 
Infection and immunity  2008). The different groups of experimentation will be as follow: group 1, mice treated 
only with a saline solution; group 2, mice treated with wild-type B.subtilis spores; groups 3 and 4 are mice 
treated with recombinant B. subtilis spores in whichTasA is fused to peptides (102-107) Egtrp and (102-278) 
EgTrp, respectively. In this experiment, blood and feces samples will be collected on days 0, 20 , 41 and 50 
after the first immunization, to analyse an immune response against the EgTrp protein and to determine the Ig 
classes that are produced. Also, the persistence in gut of B.subtilis will be determined by shedding of spores in 
feces. For this purpose feces will be collected during 7 days after the first immunization. On day 50, mice will 
be euthanized to analyse the T cell proliferation in spleen and MLN (mesenteric lymph nodes) and histologic 
analysis of the gut sections. The experiment will be performed twice. 
Number of experimental groups   4 
Number of mice per group   6 
Number of mice per experiment 24 
Total number of mice              48 
Experiment #2: Evaluation of an immune response of Balb/C female mice treated with spores expressing  
peptides from E. granulosus paramyosin (EgA31). The aim of this experiment is to determine if mice treated 
with recombinant B. Subtilis spores expressing different peptides of EgA31 are able to induce an immune 
response against these specific peptides. For this purpose, we will need a total of sixty,six weeks-old Balb-c 
female mice, divided in 5 groups of six mice each. All the groups will be inoculated orally through gavage with 
an identical volume of a suspension of spores in saline solution (200µl). Animals will be immunized three times 
at days: 1, 21 and 42, with  an amount of 5e10 spores per immunization (Hoang et al., Infection and immunity  
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2008). The different groups of experimentation will be as follow: group 1, mice treated only with a saline 
solution; group 2, mice treated with wild-type B.subtilis spores; groups 3 , 4 and 5 are mice treated with 
recombinant B. subtilis spores in whichTasA is fused to peptides (170-369) EgA31, (370-583) EgA31 and 
(170-585) EgA31, respectively.  In this experiment, blood and feces samples will be collected on days 0, 20 , 
41 and 50 after the first immunization to analyse an immune response against the EgA31 protein and to 
determine the Ig classes that are produced. Also, the persistence in gut of B.subtilis will be determined by 
shedding of spores in feces. For this purpose feces will be collected during 7 days after the first immunization. 
On day 50, mice will be euthanized to analyse the T cell proliferation in spleen and MLN (mesenteric lymph 
nodes) and histologic analysis of the gut sections. The experiment will be performed twice. 
Number of experimental groups   5 
Number of mice per group   6 
Number of mice per experiment 30 
Total number of mice              60 
Experiment #3: Evaluation of an immune response of Balb/C female mice treated with spores expressing  
peptides from E. granulosus CRISP. The aim of this experiment is to determine if mice treated with 
recombinant B. Subtilis spores expressing different peptides of CRISP are able to induce an immune response 
against these specific peptides. For this purpose, we will need a total of sixty,six weeks-old Balb-c female 
mice, divided in 5 groups of six mice each. All the groups will be inoculated orally through gavage with an 
identical volume of a suspension of spores in saline solution (200µl). Animals will be immunized three times at 
days: 1, 21 and 42, with  an amount of 5e10 spores per immunization (Hoang et al., Infection and immunity  
2008). The different groups of experimentation will be as follow: group 1, mice treated only with a saline 
solution; group 2, mice treated with wild-type B.subtilis spores; groups 3 , 4 and 5 are mice treated with 
recombinant B. subtilis spores in whichTasA is fused to peptides A-CRISP, B-CRISP and C-CRISP, 
respectively.  In this experiment, blood and faeces samples will be taked  on days 0, 20 , 41 and 50 after the 
first immunization to analyse an immune response against the CRISP protein and to determine the Ig classes 
that are produced. Also, the persistence in gut of B.subtilis will be determined by shedding of spores in feces. 
For this purpose feces will be collected during 7 days after the first immunization. On day 50, mice will be 
euthanized to analyse the T cell proliferation in spleen and MLN (mesenteric lymph nodes) and histologic 
analysis of the gut sections. The experiment will be performed twice. 
Number of experimental groups   5 
Number of mice per group   6 
Number of mice per experiment 30 
Total number of mice              60 
Experiment #4: Evaluation of an immune response of Balb/C female mice treated with different ratios of 
spores expressing TasA fused to  E. granulosus peptides tropomyosin (EgTrp) and paramyosin (EgA31). The 
aim of this experiment is to determine if mice treated with combinations at different ratios of recombinant B. 
Subtilis spores expressing the best responding TasA fused to EgTrp from experiment #1 and the best 
responding TasA fused to EgA31 peptides from experiment #2 are able to enhance an immune response 
against one or two of the specifc antigens in relations to a single spore immunization. For this purpose, we will 
need a total of eighty-four,six weeks-old Balb-c female mice, divided in 7 groups of six mice each. All the 
groups will be inoculated orally through gavage with an identical volume of a suspension of spores in saline 
solution (200µl). Animals will be immunized three times at days: 1, 21 and 42, with an amount of 5e10 spores 
per immunization (Hoang et al., Infection and immunity  2008). The different groups of experimentation will be 
as follow: group 1, mice treated only with a saline solution; group 2, mice treated with wild-type B.subtilis 
spores; group 3, mice treated with recombinant B. subtilis spores with TasA fused with EgTrp (selected from 
experiment #1);group 4,mice treated with recombinant B. subtilis spores with TasA fused with EgA31 (selected 
from experiment #2),  groups 5, 6 and 7, mice treated with a combination of recombinant B.subtilis spores 
expressing TasA fused to EgTrp (selected from experiment #1) and recombinant B.subtilis spores expressing 
TasA fused to EgA31 (selected from experiment #2) at ratios; 1:1 (2.5e10 CFU Egtrp: 2.5e10 CFU EgA31); 
2:1 (3.4e10 CFU EgTrp: 1.6e10 CFU EgA31) and 1:2 (1.6e10 CFU EgTrp: 3.4e10 CFU EgA31), respectively. 
In this experiment, blood and feces samples will be collected on days 0, 20 , 41 and 50 after the first 
immunization to analyse an immune response against the EgTrp and EgA31 proteins and to determine the Ig 
classes that are produced. Also, the persistence in gut of B.subtilis will be determined by shedding of spores in 
feces. For this purpose feces will be collected during 7 days after the first immunization. On day 50, mice will 
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be euthanized to analyse the T cell proliferation in spleen and MLN (mesenteric lymph nodes) and histologic 
analysis of the gut sections. The experiment will be performed twice. 
*CFU: colony-formning unit 
 
Number of experimental groups   7 
Number of mice per group   6 
Number of mice per experiment 42 
Total number of mice              84 
Experiment #5: Evaluation of an immune response of Balb/C female mice treated with different ratios of 
spores expressing TasA fused to  E. granulosus peptides  tropomyosin (EgTrp) and CRISP. The aim of this 
experiment is to determine if mice treated with combinations at different ratios of recombinant B. subtilis 
spores expressing the best responding TasA fused to EgTrp from experiment #1 and the best responding 
TasA fused to CRISP peptides from experiment #3 are able to enhance an immune response against one or 
two of the specifc antigens in relations to a single spore immunization. For this purpose, we will need a total of 
eighty-four,six weeks-old Balb-c female mice, divided in 7 groups of six mice each. All the groups will be 
inoculated orally through gavage with an identical volume of a suspension of spores in saline solution (200µl). 
Animals will be immunized three times at days: 1, 21 and 42, with an amount of 5e10 spores per immunization 
(Hoang et al., Infection and immunity  2008). The different groups of experimentation will be as follow: group 1, 
mice treated only with a saline solution; group 2, mice treated with wild-type B.subtilis spores; group 3, mice 
treated with recombinant B. subtilis spores with TasA fused with EgTrp (selected from experiment #1);group 
4,mice treated with recombinant B. subtilis spores with TasA fused with CRISP(selected from experiment #3), 
groups 5, 6 and 7, mice treated with a combination of recombinant B.subtilis spores expressing TasA fused to 
EgTrp (selected from experiment #1) and recombinant B.subtilis spores expressing TasA fused to CRISP 
(selected from experiment #3) at ratios; 1:1 (2.5e10 CFU Egtrp: 2.5e10 CFU CRISP); 2:1 (3.4e10 CFU EgTrp: 
1.6e10CFU CRISP) and 1:2 (1.6e10 CFU EgTrp: 3.4e10 CFU CRISP), respectively. In this experiment, blood 
and feces samples will be collected on days 0, 20 , 41 and 50 after the first immunization to analyse an 
immune response against the EgTrp and CRISP proteins and to determine the Ig classes that are produced. 
Also, the persistence in gut of B.subtilis will be determined by shedding of spores in faeces. For this purpose 
feces will be collected during 7 days after the first immunization. On day 50, mice will be euthanized to analyse 
the T cell proliferation in spleen and MLN (mesenteric lymph nodes) and histologic analysis of the gut 
sections. The experiment will be performed twice.  
Number of experimental groups   7 
Number of mice per group   6 
Number of mice per experiment 42 
Total number of mice              84 
Experiment #6: Evaluation of an immune response of Balb/C female mice treated with different ratios of 
spores expressing TasA fused to  E. granulosus peptides paramyosin (EgA31) and CRISP. The aim of this 
experiment is to determine if mice treated with combinations at different ratios of recombinant B. Subtilis 
spores expressing the best responding TasA fused to EgA31 from experiment #2 and the best responding 
TasA fused to CRISP peptides from experiment #3 are able to enhance an immune response against one or 
two of the specifc antigens in relations to a single spores immunization. For this purpose, we will need a total 
of eighty-four,six weeks-old Balb-c female mice, divided in 7 groups of six mice each. All the groups will be 
inoculated orally through gavage with an identical volume of a suspension of spores in saline solution (200µl). 
Animals will be immunized three times at days: 1, 21 and 42, with an amount of 5e10 spores per immunization 
(Hoang et al., Infection and immunity  2008). The different groups of experimentation will be as follow: group 1, 
mice treated only with a saline solution; group 2, mice treated with wild-type B.subtilis spores; group 3, mice 
treated with recombinant B. subtilis spores with TasA fused with EgA31 (selected from experiment #2);group 
4,mice treated with recombinant B. subtilis spores with TasA fused with CRISP (selected from experiment #3),  
groups 5, 6 and 7, mice treated with a combination of recombinant B.subtilis spores expressing TasA fused to 
EgA31 (selected from experiment #2) and recombinant B.subtilis spores expressing TasA fused to CRISP 
(selected from experiment #3) at ratios; 1:1 (2.5e10 CFU EgA31: 2.5e10 CFU CRISP); 2:1 (3.4e10 CFU 
EgA31:1.6e10 CFU CRISP) and 1:2 (1.6e10CFU EgA31: 3.4e10 CFU CRISP), respectively.  In this 
experiment, blood and faeces samples will be taked  on days 0, 20 , 41 and 50 after the first immunization to 
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analyse an immune response against the EgA31and CRISP proteins and to determine the Ig classes that are 
produced. Also, the persistence in gut of B.subtilis will be determined by shedding of spores in feces. For this 
purpose feces will be collected during 7 days after the first immunization. On day 50, mice will be euthanized 
to analyse the T cell proliferation in spleen and MLN (mesenteric lymph nodes) and histologic analysis of the 
gut sections. The experiment will be performed twice. 
Number of experimental groups   7 
Number of mice per group   6 
Number of mice per experiment 42 
Total number of mice              84 
Experiment #7: Evaluation of an immune response of Balb/C female mice treated with different ratios of 
spores expressing TasA fused to E. granulosus peptides tropomyosin (EgTrp), paramyosin (EgA31) and 
CRISP. The aim of this experiment is to determine if mice treated with combinations at different ratios of 
recombinant B. subtilis spores expressing the best responding TasA fused to EgTrp from experiment #1; 
recombinant B. subtilis spores expressing the best responding TasA fused to EgA31 from Experiment #2 and 
the best responding TasA fused to CRISP peptides from experiment #3 are able to enhance an immune 
response against one, two or three of the specifc antigens in relations to a single or double (experiments #4, 
#5 and #6) spores immunization. For this purpose, we will need a total of hundred and eight,six weeks-old 
Balb-c female mice, divided in 9 groups of six mice each. All the groups will be inoculated orally through 
gavage with an identical volume of a suspension of spores in saline solution (200µl). Animals will be 
immunized three times at days: 1, 21 and 42, with an amount of 5e10 spores per immunization (Hoang et al., 
Infection and immunity  2008). The different groups of experimentation will be as follow: group 1, mice treated 
only with a saline solution; group 2, mice treated with wild-type B.subtilis spores;group 3, mice treated with 
recombinant B.subtilis spores with TasA fused with EgTrp (selected from experiment #1); group 4, mice 
treated with recombinant B. subtilis spores with TasA fused with EgA31 (selected from experiment #2);group 
5,mice treated with recombinant B. subtilis spores with TasA fused with CRISP (selected from experiment #3),  
groups 6, 7, 8  and 9, mice treated with a combination of recombinant B.subtilis spores expressing TasA fused 
to EgTrp( selected from experiment #1); recombinant B.subtilis spores expressing TasA fused to EgA31 
(selected from experiment #2) and recombinant B.subtilis spores expressing TasA fused to CRISP (selected 
from experiment #3) at ratios; 1:1:1 (1.66e10 CFU EgTrp: 1.66e10 CFU EgA31: 1.66e10 CFU CRISP); 1:1:2 
(1.25e10 CFU EgTrp: 1.25e10 CFU EgA31: 2.5e10 CFU CRISP); 1:2:1 (1.25e10 CFU EgTrp: 2.5e10 CFU 
EgA31: 1.25e10 CFU CRISP) and 2:1:1 (2.5e10 CFU EgTrp: 1.25e10 CFU EgA31: 1.25e10 CFU CRISP), 
respectively.  In this experiment, blood and feces samples will be taked on days 0, 20 , 41 and 50 after the first 
immunization to analyse an immune response against the EgTrp, EgA31 and CRISP proteins, to determine 
the Ig classes that are produced. Also, the persistence in gut of B.subtilis will be determined by shedding of 
spores in feces. For this purpose feces will be collected during 7 days after the first immunization. On day 50, 
mice will be euthanized to analyse the T cell proliferation in spleen and MLN (mesenteric lymph nodes) and 
histologic analysis of the gut sections. The experiment will be performed twice. 
Number of experimental groups   9 
Number of mice per group   6 
Number of mice per experiment 54 
Total number of mice            108 
TRAINING ANIMALS: Due that for this kind of immunization strategy is necessary to use gavage needles, 
that requires certain ability, we ask for 10 female Balb/C mice with the purpose to training students along the 
duration of the permit period.The students in possession on at least an LTK1E or equivalent certificate, will be 
trained by Catherine Eichwald. Note: Only people trained in oral administration (as gavage) will be allowed to 
immunize animals. 
Total number of mice             10  
SETTINGS FOR T CELL PROLIFERATION ASSAY: This assay, that is required in the experiments #1 and 
to #7, needs to be set in the lab. Two aspects are essential to be determined for this assay: 1) isolation of T 
cells from spleen and MLN (required amount of animals: 10 mice, Balb-c female from 6 weeks to 6 months 
old) (Kruisbeek AM. Curr. Prot. Immunol. (2000):3.1.1-3.1.5) and 2)T cell proliferation conditions assay 
settings. As described in literature (Kruisbeek AM et al., Curr. Prot. Immunol. (2004), 3.12.1-3.12.20), the 
culture period required for the stimulation (after cells labeling) varies for different laboratories, media and types 
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of responding and stimulator cells. Because laboratory conditions vary, it will be necessary to run a kinetic 
assay to determine the optimal time for T cell proliferation. For this purpose, it will be necessary: 15 mice Balb-
c females from 6 weeks to 6 months old. 
Total number of mice:                  25 
ACCESORY SPLEEN CELLS FOR MLN PROLIFERATION ASSAY: Purified T cells, as those purified from 
MLN, require an exogenous source of accessory non-T cells (Kruisbeek AM et al., Curr. Prot. Immunol. 
(2004), 3.12.1-3.12.20). Accessory cells function both as antigen-presenting cells and as a source of 
undefined "second signals". They are not required for cell preparations primed against cellular antigens, 
because accessory cell functions is provided by stimulator cells. For this purpose, It is required two mice 
(Balb-c, females, 6 weeks to 6 months old) per experiment. Each experiment will be performed twice.
 
 
number of mice per experiment: 4 
number of experiments:              7  
Total number of mice:               28 
For the scheme of the experimental planning, please see the appendix II section 
 
51.2 Reason for selection of method or model, showing its peculiarities / advantages (art. 137 para. 3 TSchV) 
The methodology used is the standard for immunization procedure. 
51.3 Reason for selecting animal species and, where applicable, for using animals not bred for experimental purposes 
Mouse strain: Balb/c. This mouse strain is normally used for immunization trials. 
52 Preparation of animals for the experiment (initial examination art. 135 para. 3 TSchV; adaptation art. 119 para. 1 TSchV; type of tagging 
art. 120 TSchV and art. 5 para. 2 TVV (incl. justification for invasive methods), conditioning, feed or water withdrawal, pre-treatment etc.) 
The mice will be kept at the rodent center of the Vetsuisse faculty. During the experimentation procedure the 
collection of feces is required, for this purpose each mouse will be in an individual cage. Animals will be 
individualized by ear notching. The animals will be six weeks old at the initiation of each experiment and they 
will have one week of adaptation before the inititiation of the experiment. Mice will have ad libitum access to 
sterile food and water. 
53.1 Anaesthesia and/or other means of controlling pain (preparations, doses, route and frequency of administration, period of time etc.) 
(art. 135 para. 5 TSchV) 
No anesthesia is required during the whole experimentation procedure. At exception of the ending of each 
experiment as part of the euthanasia procedure, in which animals will be inconcious previous the cervical 
dislocation. 
The animals will be immunized through gavage, meaning that a precise dose of spore need to be 
administrated to each rodent into the gastric cavity. For this purpose a gastric feeding needle with a ball tip will 
be used. This helps to prevent the introduction of the needle into the trachea, preventing further trauma to the 
oral cavity. No anestesia is required for this procedure(Hedrich, HJ and Bullock GR. The Laboratory mouse. 
Academic Press, 2004). Additionally, blood sample collection will be performed by tail vein incision. This 
methodology allowed the collection of 200µl of blood once a week. Pressure will be applied after blood 
collection to prevent hematomas. 
53.2 Reason for selection of anaesthesia and/or analgesia or, if applicable, reason not to  use such measures 
For euthanasia procedure (cervical dislocation), the anesthetic used is isoflurane with a vaporizator 
(induction: 5% isoflurane and 4% oxygen; mantention: 2% isoflurane and 3% oxygen) 
54.1 Type of procedures/manipulations and parameters to be measured in the animal (indicate sequence of events for individual 
animal/for animal group): surgical procedures (sequence), substance administration (method and site, amount and frequency), 
infections, physical treatments (radiation, etc.), follow-up examinations, sampling, reaction tests etc. Details may be provided by means 
of Standard Operating Procedure (SOP)) 
In all the experiment (#1 to #7), same kind of procedure will be used, corresponding to: 
1) Oral immunization through gavage needle using a maximum volume of 200µl of recombinant B. subtilis 
spores in saline solution. Immunization will be performed 3 times on days 1, 21 and 42. 
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2)Blood sample collection will be performed by tail vein incision. This methodology allowed the collection of 
200µl of blood once a week. Pressure will be applied after blood collection to prevent hematomas. Blood 
samples will be collected 4 times during each experiment, on days 0, 20, 41 and 50 on the experimentation 
schedule. 
3)Feces collection are required to mesure secretory antibodies into the feces of the animals and also, to 
measure the persistence of B.subtilis in the gut of the animals. In both cases, the mice need to be isolated into 
individual cages (16 cmx 21.5 cm SPF cages) in which, they will isolated for 1 day previous each scheduled 
immunization (days: 0, 20, 41 and 50) andfor 7 days after the first immunization (days: 1, 2, 3, 4, 5, 6 and 7), 
respectively. Animals will be regrouped immediately in its original experimental groups (maximun number of 
mice per cage : 6 ; size SPF cage 19 cm x 37 cm). Please note: Never will be used metabolic cages in these 
experiments. 
54.2 Duration of the series of experiments: total duration of experiment / experiment series (tabulated in an appropriate form where useful): 
full period of experiment for each individual group or animal, incl. period during which the animal is exposed to substances or other 
noxae. If animals are to be used repeatedly, indicate the interval between experiments 
Time schedule for experiments #1 to #7: 
Mice will be immunized on days 1, 21 and 42 by gavage oral administration with 200µl of a saline solution 
containing 5e10 CFU of recombinant spores. 
Mice blood samples will be performed on days 0 (pre-immune), 20, 41 and 50 through tail venipuncture. 
Mice feces samples, for antibody detection, will be acquired on days 0, 20, 41 and 50. To allowed the feces 
collection mice will be isolated during 24 hours into individual cages (NOTE: NO METABOLIC CAGES ARE 
REQUIRED FOR THIS PURPOSE) and then, immediately regrouped with its respective mates. 
For gut persistance of B.subtilis, feces collection is required for individual mouse. This will be accomplished 
on days 1, 2, 3, 4, 5, 6 and 7 of the immunization schedule ( NOTE: NO METABOLIC CAGES ARE 
REQUIRED FOR THIS PURPOSE) and then, immediately regrouped with its respective mates. 
On day 50, mice will be euthanasied by cervical dislocation with previous induction to inconciousness with 
isoflurane. 
Therefore, each experiment is comtemplated in a total period of 50 days.  
54.3 Number of animals per experiment/series of experiments: number of groups (including all variables, such as doses, periods of 
time, controls and details on staggering of experiments over time as stipulated in art. 137 para. 4 lit.c TSchV) and numbers of animals 
per line, per group, sex of animals 
Please, see also the section 51.1 
Experiment #1: (Mouse strain: Balb/c, females, six weeks old) 
Number of experimental groups   4 ; one control group and three spores groups (wt and TasA-EgTrp) 
Number of mice per group   6 
Number of mice per experiment 24 
The experiment will be performed twice 
Total number of mice           48 
 
Experiment #2: (Mouse strain: Balb/c,females, six weeks old) 
Number of experimental groups   5; one control group and four spores groups (wt and TasA-EgA31) 
Number of mice per group   6 
Number of mice per experiment 30 
The experiment will be performed twice 
Total number of mice              60 
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Experiment #3: (Mouse strain: Balb/c, females, six weeks old) 
Number of experimental groups   5; one control group and four spores groups (wt and TasA-CRISP) 
Number of mice per group   6 
Number of mice per experiment 30 
The experiment will be performed twice 
Total number of mice              60 
 
Experiment #4: (Mouse strain: Balb/c, females, six weeks old) 
Number of experimental groups   7; one control group and six spores groups (wt; TasA-EgTrp and TasA-
EgA31) 
Number of mice per group   6 
Number of mice per experiment 42 
The experiment will be performed twice 
Total number of mice              84 
 
Experiment #5: (Mouse strain: Balb/c, females, six weeks old) 
Number of experimental groups   7; one control group and six spores groups (wt; TasA-EgTrp and TasA-
CRISP) 
Number of mice per group   6 
Number of mice per experiment 42 
The experiment will be performed twice 
Total number of mice              84 
 
Experiment #6: (Mouse strain: Balb/c, females, six weeks old) 
Number of experimental groups   7; one control group and six spores groups (wt; TasA-EgA31 and TasA-
CRISP) 
Number of mice per group   6 
Number of mice per experiment 42 
The experiment will be performed twice 
Total number of mice              84 
 
Experiment #7: (Mouse strain: Balb/c, females, six weeks old) 
Number of experimental groups   9; one control group and eight spores groups (wt; TasA-Egtrp; TasA-
EgA31 and TasA-CRISP) 
Number of mice per group   6 
Number of mice per experiment 54 
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The experiment will be performed twice 
Total number of mice            108 
TRAINING ANIMALS:( Mouse strain:Balb/c, females, six weeks old) Please, see note in section 51.1 , 
training animals. 
Total number of mice              10  
SETTINGS FOR T CELL PROLIFERATION ASSAY: (Mouse strain: Balb/c, females from 6 weeks to 6 
months old)  
1) isolation of T cells from spleen and MLN      10 
2)T cell proliferation conditions assay settings  15  
Total number of mice                                         25 
ACCESORY SPLEEN CELLS FOR MLN PROLIFERATION ASSAY: (Mouse strain: Balb/c, females from 6 
weeks to 6 months old). 
number of mice per experiment:      4 
number of experiments:                   7
 
 
Total number of mice:                     28 
 
 
TOTAL ANIMALS REQUIRED IN THE PERMIT: 591  
54.4 Reason for the planned number of animal per experiment/series of experiments incl. statistical analysis of data (art. 137 para. 4 TSchV) 
The experiments were based in the 3R convention reducing the number and groups of experimental animals 
in a small number possible to be statistically significant. The data will analysed and processed using 
conventional statistical methods as significance and t-student test.  
 
55 Evaluation of the method (art. 137 para.3 TSchV) 
The data obtained (according to score sheet, in appendix I) will be processed and statistically analyzed using 
conventional statistical methods as significance and t-student test  
56.1 Expected effect  on the health and well-being of the animals (general condition, activity, water and food intake, pain reactions, 
duration and course of impairment, further behavioural parameters, growth, expected lethality, etc.) 
All the experiments are under a degree of severity I , after the oral administration through gavage of 
recombinant B. subtilis spores. No effect in the health and well-being of the mice is expected after treatment 
when compared with not treated animals. Mice wil have ad-libitum amounts intake of water and food. 
56.2 Monitoring of well-being of the animals (art. 135 para. 4 TSchV):  
- by which person(s) 
- frequency 
- criteria of evaluation 
- documentation (e.g. score sheet as stipulated in art. 144 para. 1 TSchV) 
- according to the phase of experiment 
The animals will be monitored daily after immunization by Catherine Eichwald and Bogdana Salathe. The 
criteria of well-being evaluation will be those indicated by the provided score sheet, as body-weight, behavior 
among other parameters. 
56.3 Indications concerning stress-reducing measures and criteria for premature discontinuation of the experiment (criteria for 
discontinuation; art. 135 para. 1 and 8 TSchV) and criteria for renouncement to reuse animals 
B. subtilis spores are already used as probiotic in humans and It is not expected to produce any stress in the 
animals. However, if for any unknow reason the animals have a lost in body-weight going under 10-15% a 
euthanasia procedure will be use to discontinue the experiment. The weight measurement will be performed 
during 3 days after each immunization, due that this is the period in which most of the spores are sheeded. If 
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there is a weight reduction is observed, the animals will be weighted daily until reach the correct weight or 
being required the euthanasia. 
56.4 Repartition of animals per severity degree (art. 30 j TVV) 
Degree of severity 0: for organs obtention from killing of untreated donors. 
Degree of severity I: for oral administration of recombinant B.subtilis spores through gavage. 
 
57.1 Indicate the name and/or the number of the husbandry licence  
(if there is no licence for keeping laboratory animals indicate: housing and husbandry of animals before, during, between and after 
individual experiments; space provided, cage type incl. number of animals, structuring of enclosure, run, individual or group housing, 
feeding and occupation, routine inspections by animal technicians, etc.) 
Animals are kept at Nagerzentrum Vetsuisse Faculty Zurich. Husbandary Licence: 147 
57.2 Reason for any deviations from conditions in which animals are kept as defined in the animal protection ordinance in the above-
mentioned licence for keeping laboratory animals (e.g: feed withdrawal, immobilization, single housing for social animal species) 
Mice behavior under isolation is well-tolerated with our experimental conditions. It has not been observed 
changes in behavior as well as in body-weight during the short period of isolation. In addition, mice are 
responding well when re-inserted with the other mice of their respective group. 
58 Fate of the animals: utilisation of the animals at the end of the (individual) experience; repeated use in the same or another experiment).  
Method of euthanasia (substance, doses, route of administration, etc.) 
Mice will be euthanised at the end of the experiment by cervical dislocation (with previous inconciousness 
with isoflurane) and bleeding (Experiments # 1 to #7). At the moment of the euthanasia for the other animals 
asked if it is more than 10 animals at time, the animals will euthanisied by CO2 inhalation. 
6 INFORMATION ON THE REASON FOR THE ANIMAL EXPERIMENT 
61 What other experimental methods are known (e.g. from the literature) which would allow corresponding information to be 
obtained (mention in vitro or in vivo methods art. 137 para. 2 and 3 TSchV) 
Until know there is not an in vitro method able to reproduce the interaction among the gastrointestinal tract 
and the immune system. 
62 Information on whether the project has been / is being appraised and, if so, by which institution/organization  
This project is granted by EU grant: Paravac, grant agreement number: 265862/ University number: 
75080502 to the Swiss component of the Parasitology and Virology of the Vetsuisse Faculty, University of 
Zurich. 
63 Assessment of the importance of the anticipated information or results in relation to the pain, suffering, injury or anxiety 
experienced by the animals and injury to the dignity of the animal (art. 3 and 19 para. 4 TSchG,). In this process of weighing up the 
various interests (art. 26 TVV) the desired benefits as stipulated under sections 44.1 and 44.2 must in particular be assessed and 
weighed against the stress on the animals as stipulated under sections 56.1 – 56.4 
We know from previous studies that, under the proposed experimental conditions, the animals will not 
experience pain or suffering (Maximum degree of severity I) and will not be affected in their dignity. 
In return, we expect to evaluate a novel, potentially principal means of oral immunization in animals, which 
may dramatically reduce in the future the need of vaccine-related injections in various species.  
Moreover, we address this novel approach by working towards a vaccine against E. granulosus, a tape worm 
of carnivores, which causes disease, suffering, and death in various other species, including humans, which 
may serve as intermediate hosts for the tape worm's cysts. As of today, no such vaccine is yet available.  
During the whole project, mice will have ad libitum food and water. As described above, a series of 
measures will be performed to prevent pain or, should it unexpectedly arise, shorten the suffering.  
 
Modification in experiments from permit N˚ 104/2012 (Internal number: 4787): 
”Use of recombinant Bacillus subtilis spores, as a safe carrier, for enteric immunization 
against Echinococcus granulosus in mice”. 
 
With the data obtained during our experimental trials, we concluded that mice 
were unable to produce a humoral immune response. Revising the related scientific 
literature and discussing with experts in the area, as PD Dr. A. S. Zinkernagel (Div. of 
Infection Diseases and Hospital Epidemiology, USZ), it became clear that would be 
necessary to modify our experimental trial. The main modification will be the inclusion 
of an oral treatment with broad-spectrum antibiotics, previous to the immunization of the 
mice with the recombinant spores. The purpose of the antibiotic treatment is to eradicate 
part of the mouse intestinal microflora in order to give a niche to the orally administrated 
recombinant spores. Under these new conditions, we will improve the chance of the 
recombinant spores to germinate and establish in the gut by decreasing the competition 
with the intestinal microflora. This will hopefully allow for the formation of a biofilm in 
the gut and for the expression of the antigen of interest required for GALT stimulation. 
Previous work performed by other research group has included a treatment consisting in 
an antibiotic cocktail (ampicillin, gentamicin, metronidazole and vancomycin) mixed 
with the drinking water for 1 to 2 weeks before starting the experiment [Shan M. et al., 
2013 and personal communication]. To corroborate a complete eradication of the 
intestinal microflora faeces will be collected, resuspended to the same concentration and 
50 µl will be used for colony forming units assay. 
The experiment # 1 to # 7 will keep the same experimental conditions previously 
described in the permit N˚104/2014 but before each immunization, mice will be treated 
with an antibiotic cocktail, mixed in the drinking water. This antibiotic cocktail will 
consist in autoclaved water supplemented with the following antibiotics: ampicillin 
(0.5mg/ml), gentamicin (0.5 mg/ ml), metronidazole(0.5 mg/ml) and vancomycin (0.25 
mg/ml), and supplemented with sucralose (4mg/ml) to make it more palatable to the 
animals. This mix at been used by different research groups and is considered safe, with 
no health issues detected in mice. At the day of immunization, mice will return to normal 
drinking water. To further control the well being of the mice during the antibiotic 
treatment, the body-weight will be measured every three days. 
 Reference:  
M.Shan, M. Gentile, J. R. Yeiser, A. C. Walland, V. U. Bornstein, K. Chen, B. He, L. Cassis, A. 
Bigas, M. Cols, L. Comerma, B. Huang, J. M. Blander, H. Xiong, L. Mayer, C. Berin, L. H. 
Augenlicht, A.Velcich, A. Cerutti. (2013) Mucus Enhances Gut Homeostasis and Oral Tolerance 
by Delivering Immunoregulatory Signals. Science 342, 447-453. 
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ANNEX II: Dog Animal Experiment Permission 
 
  
ANNEX II 


Original to the licensing authority 
Animal experiments Form. A No. ................................... 
  (to be completed by the authorities) 
Application for licence to perform animal experiments 
1 Address of applicant (contact person, institute, firm) 
Prof. Dr. Mathias Ackermann 
Institute of Virology, Vetsuisse Faculty 
Wintherturerstrasse 266a, 8057 Zürich 
 
 
 E-mail; phone no. mathias.ackermann@vetvir.uzh.ch; 044658702 
2 Address of cantonal authority 
 Katonales Veterinäramt 
Culmanstrasse 1, 8090 Zürich 
 
 
3 TITLE OF EXPERIMENT / PROJECT 
 Recombinant Bacillus subtilis: A safe carrier for oral vaccine administration in dogs 
31 Field of study or area of application: 
 Medicine, veterinary medicine, parasitology, bacteriology, immunology. 
32  [N] new application 
 [R] application for renewal (no. ) 
 [S] supplementary application (no. ) →Amendment   type of method 
  number of animals / animal species 
  validity / period of extension 
  other (give corresponding figures in application)  
*In the case of supplementary applications, please only note or highlight amendments 
33 ANIMAL SPECIES Total number 
per application 
Source 
(a-c) 
 dog (Beagle) 13 b 
    
    
    
 
Source: (a): from a previous experiment; 
(b): from a recognized animal breeding or husbandry facility (article 59b, OPA); 
(c): from another source, namely:  
Names and addresses of suppliers:  
 
 
34 Address of place where animals are kept: Stigenhof, Embrach 
Vetsuisse ZH dog holding facility 
 
 Use of genetically modified animals* :  yes  no  
 *Datasheets for registration and characterization of genetically modified animals must be attached. 
35 Maximum expected degree of stress: 1 (for details: see section 56.4) 
36 Overall duration of project: 1 year 
 Scheduled starting date: immediately 
37 List of persons who perform or supervise operations and interventions in the experiment: 
People who supervise or perform experiments must meet the training and continuing education requirements as defined in the 
“Ordinance on the training and continuing education of specialists for animal experiments“ dated 12 October 1998. 
The corresponding appendix for “persons involved and certificates of training and continuing education” must be completed and copies 
of the certificates enclosed. 
Application (Form. A) - 2 - No. ........................................ 
  (to be completed by the authorities) 
Short title: 
 __________________________________________________________________________________________________________________ 
Original to the licensing authority 
38 The signing scientific institute or laboratory director (article 61a, para. 1, OPA) confirms that the people listed under section 37 are 
familiar with the regulations of the LPA and the OPA applicable to animal experiments and that they meet the training and continuing 
education requirements (article 59d, OPA). 
 
  
Zürich, 1st March 2009 Mathias Ackermann 
Place and date Name and signature 
  
39 Study director: if more than one person performs this function, their area of responsibility must be defined as described in section 37. 
Signature of principal study director: (article 59d, OPA): 
  
Zürich, 1st March 2010 Peter Deplazes 
Place and date Name and signature 
  
4 INFORMATION ON THE PURPOSE OR AIM OF THE EXPERIMENT (for statistics article 64b, OPA); sections 41 – 43, indicate one 
only in each case and, if applicable, add a further note or additional information in the case of detailed questions. 
41 The project is associated with 
 biological (including medical) studies in the field of basic research 
 discovery, development, and quality control (excluding safety testing) of products or devices for human and veterinary medicine 
 diagnosis of disease 
 education and training 
 protection of humans, animals and the environment by toxicological or other safety tests 
... for substances used or intended to be used mainly 
 as pharmaceutical products (including medical devices) 
 in agriculture 
 in industry 
 in private households 
 as cosmetics or toiletries 
 as food additives or 
 to determine potential or actual hazards of contaminants in the general environment 
 any other use, namely:  
 other studies, namely:  
 
42 The project is associated with 
 human diseases 
 cancer (excluding carcinogenicity studies)  
 cardiovascular diseases 
 nervous and mental disorders 
 other human diseases, namely: cystic echinococcosis 
 animal diseases, namely: cystic echinococcosis 
  no association with human or animal diseases. 
43 The project is associated with procedures required by law (registration and licensing regulations): 
 Switzerland only 
 other countries only, namely:  
 both, namely:  
  Mention the relevant guidelines or test methods: 
  
 The project has no association with procedures required by law.  
44.1 Description of the aim of the experiment (for example summary of National Science Foundation study, maximum one page): 
Cystic echinococcosis, also called hydatidosis, represents a worldwide severe public health and livestock 
problem. The causative agent of the disease is the cestode Echinococcus granulosus, which is known for its 
two-host life cycle. The adult tapeworm lives in the small intestine of its main host, i.e. carnivores, including 
dogs. Parasite eggs are shed via feces, a likely mechanism for contamination of plants used for human and/or 
animal consumption. This may lead to the infection of intermediate host (sheep, cattle, humans). In these 
animals, larval stages of the metacestode develop and start migrating, reaching internal organs where they 
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Short title: 
 __________________________________________________________________________________________________________________ 
Original to the licensing authority 
persist and may cause the dreaded disease symptoms. To complete the cycle, carnivores are infected 
following consumption of such persistently infected organs, and the adult tapeworm re-emerges to the 
ecosystem from the carnivores. 
According to mathematical models, the parasite's cycle may be interrupted through successful vaccination of 
carnivores [Torgerson PR. 2006.Parasite Immunol. 28, 295-303]. An oral vaccination strategy using recombinant 
Salmonella typhimurium as carrier has previously been developed and tested in dogs. The recombinant bacteria 
were engineered to produce the E. granulosus antigens EgA31 and EgTrp. Upon immunization, the vaccine 
conferred only partial protection, i.e. the parasite burden in vaccinated dogs was reduced by 70-80% and the 
development rate in the remaining worms was also affected [Petavy A-F., et al. 2008. Plos neglected tropical 
diseases, 2(1):e125]. These data suggest that the antigens used have the desired potential to create an immune 
response in the host. However, the antigen carrier (Salmonella) has three major drawbacks: (1) the number of live 
bacteria reaching the duodenum, where immunity is supposed to develop, is dramatically reduced upon passage 
through the stomach, making the effectiveness of the vaccine unreliable; (2) expression of the recombinant vaccine 
proteins is unstable because they are encoded on plasmids; (3) there is a general skepticism against Salmonella 
as vaccine carrier because other members of this genus are associated with disease in humans and animals.  
The gram-positive bacteria Bacillus subtilis is used as probiotic in both, humans and animals, and in contrast to 
Salmonella, it is considered safe for oral use in food supplements [Duc & Cutting. Expert. Opin. Biol. Ther., 
2003,3:1263-70; Tam et al., J. Bact. 2006,188:2692-700 and Hong et al. J.Appl. Microbiol, 2008, 160:134-43]. The 
genetics of B. subtilis sporulation have been extensively studied. In a spore, the chromosome is condensed in the 
core spore, which is surrounded by layers of lipid membranes and modified peptidoglycan. The spore coat is a very 
important structure, laminated by a proteinaceous shell that provides resistance against harsh environmental 
conditions, including heat, acids, organic solvents and enzymes. The outermost layer of the spore coat is 
composed of at least five proteins: CotA, CotB, CotC, CotD and CotG.  
Spore coat proteins have already been used as fusion partners to generate successful vaccines against bacterial 
diseases in murine models, for example: (1) a CotB and CotC fusion to peptides from B. anthracis, and (2) the 
CotB fusion to the toxoid alpha from Clostridium perfringens [Duc et al.Vaccine.2007, 25:346-55 and Hoang et 
al.Infect Immunol. 2008, 76:5257-65]. TasA, an extracellular protein of B. subtilis, which is secreted but also found 
in association with both cells and spores, has recently stirred considerable scientific interest. TasA is essential for 
the formation and structural integrity of B. subtilis biofilms [Aguilar et al. Curr Opin Microbiol. 2007; 10:638-43; 
Vlamakis et al.Genes Dev, 2008, 22:945-53; Lemon et al.Curr Top Microbiol Immunol. 2008, 322: 1-16 and 
Romero D et al.,Proc. Natl. Acad. Sci. USA. 2010, 107 (5):2230-4]. This is particularly interesting since there is 
evidence suggesting that B. subtilis strains could persist in the mouse gut, suggesting that they have adapted to 
carry out their entire life cycle within the gastrointestinal tract (GIT). This makes TasA an attractive candidate for 
both antigen presentation and continuous stimulation of immunity. Indeed, there is evidence suggesting that 
vegetative cells of B. subtilis play a primary role in the development of gut-associated lymphoid tissue (GALT) and 
somatic diversification of the Ig genes, when these cells were introduced into germ-free appendices of rabbits 
[Rhee et al. J Immunol. 2004, 172:1118-24]. Subsequent studies demonstrated that orally administrated B. subtilis 
spores in mice were able to germinate, proliferate and then re-sporulate in the gut [Tam et al. J Bact. 2006, 188: 
2692-700).  
B. subtilis is considered a safe probiotic. It may therefore be well accepted in the community; its spores are highly 
resistant against harsh conditions, which makes them well-suited for their use as oral vaccines; it may form biofilms 
in the gut, which may be a great advantage for generating a desired local immune response. Finally, a spore-based  
vaccine would be inexpensive to produce and would not need a cold chain, making it very attractive for 
commercialization. B. subtilis spores may provide a prototype for generating specific immune responses against 
various enteric disease organisms. However, there is no information available regarding its behaviour as an oral 
vaccine-delivery system in dogs. To establish this crucial data, we suggest to perform a series of pilot experiments. 
 
44.2 Basic question which experiment is designed to answer; status of research; presentation if what is not yet sufficiently well-known: 
 
In the present application, we would like to perform a pilot study addressing the following questions: (1) Will 
recombinant B. subtilis spores safely survive the passage through the stomach of orally vaccinated dogs? (2) 
Will they germinate in the small intestine and form a biofilm in the gut of those dogs? If yes, which part of the 
intestine will host the biofilm? (3) Will the dogs raise an immune response against a model recombinant protein 
(mCherry) delivered through B. subtilis? (4) Will the dogs, orally vaccinated with recombinant B. subtilis, raise 
an immune response against the E. granulosus antigens EgA31 or EgTrp, when these antigens are genetically 
fused to TasA? 
 
IMPORTANT NOTICE: The pilot study will be performed in two steps. In the first step, we will address the 
questions 1, 2, and 3. Based on the knowledge gained there, we will address question 4 in a second step. 
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5 INFORMATION ABOUT THE METHOD (descriptions and note on sections 51 - 59) 
51.1 Experimental design (overview of the method, the course of the project, name of animal model where applicable) 
 
EXPERIMENT #1 (outline): To be effective as a vaccine delivery vector, B. subtilis has to overcome the harsh 
conditions of the passage through the stomach when orally administered. To monitor this first task, we have 
generated a recombinant B. subtilis that expresses luciferase. Luciferase is a light-emitting protein that can be 
visualized in vivo by using the IVIS system, a highly sensitive camera that non-invasively and quantitatively 
detects light even when emitted from within an organism. For the experiment, we will inoculate a small number 
of dogs with such bacteria before monitoring light emission from within the gut of these animals. Once the 
bacterial spores have safely passaged through the stomach, they will germinate and start replication. 
Increasing amounts of light will be emitted with increasing numbers of bacteria. IVIS imaging will allow to 
monitor over time the anatomical location of highest bacterial replication, which is very important for vaccine 
efficacy. The second question asks whether or not the bacteria are able to form a biofilm at the desired 
location. To monitor this event, we have our B. subtilis vector engineered to produce the fluorescent protein 
mCherry as a fusion protein with TasA (TasA-mCherry). In preliminary in vitro experiments, we have 
established that this fusion protein is present in high amounts in the biofilm and that, importantly, it does not 
interfere with biofilm formation. Therefore, we will be able to detect the location and quantify of biofilm 
formation at the end of the experiment by using fluorescence microscope techniques. Thirdly, we will monitor 
the sera of the experimental animals for antibody formation against mCherry, which may provide a first hint 
towards the suitability of our antigen presentation approach in the new system. In addition, collected feces 
samples will be analyzed for antibodies (potential IgA in feces) against mCherry as well as for the presence of 
B. subtilis spores, which will be a good indicator for persistence of B. subtilis in the gut.  
EXPERIMENT #1 (time table, number of animals, and doses): Animals of up to 700 g bodyweight can be 
accomodated in the IVIS for monitoring of luciferase activity. Therefore, we will use a group of five, 
approximately 10 days old Beagle puppies (close to 700g). On days 1, 21 and 42 of the experiment, four 
animals will be orally immunized with a dose of 5e10 cfu recombinant B. subtilis spores in 1 ml volume of milk, 
whereas one animal will serve as unimmunized control. Similar doses of Bacillus cereus, a strain of the same 
genus than Bacillus subtilis, have been reported as having no adverse effects when administrated to dogs as 
probiotics [Biourge V. et al., J. Nutr. 1998; 128:2730S-2732S]. IVIS monitoring will be done at 2, 6 and 24 
hours and 2, 3 and 7 days post-inoculation. The puppies may be narcotized for IVIS monitoring, which will not 
take longer than 10 minutes per dog and per analysis. Blood for serological analysis will be taken from the 
jugular vein prior to inoculation as well as once per week until the end of the experiment. For control purposes, 
blood will also be taken from the bitch. On day 60, the inoculated animals and the negative control will be 
euthanazied and samples of the gut will be taken for fluorescence microscopy to visualize the biofilms as well 
as for molecular (PCR detection of B. subtilis) and bacteriological (evaluation of the intestinal flora) analyses 
as well as histological analyses (potential inflammatory responses, properties of the biofilm, etc.) to determine 
the state of infection.  
EXPERIMENT #2: After careful analysis of the results obtained from the first experiment, we suggest to follow 
up with a second pilot experiment, this time using B. subtilis expressing a fusion of TasA to the E. granulosus 
antigens EgA31 or EgTrp. The readout will be very similar to the first experiment (see above) but may require 
changes in the time tables, age of experimental animals, dose of inoculated spores, etc. Importantly, this 
second series will provide serological evidence (detection of antibodies against EgA31 or EgTrp or both) as to 
whether or not our approach might be suitable at all in the context of vaccination against E. granulosus.  
 
EXPERIMENT #2: Since IVIS monitoring is not planned for the second experiment, the age and body weight 
of the experimental dogs is not as crucial any more. Therefore, the age of the animals can be adjusted to fully 
guarantee a mature immune system. Two groups of 4 dogs will be immunized three times with a dose of 5e10 
cfu of recombinant spores from B. subtilis carrying: a fusion of TasA-EgA31 (group 1) and a fusion of TasA-
EgTrp (group 2) in a volume of 1 ml milk solution. A second immunization will be given on day 21, and a third 
immunization on day 42. Serum samples for detection of antibodies against EgA31 and EgTrp will be taken 
prior to inoculation and weekly thereafter. Growth and shedding of B. subtilis in the dogs will be monitored by 
isolation from collected feces. The experiment will be terminated at 60 days after the first inoculation. 
For biological safety reasons (Meldung A90029), all feces from immunized dogs that are not used for analyses 
will be collected and safely eliminated to avoid the uncontrolled release of the spores into the enviroment. At 
the end of the experiments, the facilities will be desinfected using hypochloride. Wash-off fluid will be collected 
and incubated with hypochloride (2.6% final concentration) for 15 min before being diluted and discarded.  
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51.2 Reason for selection of method (or model) showing its peculiarities / advantages 
Dogs play a crucial role in the epidemiology of E. granulosus and associated disease of humans and husbandry 
animals. Thus, successful vaccination of dogs may eliminate or at least reduce the risk of humans and animals 
to suffer from Cystic Echinococcosis. Oral vaccination has the promise of inducing a robust immune 
protection, where it is most needed, namely in the gut of dogs, where the tapeworm has established and, thus, 
where the source of shedding of the parasite's eggs is located. Bacterial spores are known to resist and 
survive harsh conditions, such as passage through the stomach. Therefore, they are well suited to carry the 
recombinant antigens to the location in the gut, where immunity should develop. B. subtilis is well accepted as 
a probiotic and has, therefore, the potential to be commercialized as a vaccine carrier, provided that it proofs 
to be suitable for oral vaccination purposes. Moreover, spore-vaccines can be produced inexpensively, which 
makes them also attractive for applications in third world countries. 
 
51.3 Reason for selecting animal species (breeds to be listed) and, where applicable, for using animals not bred for experimental purposes 
Dogs are the ideal target for vaccination against E. granulosus. Therefore, the validation of B. subtilis spores 
as carrier for the specific antigens in dogs is an essential step in the process. The selected breed of dog for 
this experiment will be the Beagle from our faculity's own breeding facilities. Their puppies at 10 days have a 
size of approximately 700 g, the limit size requirement for fitting into the IVIS camera chamber.  
52 Special preparation of animals for the experiment (adaptation, type of tagging, conditioning, feed or water withdrawal, pretreatment etc.) 
The animals will be kept at the dog holding facility of the Vetsuisse faculty, University of Zürich. 
The animals will be tagged before weaning through the implantation of a transponder (microchip), as denoted 
into the Art 59c, TSchV. Additionally, application of the microchips will be carried out by qualified staff. 
53.1 Narcosis and/or other analgesics (preparations, doses, route and frequency of administration, period of time etc.) 
For experiment #1, narcosis of the puppies is required during the IVIS monitoring procedure  
 
For this purpose, the anesthetic chosed is Sevoflurane at 1.5 MAC (minimum alveolar concentration). This 
anesthetic is well accepted due to the follow properties: inhalation via mask, colourless, very short acting and 
only 2-3% of it is metabolized. This procedure will be under the consultation of Prof. Dr. Regula Bettschart 
DVM, an renowned expert for narcosis in dogs. 
53.2 Reason for selection of narcosis or analgesia or, if applicable, reason for not using narcosis or other measures to reduce discomfort 
(e.g. use of analgesics) 
The narcosis will be applied to avoid stressing of the puppies in the IVIS chamber. The IVIS procedure by itself 
is non-invasive but the puppies need to remain motionless in the dark chamber for adequate picture 
acquisition. The chamber is equipped for gas application. Each examination will take approximately 10 
minutes. 
 
54.1 Type of intervention/manipulation and parameters to be measured in the animal (procedure for individual animal/for animal group): 
surgical interventions (general procedure), substance administration (method and site, amount and frequency), infections, physical 
treatments (radiation, etc.), procedural controls, obtaining of samples, reaction tests etc. 
Dogs will be immunized orally three times with 5e10 cfu of recombinant spores/dose. This procedure will be 
performed by application through gavage. The IVIS chamber will be used only after the first immunization. 
 
Time Table Experiment #1 
Procedure  Timing     Details 
Oral immunization 1, 21,42 (dpi)    5e10 cfu bacterial spores in 1 ml per os 
IVIS chamber 2, 6, 24 (hpi) and 2, 3, 7 (dpi)  Narcosis, approximately 10 min per time per dog; 
        prior and post narcosis, the puppies will be kept  
        with their mother 
Blood sampling 0, 7, 14, 21, 28, 35, 42, 49, 56, 60 (dpi) <1 ml/100 g bodyweight 
(dpi= day post inoculation; hpi= hour post inoculation) 
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Time Table Experiment #2 
Procedure  Timing     Details 
Oral immunization 1, 21,42 (dpi)    5e10 cfu bacterial spores in 1 ml per os 
Blood sampling 0, 7, 14, 21, 28, 35, 42, 49, 56, 60 (dpi) <1 ml/100 g bodyweight 
(dpi= day post inoculation) 
For more details see also section 51.1. 
54.2 Duration of experiment/series of experiments: total duration of experiment for each individual group or animal, incl. period during which the 
animal is exposed to substances or other noxae. 
Experiment #1 and #2 will have a duration of 60 days, each from the first immunization. Making a total of 120 
days. This period does not includ the time required for breeding and data analysis. 
54.3 Number of animals per experiment/series of experiments: number of groups (including all variables, such as doses, periods of time, 
controls) and numbers of animals per group 
Experiment #1  
4 animals to be vaccinated (recombinant spores TasA-mCherry/LuxCDABE) 
1 animal as non-vaccinated control 
Total animal/experiment: 5 
 
Experiment #2 
number of groups: 2 (recombinant spores TasA-EgA31 and recombinant spores Tas-EgTrp) 
number animals/group:4 
Total animals/experiment: 8 
 
TOTAL ANIMALS FOR WHOLE PROJECT: 13 
54.4 Reason for the planned numbers of animals (the breeds of animal used must be indicated) 
The numbers of animals used is the minimal number to establish significant terms of the humoral response, 
IVIS acquired images and histogical analysis from the immunized animals 
55 Type of analysis, including biometric planning 
The significance of the data obtained will be determined through t-student parameters from the average of the 
group of samples tested.  
56.1 Expected effect on the well-being of the animals (activity, water and food intake, pain reactions, duration and course of harmful 
impairment, further behavioural parameters, growth, expected lethality, etc.) 
During the whole experimental procedure dog bitches and puppies will be provided with ad-libitum water and 
food. Dogs will be maintained indoors during the whole experimentation in order to meet the following 
requirements: control of odor and noise, appropriate utilities (as sewage and water); outside windows and 
skylights; sheltered structures that must be large enough to permit each animal to sit and lie down in a normal 
manner and to turn around freely; protection from the elements and extreme temperatures at all times. 
Moreover, in accordance with art. 31, dogs will be allowed to have daily at least 30 minutes of activity in open 
air. This will include weekends and holidays. 
In experiment #1: Puppies will be immunized with 5e10 cfu of the spores/dose once they are 700g (approx. 10 
days old). For in vivo imaging (IVIS proceduce), the animals will have to be transported from Stigenhof to the 
IVIS facility in Zurich. In order to avoid unneccessary stress, the bitch and her entire litter will be transported 
and kept together with exception of the 10 min required for monitoring, during which time the puppies are 
under narcosis (sevoflurane, as described in section 53.1). The IVIS facility is equipped to hold animals for 
short periods. For keeping the animals in between of the first two measurements, quiet and adequate facilities 
are available. During the whole procedure, the animals will be monitored for glucose status, body temperature, 
breathing (thorax movement) and pulse. 
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To further reduce stressing of the bitch, we shall not use entire litters for the experiments (both #1 and #2). At 
least one or two puppies per bitch will remain excluded from the experiment in order to avoid problems with 
the bitch's mammary gland and lactation at the end of the expermiment. 
Blood sample from puppies will be collected from the jugular vein. Not more than 1ml/100g body weight/week 
will be taken (due to the immaturity of the sympathic system in neonates, they cannot easily compensate 
volume loss). 
 
56.2 Monitoring of well-being: frequency, criteria of assessment, documentation (e.g. score sheet) according to phase of experiment 
The animal well-being will be followed by a score-sheet as indicated into apendix I 
56.3 Criteria for stress-reducing measures and (premature) discontinuation of the experiment (criteria for withdrawal) and for not re-using the 
animals, 
The criteria used to terminate individual animals during the ongoing experiments are described in the score 
sheet (appendix I). All animals that present three or more of the critical characteristics will immediately be 
sacrified to avoid unnecessary (though unexpected) suffering. 
56.4 Estimated number of animals per severity grade 
Severity I: animals immunized with recombinant luminescent spores of Bacillus subtilis and anesthetized to 
trace and quantify the growth of germinated vegetative bacterial cells in the pup's guts. 
Number of animals severity 0: 8 
Number of animals  severity I: 5 
 
 
57.1 Husbandry and care of animals before, during, between, and after the various experiments (available space, structure, run, keeping 
individually or groups, feeding and activity, routine checks by the animal keeper; in the event of repeated use, also indicate the interval 
between experiments) 
The dog bitches and puppies will be kept at the dog holding facility Stigenhof of the Vetsuisse Faculty, 
University of Zürich. The required conditions for this purpose have been established according to the swiss 
ordinance. Conventional conditions can be applied, with exception of two hygienic conditions (Meldung 
A90029): (1) feces is to be collected and to be safely disposed of; (2) decontamination of the facility using 
hypochloride at the end of the experiment.  
The animals will receive sufficient food and water as stipulated by the cf. art2, para 1 TSchV.  Additionally, 
breeding bitches will be housed together with their pups for at least 8 weeks. Young dogs raised in the litter by their 
mothers can later be kept among congeners. All the dogs before, during and after experiments (this last only for 
experiment #2) will be housed, fed and supplied with medical attention in keeping with the state article (cf. art 15, 
para 3 TSchG). The group holding will be kept in the dimension established in appendix 1, Table 152, TSchV. 
57.2 Reason for any deviations from conditions in which animals are kept as defined in the animal protection ordinance (incl. feed withdrawal, 
immobilization) 
n/a 
58 Method of sacrifice, use of animals after completion the (individual) experiment (repeated use in the same or another experiment) 
The animals will be euthanized through a three times overdose of intravenous barbiturate (sodium 
pentobarbitone) dose (80 mg/kg) [Close, B et al., Recommendatiosn for euthanasia of experimental animals: 
Part 2. Laboratory Animals (1997) 31, 1-32]. 
6 INFORMATION ON REASON FOR THE ANIMAL EXPERIMENT 
61 What other experimental methods are known (e.g. from the literature) which would allow corresponding information to be obtained 
(mention any in vitro or in vivo methods) 
There is no in vitro method described in the literature that would allow corresponding information to be 
obtained.  
62 Information on whether the project has been / is being appraised and, if so, by which institution/organization 
This project as been applied as a European Community grant as:"…." . Form A for pilot experiments in mice 
had been approved from cantonal veterinary office with the number: 157/2009. 
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63 Assessment of the importance of the anticipated information or results obtained in relation to the pain, suffering, injury or anxiety 
experienced by the animals 
This experiment is designed as a pilot study to test a novel potential oral vaccination procedure for dogs. If 
successful, a whole new generation of oral vaccines for dogs may be envisioned. Thus, in the future, dogs 
may have to less often encounter the slightly stressful procedure of vaccine injections. Furthermore, this 
experiment may serve to establish a successful vaccine against E. granulosus. 
The experimental dogs will be maintained in high standard care during the whole experimentation period. 
Pups will be kept all the required time (8 weeks) with the bitch to avoid anxiety and unnecessary stress. As 
mentioned in section 57.1., young animals from the same litter will be housed with congeners. 
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